17th Scientific Meeting of the Korean Society of Nephrology Seoul, Korea May 16–17, 1997  by unknown
ABSTRACTS
17th Scientific Meeting of the Korean Society of Nephrology
Seoul, Korea
May 16–17, 1997
Cadmium binding and sodium-dependent solute transport in renal
tubular luminal membranes. J.Y. Kim, D.W. Ahn, Y.M. Kim, K.R. Kim, and
Y.S. Park, Department of Physiology, Kosin Medical College, Pusan, Korea.
Exposure to cadmium induces alterations in renal transport systems for
glucose, amino acids, phosphate and dicarboxylates. To investigate if these
alterations are associated with a cadmium binding to the membrane,
cadmium binding and Na1-dependent uptakes of D-glucose, L-alanine,
phosphate, and succinate were determined in brush-border membrane
vesicles (BBMV) derived from rat kidney cortex. Cadmium uptake by
BBMV showed time and concentration dependence. Changes in medium
osmolality had no effect on cadmium uptake, indicating that the process
involves primarily binding of cadmium to membrane component(s).
Scatchard analysis indicated that there exist two major classes of binding
site, differing in affinity and number of sites. Increase in cadmium
concentration in the medium from 25 to 200 mM resulted in a progressive
increase in cadmium binding to the membrane and a decrease in
Na1-dependent transport of D-glucose, L-alanine, succinate and phos-
phate. These results suggest that during chronic exposure to cadmium-free
cadmium ions liberated in renal tubular cells may directly interact with
brush-border membranes and impair Na1-dependent solute transport
systems.
Atrial mRNA and plasma levels of atrial natriuretic peptide in rats with
chronic renal failure. M.K. Kang, J.H. Bae, W.K. Park, and H.C. Kim,
Department of Physiology, Internal Medicine, Keimyung University, Daegu,
Korea. The aim of this study was to assess the adaptive changes in plasma
level of atrial natriuretic peptide (ANP) and its atrial mRNA expression in
experimental rat model of chronic renal failure. Material and methods:
Male Sprague-Dawley rats weighing 250–300 g were divided into control
rats, sham operated rats, and subtotal nephrectomized rats. Chronic renal
failure was induced by 5/6 nephrectomy that two-thirds of the left kidney
was ligated and the contralateral kidney was removed 1 week later.
Results: In the rats with 2/3 pole ligation, there were no significant
changes in mean arterial pressure (MAP), heart rate, BUN and serum
creatinine compared to the sham-operated rats. Expression of atrial ANP
mRNA showed initially the higher values and plasma renin activity (PRA)
were lower than the sham-operated rats. After 5/6 nephrectomy, MAP,
heart rate, BUN and serum creatinine increased, and PRA showed more
sustained lower values than the control rats. The changing pattern of
plasma ANP mRNA expression that showed biphasic peaks with the first
increase at 1 to 3 days and the second increase at 28 days after
nephrectomy. There was a significant positive correlation (P , 0.01)
between plasma ANP level and MAP, and a negative correlation (P ,
0.05) between plasma ANP and PRA. Conclusion: These results suggest
that the secretion and the synthesis of ANP respond rapidly to the reduced
renal mass, and ANP may play an important regulatory role during the
renal adapting process in rats with experimental chronic renal failure.
Effects of chronic hypokalemia on expression of Na/K-ATPase isoforms
in rat renal medulla. K.Y. Ahn, S.C. Kim, T. Heo, B.C. Moon, and B.C.
Kone, Department of Anatomy, Chonnam University Medical School,
Kwangju, Korea; Departments of Internal Medicine and Integrative Biology,
The University of Texas Medical School at Houston, Houston, USA. Chronic
hypokalemia alters Na/K-ATPase a subunit isoform gene expression in
several tissues. While it is established that Na/K-ATPase activity increases
during K depletion in the OMCD and does not significantly change in the
CCD, little is known about the adaptive responses of Na/K-ATPase
isoforms in these and other nephron segments. Accordingly, we used
Northern analysis, in situ hybridization (ISH), and immunohistochemistry
(IHC) to characterize the relative level of expression and cellular distri-
bution of Na/K-ATPase isoforms in normal and K-deprived (2 weeks) rats.
Isoform-specific 32P-labeled cDNA (for Northerns) or digoxigenin-labeled
cRNA (for ISH) probes were used as previously reported. Isoform specific
anti-rat Na/K-ATPase a1 and b1 subunit antibodies were used for IHC. In
both normal and K-deprived rats, a1 mRNA levels were much greater
than those of a2 or a3 in cortex, outer and inner medulla. However,
mRNA levels for each isoform were several-fold greater in inner mudulla
of K-deprived rat compared to controls. In contrast, a isoform mRNA
levels in cortex and outer medulla were comparable between the two
groups. By ISH and IHC, mRNA for each a isoform and polypeptide for
a1 and b1 subunit were observed in the proximal tubule, CTAL, MTAL,
DCT, the connecting segment, and CCD. Both groups were much greater
in the proximal portion of inner stripe of the OMCD and proximal portion
of the IMCD, and less in the MTAL of K-deprived rats compared to
controls. We conclude that chronic hypokalemia enhances expression of
Na/K-ATPase isoforms in the proximal OMCDi and proximal IMCD, but
not other nephron segments. Since the Na pump also contributes to
medullary H1 secretion by transporting NH4
1, the increased Na/K-
ATPase isoform levels may, in part, account for the increased net acid
secretion during chronic hypokalemia.
Regulation of angiotensin II AT1 and AT2 receptors in neonatal
ureteral obstruction. K.H. Yoo, V.F. Norwood, and R.L. Chevalier, Depart-
ment of Pediatrics, Korea University, Seoul, Korea; Department of Pediatrics,
University of Virginia, Charlottesville, Virginia, USA. Chronic unilateral
ureteral obstruction (UUO) in early development results in profound
vasoconstriction and arrested growth of the ipsilateral kidney that is
associated with marked activation of the renin-angiotensin system. To
investigate the response of the AT1 and AT2 subtypes of the angiotensin
II (Ang II) receptors to this process, 82 Sprague-Dawley rats underwent
UUO or sham-operation (S) in the first 48 hours of life and were studied
1 to 28 days later. Renal messenger RNA (mRNA) was quantified by
Northern and dot-blot hybridization with cDNA probes for renin, AT1
and AT2 receptor. In addition, AT1 and AT2 receptor binding and
distribution were determined by radioligand binding autoradiography at 1
and 28 days after operation. In S animals, renal renin mRNA decreased
from 1 to 28 days, whereas UUO resulted in a sustained ipsilateral
increase of renal renin mRNA from 14 to 28 days. In S rats, AT1 mRNA
increased from 1 to 14 days after which it decreased. Following ipsilateral
UUO, AT1 mRNA was suppressed by 30% at 1 day, but had increased
50% more than S at 28 days. AT2 receptor mRNA fell rapidly in S kidneys
from 1 to 3 days of age, after which levels were not different. Compared
to S, AT1 and AT2 receptor binding was decreased by ipsilateral UUO at
1 day while AT1 binding was increased at 28 days. AT1 and AT2 binding
was not affected by contralateral UUO. In summary, ipsilateral UUO
decreased AT1 and AT2 receptor mRNA and binding at 1 day, but
increased AT1 mRNA and binding at 28 days when renin expression was
also increased. We conclude that dysregulation of Ang II receptors may
contribute to the vasoconstriction and interstitial fibrosis of the neonatal
kidney to prolonged UUO.© 1998 by the International Society of Nephrology
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Down-regulation of aquaporin-2 water channel expression in kidney
inner medulla of hypercalcemic rats. J.H. Earm, J.S. Han, and S. Nielsen,
Department of Internal Medicine, Chungbuk National University, Cheongju,
Korea and Seoul National University, Seoul, Korea; Department of Cell
Biology, Institute of Anatomy, University of Aarhus, Aarhus, Denmark.
Polyuria and a urinary concentration defect are frequently associated with
hypercalcemia. Aquaporin-2 (AQP2) is a vasopressin-regulated water
channel, and is known to be associated with a range of congenital and
acquired nephrogenic diabetes insipidus. We examined the effect of
hypercalcemia on the expression of AQP2 in rat kidney inner medulla.
The rats were fed with a rat chow containing 4.25 mg dihydrotachysterol
(DHT) per kg rat chow for 7 days to induce hypercalcemia. Membrane
fractions were prepared from inner medulla. The kidneys from additional
rats were fixed for immunocytochemistry. Immunoblotting and densitom-
etry revealed a decrease in AQP2 expression to 45.7 6 6.8% of controls
(N 5 11 for hypercalcemia, N 5 9 for controls, P , 0.001). Urine
production increased in parallel, from 11.3 6 1.4 to a maximum of 25.3 6
1.9 ml/day (P , 0.01), and urine osmolality decreased from 2007 6 186
mOsm/kg z H2O to 925 6 103 mOsm/kg z H2O (P , 0.01). Immunocyto-
chemistry confirmed decreased AQP2 labeling in principal cells of collect-
ing duct. AQP2 labeling was predominantly observed in cytoplasm,
although there was mild labeling in apical plasma membrane in sections
from the other hypercalcemic rat. In summary, the results of this study
demonstrate that hypercalcemia results in a decrease in AQP2 expression
in inner medulla of rat kidney. In conjunction with reports of reduced
AQP2 expression after lithium treatment, potassium deficient diet and
bilateral ureteral obstruction, these results suggest that a decrease in
AQP2 expression may be a common feature of various polyuric states.
Differential effect of t-butylhydroperoxide on phosphate transport and
irreversible cell injury in primary culture of rabbit renal proximal tubule
cells. Kwon Moo Park, Sun Hee Go and Yong Keun Kim, Department of
Physiology, College of Medicine, Pusan National University, Pusan, Korea.
Underlying mechanism of oxidant-induced membrane transport function
remains to be defined. Whether physical cell injury is a cause of alterations
in membrane transport function remains unclear. The present study was
undertaken to determine whether oxidant-induced impairment of mem-
brane transport function results from irreversible cell injury and lipid
degradation. Membrane transport function and irreversible cell injury
were estimated by measuring phosphate uptake and Trypan blue exclu-
sion, respectively. Lipid degradation was determined by arachidonic acid
release. t-Butylhydroperoxide (t-BHP) inhibited phosphate uptake in a
dose-dependent manner, which was significant at 0.025 mM. Similarly, the
oxidant caused a significant increase in arachidonic acid release at 0.01
mM. However, the effective concentration for irreversible cell injury was
approximately 20-fold higher (0.5 mM) than that for inhibition of phos-
phate uptake. The arachidonic acid release induced by t-BHP was
prevented by PLA2 inhibitor, mepacrine. However, the reduced phosphate
uptake by t-BHP was not altered by the inhibitor. These results indicate
that the underlying mechanism of oxidant-induced inhibition of phosphate
uptake is different from that of irreversible cell injury and is not associated
with PLA2 activation.
Effects of oxygen radical scavengers and antioxidant on renal function
in a rabbit model of ischemic acute renal failure. S.Y. Kim, H.J. Yoo, C.H.
Kim, and Y.K. Kim, Departments of Pediatrics and Physiology, College of
Medicine, Pusan National University, Pusan, Korea. Several in vivo and in
vitro studies have demonstrated generation of reactive oxygen species
(ROS) during ischemia/reperfusion in the kidney. However, whether ROS
play a critical role in the pathogenesis of ischemic acute renal failure
(IARF) remains controversial. The present study was undertaken to
examine whether: (1) IARF is affected by ROS scavengers or antioxidant;
and (2) lipid peroxidation plays a role in mediating ischemic acute renal
failure. Ischemia was induced by occlusion of both renal arteries for 60
minutes in rabbits. Renal function was measured for 2 days before (basal
period) and after ischemia. Catalase (8 mg/kg) and allopurinol (40 mg/kg)
were administrated 8 minutes before clamping and 8 minutes before
reperfusion, and sodium benzoate (150 mg/kg) was given 30 minutes
before clamping. Ischemia caused a significant reduction in GFR and
increase in serum creatinine concentration and fractional Na excretion
when compared with the basal values. Pretreatment of combination ROS
scavengers exerted significant protective effects against ischemic acute
renal failure. p-Aminohippurate uptake by renal cortical slices and
Na-K-ATPase activity in microsomal fraction were inhibited in ischemic
kidneys compared with nonischemic kidneys, which were significantly
prevented by pretreatment of ROS scavengers. In contrast, a potent
antioxidant DPPD which was given 24 hours before the induction of
ischemia did not improve postischemic renal function. Lipid peroxidation
in kidney tissues was not increased by ischemia, and pretreatment of
DPPD but not ROS scavengers decreased lipid peroxidation in both
nonischemic and ischemic kidneys. Hypoxia/reoxygenation injury in renal
cortical slices was not prevented by ROS scavengers (catalase, dimethyl-
urea and thiourea) and DPPD. These results indicate that postischemic
tubular dysfunction is not apparently associated with lipid peroxidation in
rabbits, suggesting that in vivo beneficial effect of ROS scavengers may not
be due to antioxidative action.
Changes of cyclins and cyclin-dependent kinases (CDK) during renal
tubular regeneration after ischemic injury. W. Kim, S.K. Park, S.K. Kang,
M.J. Kang, and G.Y. Koh, Department of Internal Medicine and Physiology,
Chonbuk National University Medical School, Chonju, Korea. The kidney
has a remarkable capacity for restoring its structure and function after
ischemic or toxic acute renal failure. Proliferation of renal tubules after
acute injury is a reactive process of renal regeneration for recovery of
renal function. Molecular and cellular mechanisms of re-entrance of renal
cells into the cell cycle after injury remain largely unknown. We have
measured correlation among the extent of proliferative activity and
expression of cyclins and CDKs, and activity of each CDK during
regeneration period in outer medullae of kidneys after ischemic injury in
rat. The ratio of proliferating cell nuclear antigen (PCNA) positively
immunostained nuclei to total nuclei per each section of the outer medulla
of kidney indicated proliferative index (PI) for this study. PI in control
period was 0.1%. The PI was increased at day 1 (13.4%), remained at a
plateau at days 3 and 5 (30.5% and 32.3%), and decreased at day 7 and day
14 (17.3% and 12.2%) after ischemic injury. Proliferative activity was
readily detectable in renal tubules, but was hardly detectable in glomeruli
or blood vessels. As the PI increased, the mRNA and protein levels of
cyclins (D1, D3, A, and B), the protein levels of CDK4 and CDK2, and the
activities of CDKs (CDK4, CDK2 and cdc2) increased in outer medullae
of kidneys after ischemic injury. These findings suggest that the temporal
induction of proliferative activity in outer medullary tubules were closely
linked with the cyclin/CDK system for regeneration of kidney after
ischemic injury.
Effect of cyclosporine A on plasma and urine endothelin-1 levels in
steroid-dependent minimal change nephrotic syndrome. J.W. Kim and
P.-K. Kim, Department of Pediatrics, The Institute of Kidney Disease, Yonsei
University College of Medicine, Seoul, Korea. Purpose: Cyclosporine A, as
an immunosuppressive agent, has been widely used with the purpose of
inducing remission of steroid-resistant and -dependent nephrotic syn-
drome. But nephrotoxicity, noted in 25% of cyclosporine A therapy, has
been the main problem, possibly leading to permanent renal damage. But
the precise pathophysiologic mechanism of nephrotoxicity has not been
clearly known. Recently, endothelin-1, produced in the endothelial cells of
blood vessels and known to be a potent vasoconstrictor, has been
associated with nephrotoxicity of cyclosporine A. Thus we assayed the
levels of endothelin-1 in blood and urine to determine the changes of
endothelin-1 concentration after treatment with cyclosporine A. Patients
and methods: Nine patients who were less than 15 years of age and were
diagnosed as steroid-dependent minimal change nephrotic syndrome from
April 1996 to December 1996 were included in this study. Assay of
endothelin-1 levels was done in blood and urine before and after 3 months
of cyclosporine A treatment. The human endothelin-1 kit (R & D system,
Minneapolis, MN; USA) was used in the procedure. Results: Nine
patients were included in the study. The mean age of children was 8.3 6
4.6 years. There was no statistically significant difference in the plasma
levels of endothelin-1 before and after cyclosporine A treatment (3.22 6
0.39 pg/ml vs. 3.84 6 1.52 pg/ml, before and after cyclosporine A
treatment, respectively, P 5 0.32). There was also no statistically signifi-
cant difference in the urine levels of endothelin-1 before and after
cyclosporine A treatment (21.8 6 5.8 pg/ml vs. 20.3 6 3.1 pg/ml, before
and after cyclosporine A treatment, respectively, P 5 0.43). Conclusions:
No significant changes of endothelin-1 levels in plasma and urine were
found. Further studies are needed with longer durations of cyclosporine A
treatment.
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The effect of albumin on the diuretic action of furosemide in nephrotic
syndrome. J.H. Earm, D.H. Kim, E.S. Jeon, W.S. Huh, J.S. Han, S. Kim, J.S.
Lee, I.J. Jang, and S.G. Shin, Department of Internal Medicine, Chungbuk
National University, Cheongju, Department of Internal Medicine and Phar-
macology, Seoul National University, Seoul, Korea. Although albumin is
frequently combined with furosemide in treating edema in nephrotic
syndrome patients, there are some controversies concerning the useful-
ness of albumin. Albumin may increase diuresis by increasing effective
circulating volume and amount of furosemide in the tubular secretion site.
On the other hand, it may decrease diuresis by decreasing active free
furosemide concentration at the site of action, or ascending limb of loop
of Henle. We studied the effect of coadministration of albumin and
furosemide in 6 patients with nephrotic syndrome. We administered
furosemide 160 mg intravenously for 1 hour with 100 ml of 20% albumin
or 5% dextrose in water by random cross-over design. We collected urine
for 24 hours to get the pharmacodynamic parameters such as urine sodium
and chloride excretion amount and urine volume. We also measured urine
and plasma furosemide concentrations by HPLC. The results were as
follows.
With albumin With D/W
24 HU volume ml/kg 42.5 6 27.5 33.6 6 17.2
24 HU Na1 excretion mmol/kg 4.23 6 3.05 3.43 6 1.52
24 HU Cl2 excretion mmol/kg 4.52 6 2.24 4.31 6 1.33
Total AUC mg/ml z hr 36.0 6 15.0 28.3 6 12.4
Plasma clearance ml/min/kg 1.48 6 1.08 1.71 6 0.88
Volume of distribution liter/kg 0.10 6 0.02 0.13 6 0.04
Elimination half-life hr 1.51 6 0.58 1.40 6 0.66
Urine furosemide excretion % 42.9 6 23.1 43.6 6 0.18
Mean 6 SD, statistically not significant. As coadministration of furosemide
and albumin did not show any advantage phamacodynamically and
pharmacokinetically compared to administration of furosemide only, we
concluded that combining with albumin may not be recommended in the
treatment of edema in nephrotic syndrome patients.
Respiratory burst activities of neutrophils by a flow cytometry in
patients with steroid-responsive nephrotic syndrome. J.H. Cho, T.H. Um,
and C.G. Lee, Department of Pediatrics and Department of Clinical
Pathology, Seoul Paik Hospital, College of Medicine, Inje University, Seoul,
Korea. We attempted to prove that respiratory burst activities of neutro-
phils would decrease in patients with steroid-responsive nephrotic syn-
drome, which seemed to be a pathogenetic factor for the infection. The
subjects were comprised of 11 patients with steroid-responsive nephrotic
syndrome, 8 were in relapse, and 6 were in remission, respectively (3 of
them were tested 2 times in relapse and remission). The controls were 11
healthy medical students. Respiratory burst activities of neutrophils were
measured by flow cytometry, which detected the amount of autofluores-
cence emitted by neutrophils treated with DCF-DA. In this study,
respiratory burst activity of neutrophil was defined as a ratio of MFC in
the stimulated PMA and in the rest (MFC in PMA/MFC in rest). Data
were analyzed with Median test and Wilcoxon signed rank test using SAS
6.04. The results were as follows.
Control
(N 5 11)
Mean 6 SD
T-NS
(N 5 11)
Mean 6 SD
RL-NS
(N 5 8)
Mean 6 SD
RM-NS
(N 5 6)
Mean 6 SD
H-Chol
(N 5 10)
Mean 6 SD
Rest 61.8 6 65.6 85.7 6 80.6 98.7 6 92.5 46.7 6 6.8 111.8 6 88.9
PMA 278.6 6 166.7 259.2 6 141.1 245.0 6 160.9 239.1 6 102.0 245.6 6 148.0
RBA 5.0 6 2.1 4.0 6 2.5 3.1 6 2.4 5.0 6 1.7 2.8 6 2.2
Abbreviations are: H-Chol, hypercholesterolemia; T-NS, total number
of SRNS; RL-NS, relapsed NS; RM-NS, remitted NS; RBA, respiratory
burst activity.
There was no significant difference in RBA between 4.0 6 2.5 of patients
with nephrotic syndrome and 5.0 6 2.1 of controls (P . 0.05). Among
patients with nephrotic syndrome, a significant difference in RBA was
found between 3.1 6 2.4 in relapse and 5.0 6 1.7 in remission (P , 0.05).
There was a significant difference between RBT of hypercholesterolemia
group 2.8 6 2.2 and RBA of control group 5.0 6 2.1 (P , 0.05). In
conclusion, hypercholesterolemia may reduce respiratory burst activities
of neutrophils and be associated with the risk of infection in nephrotic
syndrome.
Altered expression of vascular nitric oxide synthase (NOS) and guan-
ylate cyclase isozymes in 2-kidney, 1-clip and DOCA salt hypertension.
K.C. Choi, I.K. Kim, D.K. Kang, M.R. Ahn, S.W. Kim, N.H. Kim, J. Lee, and
Y.J. Kang, Departments of Internal Medicine and Physiology, Chonnam
University Medical School, Kwangju, Korea. Although it has been widely
accepted that hypertension is associated with vascular endothelial dysfunc-
tion, whether and how the NOS isoforms are affected by disease states
associated with impaired production of nitric oxide (NO) such as hyper-
tension have not been examined. Nor has it been examined whether the
two isoforms of guanylate cyclases are affected differentially or in parallel.
The present study was aimed at exploring if and how the vascular
expression of NOS protein isoforms and accumulation of cGMP are
affected in hypertension. Two-kidney, one-clip (2K1C) and deoxycortico-
sterone acetate (DOCA)-salt hypertension were made in rats. Their
vascular expression of different isoforms of NOS and formation of cGMP
in responses to SNP and ANP were examined. Arterial pressure was
significantly higher in 2K1C and DOCA-salt rats compared with their
corresponding control rats. In 2K1C hypertension, the vascular cGMP
response of the cytosolic fraction to SNP was accentuated, whereas that to
ANP of the membrane fraction was not altered. On the contrary, the
cGMP formation in response to SNP was decreased, whereas that in
response to ANP was increased in DOCA-salt hypertension. The bNOS as
well as ecNOS protein isoforms were decreased in both 2K1C and
DOCA-salt hypertension. These findings are consistent with the hypoth-
esis that DOCA-salt hypertension results from a decreased activity of the
vascular NO/cGMP system. 2K1C hypertension may be complicated by a
decrease of NOS activity and ensuing development of supersensitivity to
exogenous NO donors.
Analysis of the changes of TGF-b mRNA in cortex and medulla by
semiquantitative RT-PCR in the early stage of anti-glomerular basement
membrane disease in the rabbit. R.W. Chun, J.R. Koo, H.J. Kim, K.H. Kim,
D.W. Chae, J.W. Noh, U.H. Lee, I.S. Han, M.H. Park, Department of
Internal Medicine, College of Medicine, Hallym University, and Department
of Pathology, College of Medicine, Hanyang University, Seoul, and Depart-
ment of Life Science, College of Natural Science, Ulsan University, Ulsan,
Korea. Transforming growth factor-b (TGF-b) has been regarded as the
most important cytokine in renal fibrosis after renal injury. Coimbra et al
(1989) and Border et al (1992) reported the importance of TGF-b in
fibrosis in the rabbit model CN by anti-GBM Ab and anti-u1 antibody each
induced glomerulonephritis. These studies were confined to only the
cortex and/or glomeruli. The authors also observed severe interstitial
fibrosis in the medulla in the rabbit model CN by anti-GBM Ab, and so
detected the TGF-b mRNA expression by semiquantitative RT-PCR to
observe the changes of TGF-b mRNA in medulla and cortex. They also
wanted to see the effect of removal of blood component from the tissue.
TGF-b mRNA was not expressed at all in the cortex, but was highly
expressed in the medulla of control rabbits. In rabbits of day 1, the
expression of TGF-b mRNA in medulla and cortex were not different
from that of control. The TGF-b mRNA expression began to weakly
appear in cortex at day 4, and it was more highly expressed on day 4 than
day 1 in the medulla. On day 7, the TGF-b mRNA was more strongly
expressed than day 4 in the cortex, but it was less strongly expressed on day
7 than day 4 in the medulla. There were no differences in patterns of
expression of TGF-b mRNA in between perfused tissues and unperfused
tissues, however, the intensity of expression of TGF-b mRNA was
stronger in perfused tissues than in unperfused tissues. We conclude that
TGF-b should also be related to fibrosis in medulla. Accurate separation
of biopsied tissue into cortex and medulla is needed, especially when we
do RT-PCR using biopsied tissues; removal of the blood component from
tissues may be helpful in getting a better expression of TGF-b mRNA by
RT-PCR.
Histopathologic changes of kidney in pediatric ureteropelvic junction
obstruction. S.E. Lee, S.W. Han, H.J. Chung, S.K. Choi, M.J. Kim, J.S. Lee,
and B.K. Kim, Department of Urology, Pathology, Radiology, Pediatrics,
Yonsei University College of Medicine, Seoul, Korea. A kidney in the
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growing state and the possibility of spontaneous improvement are char-
acteristics of the pediatric ureteropelvic junction obstruction (UPJO) that
make the treatment of this disease difficult. We have tried to determine
the histopathologic changes of the kidneys with UPJO relating to age,
differential renal function and urinary tract infection (UTI). The total
number of patients was 38 (40 kidneys). The age at surgery was under 3
months in 9 cases (9 kidneys), 3 to 12 months in 10 cases (10 kidneys), and
1 to 18 years in 20 cases (21 kidneys). Needle biopsies from 3 different
sites at the lower pole of the kidney were taken. The tissue was blindly
observed for the presence of irreversible change (arteriolar thickening,
glomerular sclerosis, interstitial fibrosis and periglomerular fibrosis) and
reversible change (inflammatory cell infiltration) by light microscopy.
Each pathologic finding was graded as I, II or III, and each grade was
given a numerical value. Statistical analysis was done with ANOVA. There
were no statistically significant differences in all 5 pathologic findings
regardless of patient age. Five cases (5 kidneys) with previous percutane-
ous nephrostomy (PCN) were not included in any group for analysis due
to possible histologic changes of the renal parenchyma. Inflammatory cell
infiltration, arteriolar thickening, glomerulosclerosis and periglomerular
fibrosis were statistically significant in patients with previous or present
UTI (14 kidneys) compared to the patients without UTI (26 kidneys). The
patients with a mean differential renal function less than 30% (7 kidneys)
as measured by DTPA or DMSA renal scan showed statistically significant
changes in all of the 5 histopathologic findings compared to the patients
with differential renal function greater than 30% (27 kidneys). Four cases
with bilateral UPJO (6 kidneys) were excluded from comparing the
differential renal function, and 5 kidneys with previous PCN had statisti-
cally significant pathologic change of glomerulosclerosis compared to the
others. In conclusion, although we did not determine whether pediatric
UPJO affects renal growth, it is probable that statistically significant
irreversible histopathologic changes do not occur according to age.
Considering histopathologic findings only, differential renal function and
UTI should be key factors in deciding the management of pediatric UPJO.
In addition, PCN seems to induce significant histopathologic changes of
the kidney.
The effect of mutated Wilm’s tumor 1 on the expression of PDGF-A.
H.Z. Hwang, S.J. Kim, S.J. Kang, K.W. Jeon, E.H. Bang, M.Y. Oh, E.S.
Hwang, S.H. Ko, D.K. Jin. Samsung Biomedical Research Center, Ewha
Woman’s University, College of Medicine, Seoul, Korea. Wilm’s tumor 1
(WT1) is a transcriptional factor that influences cytokines such as platelet-
derived growth factor (PDGF), transforming growth factor (TGF) and
insulin-like growth factor (IGF). Last year, we reported a Denys-Drash
syndrome case with mutation at WT1 gene. This year, we demonstrate that
the putative mutation is responsible for the renal damage of the patient.
To investigate the alteration of the mutant WT1, site-directed mutagenesis
was used to construct the expression vector carrying the mutant WT1
cDNA that was identical with the clinical case. Through the stable
transfection assay into embryonic kidney-derived 293 cells, elevated levels
of PDGF-A mRNA were detected in all the mutant transfectants in
RNase protection assay. This results suggested that mutant WT1 gene
products could not repress the transcription of PDGF-A as normally.
These consequences indicate that the mutation which the patient have is
responsible for the up-regulation of PDGF-A and is causally related to the
patient’s features.
Lymphocyte analysis in tubulointerstitium of IGA nephritis and He-
noch-Scho¨nlein purpura nephritis. S.W. Hong, and M.K. Namgoong,
Department of Pathology and Department of Pediatrics, Yonsei University,
Wonju College of Medicine, Wonju, Korea. The type of infiltrating lympho-
cytes in the interstitium of many renal diseases is the T lymphocyte. We
investigated this type of lymphocyte in the tubule and in the interstitium
of IgA nephritis (IgAN) and Henoch-Scho¨nlein purpura nephritis
(HSPN). Twelve cases were selected in IgAN and 9 cases in HSPN. The
renal tissues were stained with UCHL-1 (a marker of T lymphocyte) and
L26 (a marker of B lymphocyte) antibodies. UCHL-1 and L26 positive
cells both infiltrated interstitium in IgAN and HSPN. The infiltration of
UCHL-1 positive cell was more prominent. However, the proportion of
L26 positive cells infiltration increased with severity of the lymphocyte
infiltration in tubulointerstitium. Tubulitis, whether or not it also incor-
porated interstitial nephritis, was observed all cases with HSPN and in 6
out of 12 cases with IgAN. The predominant cell type of infiltrating tubule
was UCHL-1 positive. We conclude that B lymphocytes might play a role
in interstitial lesion in the late stage of IgAN and HSPN. T lymphocytes
also appear to have a greater role in tubulitis with HSPN rather than
IgAN.
Increased expression of TGF-b in CD41 T-lymphocytes stimulated
with mitogen from patients with IgA nephropathy. C.G. Lee, J.H. Cho, J.S.
Kim, Y.B. Chung, S.H. Noh, H.I. Koh, Department of Pediatrics, Laboratory
of Molecular Biology, Department of Internal Medicine, Inje University Seoul
Paik Hospital, Seoul, Korea. We attempted to examine the TGF-b mRNA
expression by mitogen-activated CD41 T-cells from patients with IgAN,
and correlated the levels of TGF-b mRNA expression with clinical
findings to determine its pathogenetic role in IgAN. Subjects were 38
patients with IgAN (children 13, adults 25), and normal controls were 12
healthy medical students. Serum IgA, Cr, CCr and proteinuria per day
were measured simultaneously in all subjects. Severity of glomeruloscle-
rosis in the biopsy material was indicated by percentage of global and
segmental sclerosis over total number of glomeruli examined. The expres-
sions of TGF-b of CD41 cells stimulated with mitogen, PMA and PHA,
were measured as follows: CD41 cells were isolated using Dynabeads
from PBMC seperated by Hypaque-Ficoll density gradient centrifugation.
Isolated CD41 cells adjusted to a final concentration of 1 3 106/ml were
incubated with PHA and PMA. mRNA were prepared with a Pharmacia
Quick mRNA Purification kit. Then, RT-PCR were performed to detect
gene expression of TGF-b and housekeeping genes, b-actin and GAPDH.
33P incorporated into the PCR products of respective cytokines were
counted by liquid scintillation. TGF-b mRNA expressions were denoted
as a ratio calculated from the cpm of amplified cytokine gene product over
the cpm of amplified b-actin PCR product (T/A). The levels of the TGF-b
gene expression between the subjects and controls and the comparison of
the TGF-b gene expression between groups of IgA nephritic patients were
analyzed using the Student’s t-test and the Wilcoxon rank sum test. CD41
cells from patients with IgAN expressed a higher level of TGF-b mRNA
than that of healthy controls (TGF-b/actin ratio 16.3 1 12.9 vs. 8.6 1 7.9,
P 5 0.019). Among patients with IgAN, there was no significant difference
between the high sIgA group (.300 mg/dl, N 5 14) and normal sIgA
group (,300 mg/dl, N 5 19), 15.4 1 13.4 vs. 14.7 1 11.9 (P . 0.05). There
were no significant differences between renal failure group (N 5 10) and
normal renal function group (N 5 28), between mild (,1 g/day), moderate
(1–4 g/day) and massive (.4 g/day) proteinuria groups, or between mild
(,10%), moderate (10–50%) and severe (.50%) glomerulosclerosis
groups. In conclusion, there is hyperactivity and a possible increased
TGF-b gene expression in circulating CD41 cells. However, we could not
find any explanations for increased TGF-b gene expression in CD41 cells
to be related to pathogenetic roles in IgAN.
Serum factors in nephrotic syndrome. C.G. Ihm, J.K. Park, S.P. Hong,
T.W. Lee, and M.J. Kim, Department of Internal Medicine, College of
Medicine, KyungHee University, Seoul, Korea. To investigate serum factors
affecting nephrotic syndrome, we examined production of monocyte
chemotactic peptide (MCP)-1, tumor necrosis factor a (TNFa) and
fibronectin (FN) in serum or by blood mononuclear cells (PBMC) from
nephrotic patients with minimal change disease (MCD), membranous
nephropathy (MN) or diabetic nephropathy (DN) by using ELISA. Serum
TNF-a levels were higher in patients with MN (P , 0.05). PBMC from
patients with DN (P , 0.05) or MN (P , 0.1) produced more MCP-1.
Serum FN levels were higher in patients with MN (P , 0.05). When
mesangial cells (MC) were cultured with PBMC supernatants, TNF-a
levels in PBMC supernatants correlated with production of MCP-1 or FN
by MC (P , 0.05). However, PBMC supernatants from patients did not
increase thymidine incorporation and production of MCP-1 or fibronectin
by MC. Serum from MCD or DN reduced thymidine incorporation by
MC. In conclusion, our study proposes that MCP-1 may have a role in
monocyte accumulation in DN. Increase in serum TNF-a or fibronectin
levels may be related to the pathogenesis or progression of MN.
Effect of peripheral blood mononuclear cells isolated from children
with minimal change nephrotic syndrome to rat glomerular epithelial
cells. C.W. Ko, J.H. Koo, Department of Pediatrics, Kyungpook National
University School of Medicine, Taegu, S. Korea. Minimal change nephrotic
syndrome (MCNS) is one of the most common primary nephrotic
syndrome in children. It is well known that T-cell dysfunction may play an
important role in its pathogenesis and glomerular epithelial cell (GEC)
may be a target cell in this disease. GECs synthesize glomerular basement
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membrane heparan sulfate proteoglycan (GBM HSPG), which is one of
major components of GBM anionic sites and is mainly distributed along
lamina rara externa of GBM. It plays an important role in GBM
permeability. To determine the effect of peripheral blood mononuclear
cells (PBMCs) isolated from children with MCNS to rat GECs, 10,000
PBMCs from 3 patients (5-, 10- and 11-year-old boys) or 3 healthy controls
were added into each well of 12 well plates containing confluent GECs.
GECs were observed daily by phase-contrast microscope. On the seventh
day after adding PBMCs, cellular detachment of GECs was prominent in
wells where PBMCs were isolated from children with MCNS compared to
controls. At 3200 magnification, 2 to 3 patches of GECs detachment per
field were observed in contrast to no GECs detachment in controls. It can
be said that PBMCs isolated from children with MCNS are toxic to rat
GECs. PBMCs may play a major role in the pathogenesis of MCNS.
ICAM-1 and osteopontin gene expression by proinflammatory cyto-
kines in cultured rat mesangial cells. S.K. Lee, W.S. Yang, S.K. Park, and
J.S. Park, Department of Internal Medicine, University of Ulsan, Seoul,
Korea. In order for a monocyte to accumulate at tissue sites, a release of
monocyte-specific chemotactic factors and the expression of adhesion
molecules on the tissue are needed. Intercellular adhesion molecule-1
(ICAM-1) appears to play a key role in glomerular immune injury, and
osteopontin is known as a possible chemotactic factor for monocytes, and
is produced by mainly cortical tubular epithelium in kidney. To examine
whether osteopontin or ICAM-1 mRNA is induced in cultured rat
mesangial cells by various stimuli including interleukin-1b (IL-1b, 1
ng/ml), lipopolysaccharide (LPS, 1 mg/ml), tumor necrosis factor-a
(TNF-a, 5 ng/ml), fetal calf serum (FCS, 20%), we performed Northern
blot assays as follows: After mesangial cells were cultured for 48 hours in
serum-free RPMI media, each stimulant was added and RNA was
extracted before and 3, 6, 24, 48 hours after the stimulation. GAPDH
mRNA was used to correct for variation in RNA loading and transfer
efficiency. IL-1b, LPS, TNF-a, but not FCS increased ICAM-1 gene
expression around 1.5- to 2-fold. IL-1b-induced ICAM-1 mRNA was
increased maximally at 3 hours around 2.2-folds and remained elevated for
24 hours. On the other hand, FCS increased osteopontin gene expression
around 2-folds over 48 hour period, while IL-1b, LPS, TNF-a had little
effect on its expression, which was clearly different to that we have
previously reported for MCP-1. These data demonstrate that the mesan-
gial cell itself could be the source of ICAM-1, especially osteopontin, and
responses to various stimuli for the induction of ICAM-1 or osteopontin
mRNA were quite different.
Angiotensin converting enzyme inhibition decreases growth factors
expression in the neonatal rat kidney. K.H. Yoo and R.L. Chevalier,
Department of Pediatrics, Korea University, Seoul, Korea, and Department of
Pediatrics, University of Virginia, Richmond, Virginia, USA. The renin-
angiotensin system plays an important role in renal growth and develop-
ment: exposure of the fetus or neonate to angiotensin converting enzyme
(ACE) inhibitors increases mortality, growth retardation, and results in
renal anomalies. This study was designed to investigate the effects of ACE
inhibition in the neonatal rat on the expression of genes known to
modulate renal cellular proliferation, cell interactions, and extracellular
matrix. Newborn rat pups were treated with enalapril (30 mg/kg/day) or
vehicle for 14 days, and kidneys were removed for determination of
mRNA for transforming growth factor-beta1 (TGF-b1), preproepidermal
growth factor (EGF), clusterin, and renin. Enalapril treatment resulted in
a 40% mortality by day 14, as well as reduced body and kidney weight (P ,
0.05 vs. vehicle group). Enalapril decreased renal TGF-b1 and EGF
mRNA expression, and increased renal clusterin and renin expression
(P , 0.05). These results indicate that ACE inhibition in the developing
kidney reduces the renal expression of critical growth factors, which may
account for renal growth impairment. Clusterin expression may increase
either due to blockade of tonic angiotensin-mediated inhibition, or as an
adaptive response to renal ischemia.
Anti-neutrophil cytoplasmic antibodies (ANCA) in lupus nephritis
(LN). I.J. Chin, C.S. Yim, J.E. Oh, Y.S. Park, C. Ahn, J.S. Han, S. Kim, and
J.S. Lee, Department of Internal Medicine, Division of Nephrology, Seoul
National University Hospital, Seoul, Korea. To examine the prevalence and
clinical association of ANCA and anti-MPO antibodies in patients with
LN, we examined for ANCA by indirect immunofluorescence. Anti-MPO
antibody was determined by enzyme-linked immunosorbent assay
(ELISA). These serologic results were correlated with clinicopathologic
manifestations and clinical course. ANCA were found in 19 of 51 (37.3%)
LN patients; 3 (5.9%) had cANCA and 16 (31.4) had pANCA. ANCA
were not seen in 8 SLE patients without nephritis and 30 normal controls.
ANCA indicated the presence of lupus nephritis (19/51 vs. 0/8 cases, P ,
0.05), and the incidence of diffuse proliferative nephritis (WHO class IV)
was higher in patients with ANCA than in patients without ANCA (17/19
vs. 21/32 cases, P , 0.05). During 37.2 months (median; range, 0.2 to 178
months) of the follow-up period, there was no difference in mortality
according to ANCA positivity (2/19 vs. 1/32 cases, P , 0.05). The patients
with pANCA had more severe deterioration of renal function [(the last
creatinine/initial creatinine) $2.0] than that of patients without ANCA
(3/14 vs. 0/32 cases, P , 0.05). Anti-MPO antibody was present in one case
among patients with cANCA and in six among the patients with pANCA.
We conclude that: (a) The detection of ANCA strongly indicates the
presence of severe LN and poorer renal prognosis in LN patients. (b) We
confirm that MPO was a antigen of ANCA in LN patients.
Effect of lovastatin on glomerular TGF-b1 mRNA expression and
progression of diabetic nephropathy in streptozotocin-induced diabetic
rats. H.B. Lee, S.I. Kim, and D.C. Han, Hyonam Kidney Laboratory, Soon
Chun Hyang University, Seoul, Korea. We have previously shown that
inhibition of HMG CoA reductase by lovastatin ameliorates albuminuria
and glomerulosclerosis in 5/6 nephrectomized rats (Nephrol Dial Trans-
plant 8:1534, 1993) and in streptozotocin (STZ)-induced diabetic unine-
phrectomized rat (Kidney Int 44:1181, 1993), and that in STZ-diabetic rats
lovastatin suppresses glomerular TGF-b1 mRNA expression as examined
by in situ hybridization in 2 days after but not 2 weeks after STZ [Kidney
Int 48 (Suppl 51):S61, 1995]. We extended our observation to longitudinal
study from 4 days to 12 months after induction of diabetes by STZ in rats.
Urine albumin was measured by bromocresol green method. Glomerular
surface area was measured with Image-pro (ver. 1.2; Media Cybernetics,
USA) software program on PAS-stained tissue sections, and glomerular
volume was calculated according to the Weibel and Gomez method.
Glomerular TGF-b1 mRNA was examined by Northern analysis. In
untreated diabetic rats, a fourfold increase in urinary albumin excretion,
50% increase in glomerular volume, and 60% increase in glomerular
TGF-b1 mRNA expression were observed. In lovastatin-treated diabetic
rats all these changes were almost completely abrogated. There was a
tendency for the blood glucose levels to decline in lovastatin-treated rats
beginning 1 month after STZ, but TGF-b1 mRNA remained suppressed
on days 4, 14, and 28 when blood glucose levels were elevated. The results
suggest that the renal protective effect of lovastatin in diabetes may be due
in part to suppression of TGF-b1.
Enalapril suppresses glomerular TGF-b1 mRNA and progression of
diabetic nephropathy in streptozotocin-induced diabetic rats. H.B. Lee,
D.C. Han, S.I. Kim, Hyonam Kidney Laboratory, Soon Chun Hyang
University, Seoul, Korea. Angiotensin converting enzyme (ACE) inhibition
slows the progression of diabetic nephropathy presumably by controlling
intraglomerular hypertension. Cellular and molecular mechanisms of this
renal protective effect of ACE inhibition are not clearly understood,
although evidence from experimental studies suggests that suppression of
the TGF-b/TGF-b receptor system may be involved. We, therefore,
examined the effects of enalapril on the progression of diabetic nephrop-
athy and on the glomerular expression of TGF-b1 mRNA in streptozoto-
cin-induced diabetic rats. Urine albumin was measured by bromocresol
green method. Glomerular surface area was measured with Image-pro
(ver. 1.2; Media Cybernetics, USA) software program on PAS-stained
tissue sections, and glomerular volume was calculated according to the
Weibel and Gomez method. Glomerular TGF-b1 mRNA was examined by
Northern analysis. In untreated diabetic rats, up to a fourfold increase in
urinary albumin excretion, 50% increase in glomerular volume, and 60%
increase in glomerular TGF-b1 mRNA expression were observed. Enala-
pril attenuated all these changes without affecting blood glucose levels.
The results suggest that the renal protective effect of ACE inhibition in
diabetes may be due in part to suppression of TGF-b1.
Effect of immunoglobulin and glucose on transforming growth factor-b
expression by mesangial cell. D.R. Cha, C.G. Ihm, W.Y. Cho and H.G.
Kim, Korea and KyungHee Universities, Department of Internal Medicine,
Seoul, Korea. The precise mechanism for mesangial pathophysiology in
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glomerular diseases remains uncertain. Glomerular mesangial cells syn-
thesize ECM proteins or growth factors such as transforming growth
factor (TGF)-b. Therefore, we examined effect of immunoglobulin (Ig)
and glucose on TGF-b expression by human mesangial cells and its
mechanism by using the RT-PCR method. Treatment with IgA aggregate
increased the TGF-b/GAPDH ratio expressed by mesangial cells, com-
pared to that with media alone (0.55 6 0.08 vs. 0.40 6 0.07, P , 0.05) at
24 hours, but IgG aggregate did not increase it (0.56 6 0.15). There were
no differences of TGF-b/GAPDH ratio between high glucose and normal
glucose at 24 hours. The ratio was not increased by phorbol myristate
acetate at 24 hours, and also was not affected by pre-treatment with
calphostin C, a protein kinase C (PKC) inhibitor. Therefore, the IgA
aggregate can increase TGF-b expression by mesangial cells, which may
not be mediated through PKC. High glucose has no effect on it at 24
hours.
Protein kinase C is involved in glycated low density lipoprotein-induced
TGF-b1 synthesis by mesangial cells. H. Ha, M.R. Yu, and K.H. Kim,
Department of Pharmacology, Yonsei University College of Medicine, Seoul,
Korea. Low density lipoprotein (LDL) and biochemically modified LDL
have been implicated in the pathogenesis of glomerulosclerosis in diabetes
and other forms of glomerular diseases. Glycated LDL, one of the
endogenous advanced glycosylation end-products, is increased in the
serum of diabetes mellitus. Our recent study showed significantly more
fibronectin synthesis by mesangial cells cultured with glycated LDL than
with LDL. The present study was designed to compare the effects of
glycated LDL and LDL on mesangial cell TGF-b1 mRNA expression and
protein synthesis, and to determine if protein kinase C (PKC) is involved
in glycated LDL-induced TGF-b1 synthesis. TGF-b1 is a final common
mediator of glomerular extracellular matrix expansion. It is well known
that PKC is involved in high glucose-induced TGF-b1 synthesis. Mouse
mesangial cells were incubated with varying concentrations of LDL and
glycated LDL for 4 to 48 hours. Both LDL and glycated LDL stimulated
TGF-b1 mRNA expression and protein synthesis, but glycated LDL was
1.5- to 2-fold more potent. Phorbol ester, an activator of PKC, also
stimulated TGF-b1 mRNA expression at 4 and 24 hours. Calphostin C
(100 nM), a PKC inhibitor, inhibited all LDL-, glycated LDL-, and phorbol
ester-induced up-regulation of mesangial cell TGF-b1 mRNA. These data
suggest that glycated LDL is a more potent inducer of mesangial cell
TGF-b1 synthesis than LDL, and that PKC is involved in LDL- and
glycated LDL-induced TGF-b1 synthesis.
Effect of high glucose on monocyte chemotactic peptide-1 expression by
mesangial cell. C.G. Ihm, J.K. Park, S.P. Hong, T.W. Lee, D.R. Cha, and
M.J. Kim, Department of Internal Medicine, College of Medicine, KyungHee
and Korea Universities, Seoul, Korea. It has been reported that the
glomerular infiltration of macrophages is associated with increase in
extracellular matrix in diabetic rats and with diffuse glomerulosclerosis in
patients with diabetic nephropathy. We examined effect of high glucose on
monocyte chemotatic peptide (MCP)-1 expression by human mesangial
cells (MC) and its mechanism by using ELISA and RT-PCR methods. A
50% increase in the MCP-1 production was observed in MC cultured in
high glucose medium (N 5 5, 450 mg/dl) after 24 hours and 48 hours, as
compared to normal glucose (N 5 5, 100 mg/dl) (1,496 6 75 pg/ml vs.
966 6 15 pg/ml after 24 hours; 1,910 6 93 pg/ml vs. 1,250 6 55 pg/ml after
48 hours; P , 0.005). High glucose increased the MCP-1/GAPDH ratio
expressed by mesangial cells, compared to normal glucose at 24 hours
(0.72 6 0.11 vs. 0.24 6 0.01; P , 0.05). The ratio was increased by the
addition of phorbol myristate acetate (100 nM; 0.66 6 0.14; P , 0.05). The
high glucose-induced increase in the ratio was suppressed by pre-treat-
ment with calphostin C (200 nM), a protein kinase C (PKC) inhibitor (P ,
0.05). Therefore, PKC mediates MCP-1 expression by MC, and high
glucose can increase MCP-1 expression through PKC.
Role of advanced glycosylation end products in high glucose-induced
up-regulation of TGF-b1 and fibronectin synthesis by mesangial cells.
H.-B. Lee and H. Ha, Hyonam Kidney Laboratory, Soon Chun Hyang
University, and Department of Pharmacology, Yonsei University College of
Medicine, Seoul, Korea. Advanced glycosylation end-products (AGEs) are
produced by a process involving nonenzymatic modification of tissue
proteins by physiological sugars and they accumulate in tissues as a
function of time and sugar concentration. AGEs have been implicated in
the pathogenesis of diabetic renal and vascular injury. We have recently
shown increased total kidney AGEs, urinary albumin excretion, glomeru-
lar volume, glomerular TGF-b1 mRNA, and type IV collagen and laminin
proteins in the kidneys of steptozotocin-induced diabetic rats. Aminogua-
nidine, an inhibitor of AGE formation and AGE-induced protein cross-
linking, abrogated all changes without correcting hyperglycemia, suggest-
ing an important role for AGEs in the pathogenesis of diabetic
nephropathy. In the present study, we assessed the role of AGEs in high
glucose-induced TGF-b1 and fibronectin synthesis by mesangial cells.
AGEs were measured by ELISA and TGF-b1, and fibronectin proteins by
Western blot analysis. In mesangial cells cultured with high glucose (30
mM) for 2 weeks we observed a 23% increase in AGEs, 60% increase in
TGF-b1 protein, twofold increase in fibronectin protein, and a 50%
increase in fibronectin mRNA above the values in mesangial cells cultured
with control glucose (5.5 mM). Aminoguanidine (5 mM) suppressed all the
high glucose-induced changes without affecting glucose uptake by mesan-
gial cells. These data suggest that high glucose-induced up-regulation of
TGF-b1 and extracellular matrix synthesis by mesangial cells is, in part,
mediated by AGEs.
Angiotensin converting enzyme gene polymorphism in patients with
end-stage renal disease in Korea. S.K. Jo, J.W. Yoon, D.R. Cha, W.Y. Cho,
H.K. Kim, Y.J. Kwon, H.J. Pyo, C.S. Kim, S.E. Park, C.H. Moon, S.Y. Suh,
K.S. Oh, T.S. Chung, H.J. Min, Department of Nephrology, Internal Medi-
cine, Korea University, Sungnam Central Hospital, Seoul Adventist Hospital,
Seoul Red Cross Hospital, Oh Kyung Sik Dialysis Unit, Kyung Dialysis Unit,
Eulji Hospital, Korea. Angiotensin II is known to be a mediator of the
progression of renal disease, and angiotensin converting enzyme (ACE)
inhibitor is widely used to prevent or slow the progression of renal disease.
The ACE gene is located in chromosome 17, and within intron 16 a
polymorphism exists, consisting of the presence or absence of a 287 base
pair fragment (Deletion, Insertion). DD type is reported to be related to
higher levels of angiotensin II and the development of renal disease in
insulin-dependent diabetes mellitus and IgA nephropathy. We evaluated
the relationship between the ACE polymorphism and end-stage renal
disease and cardiovascular disease. The ACE genotype was determined in
122 end-stage renal disease patients and 22 healthy controls by DNA
amplification by PCR from blood leukocytes. A total of 122 patients with
end-stage renal disease (M 5 66, F 5 56; mean age, 54.3 6 14.9; duration
of renal disease, 52.5 6 37.5 months) 47 (39%) showed the DD genotype
and this was significantly higher than control group (2, 10%; p 5 0.01).
Group N
ACE genotype
PII ID DD
CRF 122 31 (25%) 44 (36%) 47 (39%)
Control 22 10 (45%) 10 (45%) 2 (10%) 0.01
Cardiovascular disease
Hypertension 93 23 (25%) 38 (41%) 32 (24%)
Ischemic heart disease 20 6 (30%) 8 (40%) 6 (30%)
Left Ventricular Hypertrophy 67 13 (19%) 29 (42%) 25 (39%)
The above results suggest that ACE polymorphism, especially the DD
genotype, might be an adverse prognostic factor in progressive renal
disease, but there were no relationships between the ACE polymorphism
and cardiovascular disease.
Angiotensin converting enzyme gene polymorphism in diabetic ne-
phropathy in Korea. J.W. Yoon, S.K. Jo, D.R. Cha, W.Y. Cho, H.K. Kim,
Y.J. Kwon, H.J. Pyo, C.S. Kim, S.E. Park, C.H. Moon, S.Y. Suh, K.S. Oh,
T.S. Chung, H.J. Min, Department of Nephrology, Internal Medicine, Korea
University, Sungnam Central Hospital, Seoul Adventist Hospital, Seoul Red
Cross Hospital, Oh Kyung Sik Dialysis unit, Kyung Dialysis Unit, Eulji
Hospital. Diabetic nephropathy is an important cause of end-stage renal
disease in Korea and associated with morbidity and mortality in diabetes
mellitus patients. Plasma and tissue ACE levels are under the control of an
insertion/deletion (I/D) polymorphism of the ACE gene, and this poly-
morphism has shown to be associated with the risk of hypertension,
myocardial ischemia and ventricular hypertrophy. To evaluate the rela-
tionship between ACE polymorphism and prevalence of DM, nephropa-
thy, progression to ESRD, microvascular complications, and ischemic
heart disease or LVH, ACE genotype was determined in 171 diabetes
mellitus patients (64 without nephropathy, 34 with nephropathy, 73
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ESRD) and 47 non-diabetic control by extracted DNA from PBMC (DNA
kit, QIAGEN). DNA amplification was done by PCR and electrophoresed
in 1% agarose gel to detect the genotype of ACE gene. Results were as
follows (1) A total of 218 samples were evaluated and ACE genotypes
were revealed as DD type 70 (32%), ID type 91 (41%), II type 57 (26%),
respectively.
Group Number Age
ACE genotype
DD ID II
DM without
nephropathy
64 55.9 6 12.1 11 (17%) 37 (58%) 16 (25%)
DM with
nephropathy
34 57.6 6 12.2 15 (44%) 12 (35%) 7 (21%)
DM with
ESRD
73 56.3 6 11.6 29 (39%) 27 (37%) 17 (23%)
Control 47 36.2 6 13.7 15 (31%) 15 (32%) 17 (36%)
DD ID II Total
DM with
nephropathy
44 (41%) 39 (26%) 24 (22%) 107
DM without
nephropathy
17 (20%) 42 (50%) 25 (30%) 84
The DD gonotype was higher in nephropathy group than the non-
nephropathy group in DM patients. (P 5 0.0004). Cardiac events included
LVH or ischemic heart disease and were significantly higher in DD
genotype (P 5 0.004). Microvascular complications such as retinopathy
and neuropathy were not significantly related with the ACE gene poly-
morphism (P 5 0.07, 0.15). From the above results, the ACE gene
polymorphism was observed variously and DD genotype was significantly
higher in nephropathy patients. This suggests that the DD genotype might
be involved in the progression of diabetic renal disease.
Angiotensin converting enzyme (ACE) gene polymorphism: Its relation-
ship to the progression of diabetic nephropathy and hypertension. J.S.
Lee, J.S. Jeon, M.S. Park, S.D. Hwang, and H.B. Lee, Department of Internal
Medicine, College of Medicine and Hyonam Kidney Laboratory, Soon Chun
Hyang University, Seoul, Korea. The genes responsible for genetic predis-
position to diabetic nephropathy are not known, but the genes of the
renin-angiotensin systems are plausible candidate genes. To elucidate the
contribution of ACE gene polymorphism to the genesis, progression and
outcomes of various renal disease and hypertension, we typed the alleles
of the ACE gene and compared the frequency of ACE gene I/D
polymorphism among groups of 108 normal controls, 89 patients with
diabetes without nephropathy and 39 patients with nephropathy (albumin-
uria . 300 mg/day or microalbuminuria . 20 mg/min), and 106 patients
with ESRD including 20 diabetics on dialysis. The I/D polymorphism was
analyzed with PCR technique and alleles were visualized on 1.5% agarose
gels after ethidium staining. Allele frequencies in the overall patient
population differed significantly from the normal population (P , 0.05).
Distribution of genotypes was significantly different between diabetic
patients with and without nephropathy (P 5 0.018) and a significant trend
was observed in ACE gene polymorphism among diabetics without
nephropathy, with nephropathy and diabetics on dialysis (P 5 0.004).
Significant difference in genotype distribution was also found between
normal controls and patients with ESRD on dialysis (P 5 0.000). No
significant difference in genotype distribution was found between patients
with and without hypertension (P 5 0.171). We conclude that a significant
association was observed in 4 groups of normal controls (N 5 108) vs.
diabetic patients without (N 5 89) and with nephropathy (N 5 39), and
106 patients with ESRD including 20 diabetics on dialysis. If the associa-
tion between the ACE genotype and various nephropathies are confirmed,
it would be reasonable to target patients with the DD genotype for
antihypertensive therapy, most probably with an ACE inhibitor at an early
stage.
Association between apolipoprotein E polymorphism and diabetic
nephropathy in non-insulin dependent diabetes mellitus. S.J. Kim, C.K.
Lee, S.Y. Lee, C.H. Park, H.Y. Lee, D.S. Han, S.K. Ha, J.H. Kim,
Department of Internal Medicine, Department of Clinical Pathology, Yonsei
University, College of Medicine. Apolipoprotein E (Apo E) has been known
to have an important function for lipoprotein metabolism as a low density
receptor or hepatic apo E receptor. Apo E has three isoforms, «2, «3, and
«4, produced by structural genes. Each individual should show one of six
genotypes, «2/2, «2/3, «2/4, «3/3, «3/4, or «4/4. The Apo «2 allele is known
to be associated with high serum levels of triglycerides and apo «4, high
levels of cholesterol in the general population. Apo E polymorphism was
suggested to be associated with hypertriglyceridemia in diabetes mellitus.
The aim of this study was to analyze the effect of Apo E polymorphism on
diabetic nephropathy in non-insulin dependent diabetes mellitus
(NIDDM). This study was performed on patients with diabetic nephrop-
athy (N 5 34) and diabetic patients without nephropathy (N 5 60). In
diabetic patients, Apo E allele frequency revealed «2/2 3%, «2/3 6%, «3/3
76%, and «3/4 15% in the diabetic nephropathy group, and «2/3 13%, «2/4
2%, «3/3 70%, «3/4 13%, and «4/4 2% in normoalbuminuria group. There
was no significant difference between two groups. Also, there was no
significant difference in the level of total cholesterol, triglycerides, low
density lipoprotein, lipoprotein(a) [Lp(a)] between two groups. Plasma
lipid and lipoprotein levels were no significant difference among the Apo
«2 («2/2, «2/3) and «3/3 groups of diabetic nephropathy and the Apo «2
(«2/3, «2/4) and «3/3 groups of NIDDM without nephropathy. These
results suggest that Apo E polymorphism is not associated with the
diabetic nephropathy in NIDDM patients.
Study on serum lipoprotein(a) concentration and apolipoprotein(a)
phenotype in Ig A nephropathy patients. Y.K. Lee, S.W. Kim, J.H. Shin, Y.J.
Kwon, H.J. Pyo, Department of Internal medicine and Family Medicine,
College of Medicine, Korea University, Seoul, Korea. Lipoprotein(a) [Lp(a)]
is an independent risk factor for atherosclerosis and thrombosis, and may
be modulatory effects on nephrosclerosis. Also, serum Lp(a) concentra-
tion is associated with renal failure, hypoalbuminemia and the apolipopro-
tein(a) [Apo(a)] phenotype. We performed this study to determine
relationship between IgA nephropathy and Lp(a). And we evaluated 99
patients with IgA nephropathy diagnosed by renal biopsy, as the disease
group, and 102 normal subjects, as the control group. We measured serum
Lp(a) concentration, Apo A and Apo B, and determined the Apo(a)
phenotype by the Phast system. (1) In the disease group, (mean age
36.77 6 10.99; M:F 1:0.83) serum creatinine level was 2.62 6 3.83 mg/dl,
and 24-hour urine protein was 2.05 6 2.30 g/day. The serum albumin level
of the disease group (4.10 6 0.72 g/dl) was lower than that of control
group. (4.84 6 0.29 g/dl, P , 0.001). (2) Serum Lp(a) concentration of
disease group was higher than that of control group. (42.62 6 38.17 vs.
15.48 6 15.63 mg/dl, P , 0.001) Serum Lp(a) concentration in patients
who had a serum creatinine below 1.3 mg/dl, 24-hour urine protein below
1 g/day and serum albumin level above 4 g/dl (29 patients) was higher than
control group (P , 0.001). (3) Apo(a) phenotypes of disease group
consisted of mainly the S5 (37.4%), S5S5 (21.2%) and S4S5 (12.1%)
isoforms, and those of the control group were similar. However, the serum
Lp(a) concentration of disease group was higher than that of control
group in each phenotype. (4) In all study subjects, serum Lp(a) concen-
tration was correlated with serum Apo B, albumin, hemoglobin, creati-
nine, total cholesterol and LDL cholesterol level. Apo B and hemoglobin
were significant factors by multivariate analysis. In disease group, serum
Lp(a) concentration was correlated with Apo B, total cholesterol and LDL
cholesterol. Apo B was also significant factor by multivariate analysis. (5)
Serum Apo B concentration in disease group was higher than that of
control group. (111.93 6 36.92 vs. 102.22 6 30.35 mg/dl, P 5 0.046). This
study showed that serum Lp(a) concentration of patients with Ig A
nephropathy was higher than control, and risk factor for Lp(a) was not the
Apo(a) phenotype but Apo B. We suggest that the study to clarify the role
of Apo B and Lp(a) in IgA nephropathy is followed.
Comparison of the urine RBC phase contrast microscopy and immu-
noperoxidase stain in differentiation of renal and nonrenal hematuria.
D.H. Kim, N.J. Kwak, K.S. Shin, D.H. Lee, W.J. Kim, J.H. Earm, Department
of Internal Medicine, Clinical Pathology, and Urology, Chungbuk National
University, College of Medicine, Cheongju, Korea. Differentiation of renal
(RH) and non-renal (NRH) hematuria is important in the diagnosis and
treatment of the patients with hematuria. Although quantitation of urine
protein, urine red blood cell (RBC) morphology by phase contrast
microscopy (PCM), and urine RBC size distribution have been used as the
screening tests for localizing the origin of hematuria, they could not
differentiate the origin exactly. Recently, the urine RBC immunoperoxi-
dase (IPx) staining method using antibody against Tamm-Horsfall protein
was developed, but there was no report on the usefulness of IPx in Korea.
We validated the usefulness of IPx by comparing it with the PCM in the
same patients. Both PCM and IPx were performed in 26 patients with RH
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confirmed by renal biopsy and 23 patients with NRH, confirmed by
radiologic and/or pathologic studies who were admitted to Chungbuk
National University Hospital from January 1996 to December 1996. The
age of RH and NRH group were 36.6 6 15.0 and 56.5 6 22.2 years. The
male to female ratios were 11:15 and 17:6, respectively. A total of 35.7 6
30.4% (range 0–89%) of urine RBC were stained by IPx in RH group and
only 1.6 6 4.4% (range 0–16%) were stained in NRH group (P , 0.001).
Median values were 35% and 0%, respectively. A total of 23.4 6 29.9%
(range 0–88%) of urine RBC by PCM were counted as dysmorphic RBC
in the RH group and 5.7 6 13.6% (range 0–60%) were counted in the
NRH group (P , 0.05). Median values were 10% and 0%, respectively. At
the cut-off value of 20%, the sensitivity and specificity of IPx were 57.7%
and 100%. At the cut-off value of 30%, those of PCM were 30.9% and
95.7%, respectively. When comparing overall test performance by calcu-
lating AUCs of ROC (receiver operating characteristics) curve, IPx was
better than PCM. There was no NRH case which has 20% and more IPx
(1) cells. IPx was better than PCM in localizing the origin of hematuria.
The NRH might be excluded when IPx (1) cells are more than 20% of
total urine RBC.
Use of on-site, direct light microscopic examination on renal biopsy
specimens. J.W. Noh, J.S. Lee, H.R. Kim, J.R. Koo, H.J. Kim, K.H. Kim,
R.W. Chun, D.W. Chae, J.W. Shim, H.T. Kim, I. Yang, M.K. Shin, M.H.
Park, Department of Int. Med., Anatomical Pathology, Clinical Pathology,
Radiology, College of Medicine, Hallym University Anatomical Pathology,
Seoul Red Cross Hospital, Department of Pathology, College of Medicine,
Hanyang University, Seoul, Korea. Recently, preliminary examination of
biopsy specimens using dissecting microscopy to know whether there are
enough glomeruli is being adopted gradually by several pathologists. Still
most of nephrologists do not know this method or how to do it. Moreover,
dissecting microscopy is not a popular equipment and a pathologist can
not always be at the biopsy room. The authors devised a method of on-site
direct examination of biopsy specimens using simple light microscopy to
know whether each has enough glomeruli. This method was used in 36
biopsies in 17 patients and 6 biopsies in 6 rabbits using Tru-cut needles
and gun biopsy needles. This method can be done by a nephrologist, so we
could decide whether another biopsy sample was needed on site of
performing the renal biopsy. Results were as follows: (1) 30 biopsies in 15
among 17 patients were performed using the Tru-cut needle. Glomeruli
were found in 27 but not in 3 among 30 biopsy samples by on-site direct
light microscopic examinations, and the same result was seen again by
regular microscopic examinations. (2) Six biopsies in 2 among 17 patients
were performed using gun biopsy needles (18G). Glomeruli were found in
all 6 biopsy specimens from 2 patients, and the same result was seen again
by regular microscopic examinations. (3) Authors could find glomeruli in
6 biopsy specimens from 6 rabbits, and the same result was seen again by
regular microscopic examinations. (4) Identification of glomeruli through
on-site direct light microscopic examination in the biopsy specimen
acquired by gun biopsy was easier than that in the biopsy specimen
acquired by Tru-cut biopsy. (5) The most appropriate magnification for
the identification of human glomeruli was 3100 and 340 was best for the
identification of rabbit glomeruli. This method can be applied for com-
partmentalization to get small portions of biopsy tissues containing
glomeruli for IF and/or EM study and for quantitative RT-PCR, etc.
Post-biopsy arterio-venous fistula: Echo-Color Doppler evaluation of
its incidence and evolution. J.K. Kwon, T.H. Lee, K.J. Jang, S.B. Park, H.C.
Kim, and C.H. Shon, Department of Internal Medicine, Diagnostic Radiol-
ogy, Keimyung University School of Medicine, Taegu, Korea. The incidence
of arterio-venous fistulas (AVF) after percutaneous renal biopsy has been
reported in 15 to 18% of patients. In most cases, they are clinically silent
and resolve spontaneously, however, some might cause serious problems
such as persistent hematuria, renovascular hypertension, or high output
cardiac failure. Between August 1995 and February 1997, we prospectively
studied 270 consecutive ultrasound-guided percutaneous renal biopsies to
evaluate the frequency of AVF and its natural course. All biopsied
patients were monitored through a routine follow-up Echo-Color Doppler
sonography at post-biopsy 1, 7, 14, and 30 days. Twenty-seven (10%) were
diagnosed to have AVF. There was no statistically significant difference in
the incidence of AVF between native and transplanted kidney biopsies.
Most AVF were small (,1.5 cm) and gross hematuria was seen in 6 cases
(20%). A large hematoma (thickness above 2 cm) was observed in 9 cases
(53%) of 17 native kidneys and there was no hematoma in 10 transplanted
kidneys. This difference was statistically significant (P 5 0.008). At
follow-up, AVF resolved spontaneously in 23 cases (85%). Two patients
required selective arterial embolization, one developed spontaneous rup-
ture of AVF, and one had persistence of AVF for 10 months.
Crescentic glomerulonephritis: A review of 24 cases. J.K. Kwon, T.H.
Lee, S.H. Seo, S.B. Park, H.C. Kim, and K.K. Park, Department of Internal
Medicine, and Pathology, Keimyung University School of Medicine, Taegu,
Korea. Twenty-four patients with crescentic glomerulonephritis (crescents
in .50% of glomeruli) were observed during a period of last 14 years.
There were 10 men and 14 women aged 6–75 years (mean 28 6 18). Initial
clinical features included; edema (83%), hypertension (75%), oliguria
(67%), and a decreased renal function (serum creatinine .5 mg/dl, 33%).
Immune-complex mediated disease was presented in 13 cases (54%),
including 6 systemic lupus erythematosus, 3 post-streptococal glomerulo-
nephritis, 3 Henoch-Scho¨nlein purpura, and 1 IgA nephropathy. Pauci-
immune disease was presented in 11 cases (46%), including 3 Wegener’s
granulomatosis, and 8 idiopathic crescentic glomerulonephritis. However,
there was none of anti-GBM-mediated disease in our study. Renal biopsy
showed large crescents in .80% of the glomeruli in 13 cases (54%) that
were predominantly fibrocellular. Thirteen patients (54%) were treated
with prednisolone alone; 10 of them received pulse doses of corticoste-
roids. Three patients were treated with prednisolone and cyclophospha-
mide IV pulse. Two cases received plasma exchange. In 17 patients, there
was an inexorable progression of renal failure, three showed recovery of
renal function, and one showed partial improvement but subsequently had
varying degrees of renal insufficiency. On follow-up, three patients were
dead, two from respiratory failure with severe pulmonary hemorrhage,
and one from opportunistic pulmonary infection during immunosuppres-
sive therapy. In conclusion, a poor prognosis is associated with large
crescents in 80% or more glomeruli and increased serum creatinine level
at the time of diagnosis.
Effect of cyclosporine on steroid dependent or resistant nephrotic
syndrome. J.S. Jeon, C.K. Kim, K. Hwangbo, M.S. Park, S.D. Hwang, H.B.
Lee, Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul,
Korea. To evaluate the effect of cyclosporine on steroid dependent or
resistant nephrotic syndrome, 14 patients (pt) with FSGS and 5 patients
with MCNS were included in this study. Cyclosporine was used in 13 pt
(group 1) and cyclophosphamide in 6 pt (group 2). Ten patients in group
1 and 4 in group 2 were male. The average age was 35.0 (17–46) years and
26.3 (17–39) years in groups 1 and 2, respectively. At the beginning of the
study serum creatinine, albumin, and cholesterol levels did not differ
between the two groups. In group 1 complete remission (CR) was
observed in 3 pt at the mean of 9.7 weeks after cyclosporine, partial
remission (PR) in 7 pt after 9.7 weeks, and no response (NR) in 3 pt after
up to 16 weeks. In group 2 CR in 2 pt after 12 weeks of cyclosporine, PR
in 1 pt after 4 weeks, and NR in 2 pt after up to 16 weeks and 1 pt after
8 weeks. Twenty-four hour albuminuria corrected with creatinine (UAlb/Cr)
decreased from 6.45 6 4.57 to 3.33 6 2.69 in group 1 (N 5 8) and from
6.86 6 5.72 to 3.19 6 3.71 in group 2 (N 5 6) at 4 weeks. The difference
was not statistically significant. UAlb/Cr decreased significantly in group 1
(N 5 10, 7.92 6 6.73 vs. 3.89 6 5.94, P , 0.05), but no statistical
significance was observed in group 2 (N 5 4, 6.78 6 6.39 vs. 2.89 6 1.80).
Facial flushing was observed in 1 pt with cyclosporine 5 mg/kg of body
weight (BW), which improved after reducing the dose to 2.5 mg/kg of BW.
No complications were observed in pt with cyclosporine 2.5–3 mg/kg of
BW and pt with cyclophosphamide. In conclusion, complete or partial
remissions were observed in 61.5% and 50% in groups 1 and 2, respec-
tively, without any significantly adverse effect. It will be necessary to
extend the study and recruit more patients to evaluate the effect of
cyclosporine on steroid dependent or resistant nephrotic syndrome.
Therapeutic effects of cytotoxic agents (cyclophosphamide and
chlorambucil), cyclosporine and levamisole in children with steroid-
dependent nephrotic syndrome. C.R. Park, H.-S. Lim, U.-S. Noh, C.-W.
Koh, and J.-H. Koo, Department of Pediatrics, School of Medicine, Kyung-
pook National University, Taegu, Korea. The present study was undertaken
to compare the therapeutic efficacy of cytotoxic agents (cyclophosphamide
& chlorambucil), cyclosporine and levamisole in 88 children with steroid-
dependent minimal-change nephrotic syndrome, who have been followed
up in the Pediatric Department, Kyungpook National University Hospital
from 1985 to 1995. Cyclophosphamide and chlorambucil were given for 8
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weeks (cyclophosphamide in 36 and chlorambucil in 13 cases) or 12 weeks
(cyclophosphamide in 34 and chlorambucil in 12 cases), and cyclosporine
(3–5 mg/kg/day) and levamisole (2–2.5 mg/kg alternate day) were given for
6–12 months. The results were as follows. Results of cytotoxic therapy at
the end of the first year, were remission rates with a 12 week course of
cyclophosphamide (53%) better than with a 12 week course of chloram-
bucil (33%) or 8 week course of either drug. However, at the end of the
second year, no difference was noted in the remission rate between the 12
week course of cyclophosphamide (19%) and chlorambucil (17%). Of
cyclosporine therapy, out of 44 cases, 28 (64%) showed sustained remis-
sion, 8 (18%) relapsed with decreased frequency and steroid-sparing
effect, and 8 no therapeutic effects. During the treatment period, BUN,
creatinine and blood pressure remained in normal ranges. Remission rates
with the cyclosporine alone therapy without steroid in cyclosporine-
responsive children were 83%, 83%, 57% and 43% at 2, 4, 6 and 8 months,
respectively. Results of levamisole therapy in 16 cases, 8 (50%) showed
sustained remission, 5 (31%) relapse with decreased frequency and
steroid-sparing effect, and 3 had no therapeutic effects. In one case,
transient neutropenia was observed without serious sequelae. The remis-
sion rates with levamisole alone therapy without steroid in levamisole-
responsive children were 88%, 85%, 67% and 44% at 2, 4, 6 and 8 months,
respectively. In conclusion, the present study indicates that a 12 week
course of cyclophosphamide or chlorambucil seems to be the most
effective therapy for inducing long-lasting remission in steroid-dependent
nephrotic children. Long-term use of cyclosporine or levamisole can also
be used quite effectively in achieving prolonged remission and steroid-
sparing effects without serious side effects.
Urinary tract infection and vesico-ureteral reflux in children. H.S. Lim,
C.R. Park, C.-W. Ko, and J.H. Koo, Department of Pediatrics, School of
Medicine, Kyungpook National University, Taegu, Korea. Urinary tract
infection (UTI) in children has been known to be a cause of renal damage,
leading to scar formation, hypertension and renal failure. Vesico-ureteral
reflex (VUR), frequently accompanying UTI in young children, has been
incriminated as the main factor causing scar formation. This retrospective
study has been undertaken to see the relationship among UTI, VUR and
renal scar formation. The study population consisted of 291 children (134
boys, 42 girls) with UTI, who were admitted to the Pediatric Department
of Kyungpook University Hospital during a 6-1/2 year period from January
1990 to June 1996. VUR was diagnosed by VCUG and renal scar
formation by ultrasonogram, DMSA scan (or DMSA SPECT) and IVP,
and the following results were obtained. Sexual difference showed that
below 1 year of age, male predominance (male to female, 134:42) and over
5 years of age, female predominance (male to female, 11:35) were noted.
VUR was found in 64 children (22%) and the degrees of reflux, classified
by the method proposed by “International Reflux Study in Children,” were
as follows; Grade I 4.0%, Grade II 3.0%, Grade III 2.7%, Grade IV 5.8%,
and Grade V 6.2%. There was no sexual difference. E. coli was the most
predominant infecting agent occurring in 167 children (57%), and end-
stage renal failure was diagnosed at the time of first admission in 5
children with Grade V VUR. Renal scarring was noted in 49 out of 582
kidneys (8.4%), and the incidence of scar formation according to the
degrees of VUR were as follows: Grade 0 (No reflux) 1.2%, Grade I 6.7%,
Grade II 27.3%, Grade III 29.4%, Grade IV 57.1%, and Grade V 100%.
In summary, the present study shows that renal scar formation in UTI has
a close correlation with the severity of VUR occurring more frequently in
severe reflux, so that early diagnosis and proper treatment of UTI and
VUR is of paramount importance in preventing renal damage in children
with UTI.
Early operability in infant patients with vesicoureteral reflux. D.W.
Son, S.D. Lee, Urologic Department, Pusan National University Hospital,
Korea. Diagnostic rates of vesicoureteral reflux (VUR) recently have been
very increased with an antenatal care system using fetal ultrasonography.
There is great debate about the management of VUR, early operation or
medical therapy. We attempted to achieve the rationale of early opera-
bility in infants with VUR by using a clinical survey between infants and
children aged over 1 year who were with VUR. We clinically analyzed 15
cases (25 ureters, Group I) of infant with VUR and 41 cases (64 ureters,
Group II) of children aged over 1 year who visited our department from
January 1991 to June 1996. The ratio of males to females in Group I and
II was 1.1:1 (8:7 cases) and 1.7:1 (26:15 cases), respectively. There was no
significant difference of bilaterality of VUR in Group I and II, 8 cases
(53%) and 23 cases (56%), respectively. In high grades (IV–V) of VUR,
Group I showed higher grade than group II, 14 cases (93.3%) and 25 cases
(61%), respectively. Febrile urinary tract infections occurred in 73.3% and
87.8% of groups I and II, respectively. There was significant difference in
renal scar development between group I and II, 11 cases (73.4%) and 16
cases (39%), respectively. Follow-up voiding cystourethrogram of 56 cases
at 6 months revealed no evidences of persistent reflux or other complica-
tions. There was significantly higher development of renal scarring in
group I compared with group II in spite of similar development of urinary
tract infections. Our success rate was 100% in antireflux surgery. There-
fore, we suggest early operative interventions in infants with high grade
reflux.
Antibiotic sensitivity in children with urinary tract infection (UTI)
caused by E. coli. C.R. Park, S.Y. Kim, C.W. Ko, J.H. Koo, Department of
Pediatrics, Kyungpook National University School of Medicine, Taegu, S.
Korea. UTI is one of the major genitourinary diseases in childhood, and is
mainly caused by E. coli. Ampicillin has been the first choice of antibiotic.
Recently, many reports suggest that the number of antibiotic resistance to
infectious organisms is increasing. To investigate antibiotic sensitivity to E.
coli in children with UTIs, a retrospective study was done. Study patients
consisted 50 children with UTI proven by urine culture (aged 1 months to
10 years, M:F 5 36:14) who were admitted to the Department of
Pediatrics from July 1st, 1995 to June 31st, 1996. Two urine culture and
colony counts were done, before and 48 hours after antibiotics. Causative
agents were E. coli (36/50), Proteus mirabilis (2/50), Morexella morgafni
(2/50) and so on. In antibiotic sensitivity of initial culture, 25/29 (86%)
were resistant to ampicillin, 6/17 (35%) were resistant to trimethoprim-
sufimethoxasole. Out of twenty that were caused by E. coli and ampicillin
administered, seven (33%) revealed positive at second urine culture. In
summary, E. coli causing UTI in children is resistant to ampicillin in 86%
(in vitro), and in 33% (in vivo). Conclusively, ampicillin as the first
antibiotic in children with UTI by E. coli should be reconsidered, and
another antibiotic such as cephalosporines or b-lactamase resistant anti-
biotics would be considered as the first antibiotic.
A study on the risk factors of renal scar in childhood acute pyelone-
phritis. S.J. Hwang and S.J. Lee, Department of Pediatrics, Ewha Womans
University, Mok-dong Hospital, Korea. In acute pyelonephritis (APN) of
childhood, it is very important to prevent the progression to renal scarring.
Since the 99mTc-DMSA renal scan has been found to be a sensitive
method in the diagnosis of not only renal scar but also APN, concepts
about the pathogenesis of renal scarring have been changing. The authors
observed the progression into renal scar on a follow-up study in children
with first APN who had defects on their 99mTc-DMSA renal scan, and
assessed the risk factors of renal scarring. In 49 children with first APN (32
boys, 17 girls) were studied whether APN progress to renal scar by the
follow-up 99mTc-DMSA renal scan, 6 months later at Ewha Womans Univ.
Hospital from September, 1993 to February, 1997. Children with a past
history of UTI or frequent unknown fever and definite renal scarring
including small scarred kidney on the first 99mTc-DMSA renal scan were
excluded. The clinical, laboratory and radiologic findings were compared
between 34 patients (41 kidney unit: KU) with renal scar and 15 patients
(17 KU) without renal scar. (1) The group with renal scarring included 19
boys and 15 girls, and the group without renal scarring included 13 boys
and 2 girls, showing significant gender difference (P , 0.05). The mean
age of the renal scar group at the time of diagnosis of APN was 28 6 31.6
months, which was not significantly different to 22.3 6 37.4 months of the
no renal scarring group. (2) The duration of fever before the treatment
was not significantly different between two groups. However, the highest
body temperature in the renal scarring group was 39.0 6 0.78°C, which was
significantly different to 38.5 6 1.04°C in the no renal scarring group (P ,
0.05). The number of children with both prolonged and high fever was
significantly different between renal scarring group and no renal scarring
group (42.8% vs. 13.3%; P , 0.05). (3) There was no significant difference
in the values of hemoglobin, WBC count, ESR, C-reactive protein, urine
WBC, specific gravity, BUN, serum creatinine, bacterial organism between
the two groups (P . 0.05). (4) The rate of vesicoureteral reflux (VUR) was
69.2% (27/39 KU) in the renal scar group, which was significantly different
to 22% (13/59 KU) in the no renal scar group (P , 0.05). The degree of
VUR was correlated with the rate of renal scarring (P , 0.05). (5) The
rate of breakthrough infections during the 6 months of follow-up between
two groups (17.1% vs. 20%, P . 0.05) was not significantly different. In
Abstracts 1793
high grade (III–V) VUR, the rate of renal scar was not significantly
different between surgical and medically treated groups (88.8% vs. 83.3%,
P . 0.05). In acute pyelonephritis in childhood, the risk factors for the
progression into renal scarring are female, prolonged high fever and the
presence of VUR.
Hemolytic uremic syndrome, Up-surge in Korea? J.S. Kim, E.J. Park,
S.H. Chung, S.M. Song, E.H. Chung, S.H. Ko, M.S. Park, D.K. Jin,
Department of Pediatrics, Sung Kyun Kwan University College of Medicine,
Seoul, Korea. Hemolytic uremic syndrome (HUS), known as a most
common cause of childhood renal failure in western countries, has been a
relatively rare disease in Korea. Although the reported cases were not
related to any specific cause in Korea, there was an outbreak of HUS with
bloody diarrhea in Japan last year. We report here that we experienced the
several typical HUS last year. From January 1996 to December 1996, five
patients were diagnosed as HUS at Samsung Seoul Medical Center,
Department of Pediatrics. Results are: (1) The age of onset was below 3
years in 3 cases and above 9 years in 2 cases. (2) All the cases happened
between summer and autumn. Three patients had domestic travel and 4
patients drank well or spring water before the symptoms. (3) The clinical
manifestations were generalized edema, oliguria, anuria and hematuria.
The bloody diarrhea were present in 5 cases and 1 patient had operation
with the impression of appendicitis. (4) No bacteria that was isolated from
the blood or stool samples. (5) Renal biopsies were performed in 2 cases,
because of a protracted clinical course. One showed microthrombotic
angiopathy and the other cortical necrosis with necrotizing glomeruli. (6)
Complete recovery was the outcome in 4 cases and one case progressed to
chronic renal failure. In conclusion, typical HUS associated with bloody
diarrhea, epidemic and good prognosis can be found in Korea. Careful
surveillance of the pre-clinical cases will be necessary.
Age as a prognostic factor in the acute renal failure during the pediatric
age. E.J. Park, J.S. Kim, S.H. Chong, H.K. Kim, H.Y. Lee, M.S. Park, S.H.
Ko, Y.S. Kang, D.K. Jin, Department of Pediatrics, Sung Kyun Kwan
University College of Medicine, Seoul, Korea. The management of the acute
renal failure (ARF) in pediatric patients is difficult, because the underly-
ing cause is diverse and vascular access is difficult. It has been emphasized
that age itself as well as the multiple organ failure are important
prognostic factors. To know the significance of the age factor, we tried to
review the 58 pediatric ARF cases (excluding the NICU and surgical ICU
case) in Samsung Medical Center PICU from September 1994 to Decem-
ber 1996. The results are as follows: (1) We categorized the enrolled 58
cases into 5 groups: ;1 month, ;1, 5, 10, 15 years. More than half of the
patients were younger than 1 year old. (2) When the ARF cases were
classified as pre-renal, renal, and post-renal, most of the cases (69%) were
renal origin. (3) As underlying causes, heart disease and G-I disease were
predominant in ;1 month group, and sepsis and intrinsic renal disease in
;1 year group. After 1 year of age, intrinsic renal disease was the most
common cause (43;50%). (4) Renal disease were evaluated according to
the age. SLE (;15 years old group), HUS (;10 years old group), HUS
(;5 years old group) and obstructive uropathy (;1 year old group) were
the common etiologies. (5) The renal replacement therapies were per-
formed in 41% of ARF. Hemodialysis were preferred modality in ;15
year group and ;1 year group. Peritoneal dialysis was the choice in ;5
year group and hemofiltration was in ;1 month old group. The mortality
rate was the highest (46.7%) in ;1 year old group and lowest (21.4%) in
;15 years old group. In conclusion, the underlying disorders of ARF were
different among the age groups. Among intrinsic renal diseases, HUS was
the most common cause. The difference in the mortality was dependent on
the age and underlying disease.
Initial transient neurologic recovery followed by delayed deterioration
of osmotic demyelination syndrome: case report and review. Y.J. Lee, D.W.
Park, H.S. Mun, H.J. Kim, Departments of Neurology, Radiology, and
Internal Medicine, Hanyang Univ Kuri Hospital, Kuri, Korea. In the
literature, most of the studies of severe hyponatremia during or following
its treatment have been concentrated with special references to the rate of
correction and its neurologic outcomes. Therefore, relatively few studies
analyzed the diverse clinical manifestations of neurologic symptoms or
complications during the course of treating severe hyponatremia. We
experienced a catastrophic course related to hyponatremia in a 51 year old
woman with severe rheumatoid arthritis, who underwent (lt) knee joint
replacement. Postoperatively, on day 12, she developed severe lethargy
progressing to coma, when her serum sodium (Na) concentration lowered
to 91 mEq/liter. With 3% NaCl infusion in 5 hours, she became awake with
recognizing surrounding and family members, when serum Na was in-
creased to 110 mEq/liter with the rate of its correction by 3.8 mEq/liter/hr.
In next 48 hours, her serum Na concentration increased to 128 mEq/liter
with the rate by less than 0.5 mEq/liter with 0.9% NaCl infusion, and she
was transferred out of ICU. However, 24 hours later, she fell into flaccid
quadriplegia, difficulty in speech and coma with serum Na of 135
mEq/liter, and then, remained in a locked-in condition for next 3 weeks.
The first MRI at day 3 of hyponatremia with coma did not show any
specific findings for the organic brain damage, but the second one at day
27 revealed the findings compatible with extrapontine demyelination. This
case revealed the initial transient neurologic recovery for 3 days by the
initial rapid correction of hyponatremia, then followed by delayed deteri-
oration of osmotic demyelination syndrome leading to the locked-in
syndrome. Reported cases with similar clinical course in the world
literatures were reviewed with special interests in the initial maximum rate
of correction of hyponatremia and radiologic findings. This study suggests
that clinicians treating the patients with severe symptomatic hyponatremia
should be aware of the possibility of delayed neurologic sequelae despite
the recovery of neurologic status as well as the degree of hyponatremia in
the early treatment course of hyponatremia.
Clinical analysis of severe hyponatremic patients with neurologic
symptoms. G.T. Park, H.S. Moon, H.J. Kim, Department of Internal
Medicine, Hanyang University Kuri Hospital, Kuri, Korea. This retrospective
study analyzed the clinical course of 27 consecutive patients (pts) at a
single medical center who presented with neurologic hyponatremic symp-
toms as well as a serum sodium (Na) concentration less than 125
mEq/liter. Of 27 hyponatremic patients, male to female ratio was almost
equal, 13 to 14, and mean age was 67.1 years. Twenty-five cases (92.6%)
became hyponatremic in the hospital (hospital-acquired hyponatremia),
the rest (7.4%) became hyponatremic before entering the hospital (home-
acquired hyponatremia). The most common cause of hyponatremia was
SIADH (12 pts, 44.4%), followed by hypovolemia (11 pts, 29.7%), and
edema (4 pts, 14.8%). Hyponatremic neurologic symptoms included
lethargy (33.3%), confusion with drowsy mentality (33.3%), dizziness
(18.6%), and semicoma (7.4%), respectively. The rate of increase to a
serum Na concentration to 125 mEq/liter during correction of hyponatre-
mic averaged 0.56 6 0.49 mEq/liter/hr while the maximum increase in
serum Na concentration during any period of the hospital course, mostly
initial phase, averaged 0.69 6 0.63 mEq/liter/hr in all 27 pts, of whom 18
pts (66.7%) was less than 0.5 mEq/liter/hr, 3 pts from 0.5 to 1.0
mEq/liter/hr (11.1%), and 6 pts more than 1.0 mEq/liter/hr (22.2%). All 27
pts but one recovered from neurologic symptoms due to hyponatremia
without neurologic sequale. Extrapontine demyelination syndrome with
locked in condition developed during the course of treating hyponatremia
in a number of pts, of whom serum Na concentration before treatment was
the lowest (92 mEq/liter) with the rate of correction to 125 mEq/liter by
1.2 mEq/liter/hr and the highest maximum rate of correction by 3.7
mEq/liter/hr. No one died of hyponatremia itself during the course of its
treatment, but 3 deaths of 27 pts were attributed to the pts’ severe
underlying diseases. Surprisingly, these data revealed the relatively benign
course of severe symptomatic hyponatremia. However, in assessing the
outcome of severe symptomatic hyponatremia, the initial degree of
hyponatremia as well as the rate of correction during its treatment,
particularly the maximum rate of correction, should be considered.
Mono-therapy versus dual-therapy as transcellular K shifting agents
for acute therapy of hyperkalemia on maintenance hemodialysis. H.J.
Kim, S.C. Yang, B.H. Kim, Department of Internal Medicine, Hanyang
University Kuri Hosp, Kuri, Korea. This study was aimed to evaluate the
efficacy of transcellular K-lowering effect at 1 hr following mono-therapy
(2 mEq/kg of NaHCO3 in i.v. infusion, 10 units of regular insulin with 50
ml of 50% glucose in i.v. push, or 15 mg of salbutamol in nebulizer)
compared to that of dual-therapy (NaHCO3 1 insulin with glucose,
NaHCO3 1 salbutamol, or salbutamol 1 insulin with glucose) in 10 ESRD
patients with predialysis hyperkalemia (.5.5 mEq/liter) on maintenance
hemodialysis. Bicarbonate infusion induced a significant rise in plasma
bicarbonate and pH from baseline values in both mono-therapy and
dual-therapy without any significant difference from each other. Among
the mono-therapeutic regimens, bicarbonate alone failed to lower plasma
K from baseline levels (20.1 6 0.15 mEq/liter, P 5 NS) whereas two other
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regimens effectively lowered plasma K (20.62 6 0.06 mEq/liter in insulin
with glucose, 20.57 6 0.04 mEq/liter in salbutamol, P vs. basal , 0.05 in
both). The K-lowering effects in the three combined regimens of dual
therapy were more prominent as compared to that of three regimens of
mono-therapy (20.96 6 0.08 mEq/liter in NaHCO3 1 salbutamol,
21.02 6 0.06 mEq/liter in NaHCO3 1 insulin with glucose, and 21.20 6
0.10 mEq/liter in salbutamol 1 insulin with glucose, respectively; P ,
0.05). Two patients in mono-therapy with salbutamol alone were resistant
to the hypokalemic effect, however, in dual therapy with simultaneous
administration of salbutamol and bicarbonate resolved it. In conclusion,
dual-therapeutic regimens lowered plasma potassium more effectively
than mono-therapeutic regimens, and among them, the combination of
insulin with glucose plus salbutamol could be recommended as an
efficacious and safe modality in the acute therapy of hyperkalemia in
ESRD patients.
Hyperkalemia after frog ingestion mimicking acute digitalis poisoning.
S.W. Han, H.J. Kim, Department of Internal Medicine Hanyang University of
Kuri Hospital, Kuri, Korea. It is well known that the toad skin contains
toxins, digitalis or ouabain–like compounds (DLC or OLC), which are
capable of inhibiting Na1,K1-ATPase, bufodienolide toxins. This DLC
could lead to hyperkalemia resulting from inhibition of the Na1,K1-
ATPase pump and subsequent release of K1 from cells. Therefore, as
reported in massive digitalis overdose with accidental or suicidal inges-
tions, this DLC overdose could cause potentially lethal hyperkalemia and
arrhythmia. Here, we report 3 cases admitted with similar clinical mani-
festations to toad skin poisoning, i.e., hyperkalemia in nonazotemic
condition and tachybradyarrhythmias, following the ingestion of frog
(Rana rugosa). Unfortunately, 1 out of 3 cases died with severe hyperka-
lemia, more than 8.0 mEq/liter, and bradyarrhythmia with a high-degree
AV block within 24 hours on admission. In this patient, the overall clinical
circumstance did not allow the intervention of acute hemodialysis for the
treatment of hyperkalemia, and every other conventional efforts to lower
serum K1 were tried, but repeated measurement of serum K1 concentra-
tion increased from 6.6 mEq/liter to 8.6 mEq/liter. This clinical experience
suggests that frog skin might contain toxic DLC or OLC as toad skin,
which causes severe hyperkalemia by the continuous cellular release of K1
and malignant arrhythmias due to the inhibition of the Na1,K1-ATPase.
Therefore, we could consider a DLC or OLC specific antibody to rapidly
reverse severe intractable hyperkalemia and arrhythmias in patients under
life-threatening situation mimicking acute digitalis poisoning after frog
ingestion.
Change of transtubular potassium gradient (TTKG) in kidney recipi-
ents. H.S. Yu, S.K. Park, C.K. Hong, J.S. Park, Department of Internal
Medicine, Ulsan University Medical School, Asan Medical Center, Seoul,
Korea. Hyperkalemia is frequently seen in kidney recipients after using
cyclosporine as a immunosuppressive agent because cyclosporine can
reduce K excretion at the renal tubule. In this study, we calculated TTKG
as a parameter of renal tubular K excretion and examined (1) how much
TTKG could be decreased in kidney recipients compared with normal
persons; (2) what is the relationship with serum cyclosporine level and
TTKG; (3) how much TTKG could be changed with time; and (4) what is
the usefulness of TTKG instead of spot urine K. We enrolled 35 kidney
recipients who received kidney from December 1996 to March 1997. We
checked serum cyclosporine level, serum and urine osmolarity, serum
electrolyte, urine potassium every 4 days. We enrolled 20 normal persons
whose creatinine level was normal and who had no history of any drugs
affecting to urine K excretion. In kidney recipients, serum K level was
significantly higher than normal persons (kidney recipients, 4.94 6 0.57
mmEq/liter; normal persons: 4.15 6 0.30 mmEq/liter, p Value: 0.000),
TTKG was lower than normal persons (kidney recipients, 3.02 6 0.82;
normal persons, 5.55 6 1.78, P value 0.000), serum K level showed
negative correlation with TTKG (P value 0.01), serum cyclosporine level
showed negative correlation with TTKG (P value 0.046). As times passed
after renal transplantation, the TTKG level increased (POD #4, 2.21 6
0.823 POD #8, 2.59 6 1.43 POD #12, 3.35 6 1.593 POD #16, 3.66 6
1.35 3 POD #20:3, 83 6 1.67). Spot urine K level showed a positive
correlation with TTKG (P value ,0.01) but no correlation with serum K
level (P value 0.847). These findings indicated that cyclosporine might
decrease renal tubular K excretion and induce hyperkalemia, and that as
time progressed, renal tubular function was recovered from the toxic
cyclosporine effect. We believe that TTKG more accurately reflected
renal tubular potassium excretion function than spot urine potassium
level.
Hypernatremia in patients admitted to the medical department. J. Kim,
S.J. Lee, U.S. Jeon, W. Huh, C. Ahn, J.S. Han, S. Kim, and J. Sang Lee,
Department of Internal Medicine, College of Medicine, Seoul National
University, Seoul, Korea. Hypernatremia is a metabolic disorder with high
mortality rate ranging from 40 to 70%. However, there has been no
established treatment guidelines. We tried to show the clinical character-
istics, treatment, and outcomes of hypernatremia in patients admitted to
the Department of Internal Medicine in Seoul National University
Hospital from January 1995 to December 1995. We defined hypernatre-
mia as a serum sodium concentration greater than or equal to 150
mEq/liter, and resolution as a serum sodium concentration less than 150
mEq/liter for at least 3 days. Of 12,841 admissions, 25 cases (0.2%)
developed hypernatremia, and we reviewed the medical records of 22
among them retrospectively. The mean age was 54 years (range 34 to 83
years), and male to female ratio was 1.2:1. The mean peak serum sodium
concentration was 158 mEq/liter (range, 150 to 178), and the mean
duration of hypernatremia was 4.4 days (range, 1 to 17). At the peak serum
sodium level, neurologic abnormalities were found in 15 (68%). The
primary diagnoses were: 7 (32%) cases of malignancies, 6 (27%) of liver
cirrhosis including primary liver cancers, 3 of cerebrovascular accidents,
and 2 of colitis. Causes of hypernatremia were water loss from the
gastrointestinal tract in 12 cases (55%), renal loss in 4, decreased sense of
thirst in 3 and total parenteral nutrition, hypertonic saline infusion, and
inadequate hydration in 1 case, respectively. Hypotonic fluid was used for
replacement in 11 (50%), dextrose water in 8 (36%), and isotonic in 2. The
mean total body water deficit (TBWD) was 11.4% (range, 6.7 to 21.3). In
8 cases (36%), the amount of fluid replacement during 24 hours was less
than 30% of TBWD, while more than or equal to 30% in 12 cases (55%).
Overall mortality was 59% (13/22). Out of 6 whose hypernatremia was
corrected within 24 hours, 4 patients died, whereas 3 died among 10 whose
hypernatremia was corrected after 24 hours. The mean baseline serum
sodium concentration of nonsurvivors was 129 mEq/liter (range, 118–144)
and was lower than that (142 mEq/liter, range, 128–178) of survivors (P ,
0.05). In the future, prospective studies concerning the survival related
factors and the treatment guideline will be necessary.
Clinical features of 48 probands of ADPKD. D.Y. Hwang, J.G. Lee,
H.J. Chin, J.S. Yang, S.J. Ryu, C. Ahn, J.S. Han, S. Kim, J.S. Lee, and S.H.
Kim, Department of Internal Medicine and Department of Radiology, Seoul
National University, Seoul, Korea. ADPKD (autosomal dominant polycystic
kidney disease) is one of the most common hereditary renal disease and
the leading cause of chronic renal failure. There were some reports about
the clinical features of ADPKD in Korea, but any reports about those of
probands were not noted. We analyzed data about 48 probands’ clinical
features whose family analysis and follow-up were possible. We use the
Rear’s diagnostic criteria of ADPKD with USG. The mean age of 48
probands was 45 years (range 25–64), the thirties 13 (27%), the forties 16
(35%), the fifties 9 (19%) and the ratio of male:female was 18:30. The
initial symptoms were headache, abdominal distension and flank pain
successively. Family history of ADPKD found chronic renal failure in 5
cases, hypertension in 36 cases, cerebrovascular accident in 25 cases, and
there is one case of no renal cyst in parents. Renal complications were
abdominal and flank pain in 45%, hypertension in 80%, renal and ureteral
stone in radiologic exam in 18%, gross hematuria in 23%, and suspected
cyst hemorrhage in 19%. There was upper urinary tract infection in 22%
of probands, male:female 8%:23% and E. coli was separated from urine in
2 cases. There were 21 cases (44%) of azotemia (Cr . 1.4 mg/dl), 18 cases
on initial visit, 3 cases on follow-up. Ten cases progressed toward
end-stage renal disease, and hemodialysis was initiated in 6 cases and renal
transplantation in 4 cases. The mean age of ESRD was 49 (range 35–64)
years. There were 2 cases of renal cell cancer. One case was male, 62 years
old, who was diagnosed after nephrectomy due to severe pain and
abdominal distension. The other case was female, 35 years old, diagnosed
with renal biopsy of renal mass detected by USG. Extrarenal manifesta-
tion analysis revealed hepatic cysts in 84%, pancreatic cyst 1 case, ovarian
cyst 2 cases, adrenal cyst 1 case; but there was no case of splenic cyst.
Echocardiogram was performed in 23 cases but there was no case of MVP.
Two cases of colonic diverticulosis were detected after 11 case exams.
There was 1 case of ruptured cerebral aneurysm but no case of newly
detected cerebral aneurysm in 13 MRI studies. We found 4 families that
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have more than 2 patients with CRF, 8 families that have more than 2
patients with CVA and 13 families that have more than 2 patients with
hepatic cyst.
Alport’s syndrome—A molecular genetic study. H.I. Cheong, H.W. Park,
H.S. Lee, Y. Choi, Department of Pediatrics and Pathology, Seoul National
University Children’s Hospital, Department of Pediatrics, Seoul City Boramae
Hospital, Seoul, Korea. A molecular genetic study was done with 43
patients who were clinically diagnosed with Alport’s syndrome. Pedigree
analysis revealed X-linked dominant inheritance in 31 patients (72%) and
autosomal inheritance in 3 patients (7%), and 9 patients (21%) were
sporadic cases. Kidney biopsy, performed in index cases and/or in other
family members, revealed typical glomerular basement membrane (GBM)
changes in 23 cases (group I), focal changes or diffuse thinning of GBM in
6 (group IIa). The GBM changes were minimal or were not adequately
examined (no electron microscopic examination) in 5 cases (group IIb),
and kidney biopsy was not done in 9 (group IIc). Genomic DNA was
extracted from peripheral blood nucleated cells from each patients. And
restriction fragment lengh polymorphism-Southern (RFLP-Southern) blot
and polymerase chain reaction-single strand conformational polymor-
phism (PCR-SSCP) were done. The 5 cDNA fragments covering nearly
entire coding region of the COL4A5 gene were amplified from human
fetal kidney cDNA and subcloned to be used as cDNA probes for
RFLP-Southern blot. Exons 47–51 of the COL4A5 gene in each patients
were amplified and analyzed by PCR-SSCP. We found an abnormally
migrating EcoRI restriction fragment containing exon 37 by RFLP-
Southern blot (a patient in group I with X-linked dominant mode of
inheritance). A point mutation in exon 48 (a sporadic case in group IIa)
and a deletion of about 500-bp size involving exon 49 and 50 (another
patient with X-linked dominant inheritance in group IIc) were detected by
PCR-SSCP. In conclusion, the incidence of large defects in COL4A5 gene
that can be detected by conventional RFLP-Southern blot is very low.
Thus, PCR-SSCP of all exons, showing higher detection rates, should be
used to screen the COL4A5 gene for the molecular genetic diagnosis of
Alport’s syndrome.
Alport’s syndrome—A clinicopathological study. H.I. Cheong, H.W.
Park, H.S. Lee, Y. Choi, Department of Pediatrics and Pathology, Seoul
National University Children’s Hospital, Department of Pediatrics, Seoul City
Boramae Hospital, Seoul, Korea. A clinicopathological study was done with
43 patients who were clinically diagnosed as having Alport’s syndrome.
Pedigree analysis revealed X-linked dominant inheritance in 31 patients
(72%, XD group) and autosomal inheritance in 3 patients (7%, Au
group); 9 patients (21%, Sp group) were sporadic cases. The sex ratio was
28:3 in the XD group, 1:2 in the Au group, and 4:5 in the Sp group. The
median age at the onset was 3.0 years in males and 5.6 years in females. At
the last follow-up, 20 cases (47%) had asymptomatic urine abnormalities
(AUA), 10 cases (23%) had active nephrotic syndrome (NS), and 13 cases
(30%) had chronic renal failure (CRF). The incidence of CRF was higher
in XD group than in Au and Sp groups. The median ages at the last
follow-up in male patients with AUA, NS and CRF, showing no difference
according to the mode of inheritance, were 12.6, 16.1 and 18.9 years,
respectively. The incidences of CRF, nerve deafness and eye abnormalities
in family members including index cases were 58%, 47% and 12%,
respectively, and showed no difference among the 3 groups. Kidney
biopsy, performed in 31 index cases and an additional 11 family members,
revealed typical glomerular basement membrane (GBM) changes in 26
cases (60%), focal GBM changes or diffuse thinning of GBM in 7 cases
(17%). In the remaining 9 cases (21%), the GBM changes were minimal
or electron microscopic analysis was not done. The expression of type IV
collagen a5 chain in epidermal basement membrane, studied in all cases,
was defective in 87% of the XD group, in 75% of the Sp group, and in 0%
of the Au group. The expression of type IV collagen novel chains in GBM,
studied in 7 cases, was defective in 6 cases with various patterns. In
conclusion, the variable clinical features of Alport’s syndrome may not
result from which gene is defective, but from how the gene is defective.
Prevalence of renal malformation in Turner’s syndrome in Korea. K.S.
Rho, P.-K. Kim, S.J. Chung, D.H. Kim, Department of Pediatrics, Yonsei
University College of Medicine, Seoul, Korea. The prevalence of renal
malformation in Turner’s syndrome has been quoted as being greater than
50% in older series. In 1988, Lippe’s review gave a prevalence of 33%,
significantly lower than all previous reports. In 1996, Flynn reported that
renal malformation occurs in approximately 24% of all girls with Turner’s
syndrome, and that it is seldom seen in girls with mosaic karyotype, who
form the predominant subgroup. The aim of this study was to evaluate
prevalence of renal malformation by karyotype in Turner’s syndrome in
Korea. We evaluated 81 patients with Turner’s syndrome who were
diagnosed in Yonsei University from January 1987 to December 1996.
Patients entered in this study were those for whom both karyotype and
ultrasound examination of the kidney were available. The karyotype
showed: 45,X karyotype, 29 cases (38%); mosaicism, 32 cases (40%);
structural aberration, 17 cases (22%). Of the 29 cases of pure 45,X
karyotype, 5 (17%) had abnormal renal finding, while these were found in
only 1 of the 30 mosaic cases (3%), and in 1 of the 17 structural aberration
cases (3%) between the 3 groups. The malformation included 3 cases of
horseshoe kidney, 2 cases of axial malrotation, hypoplastic kidney and
simple cyst each one. There was no statistical significance. We conclude
that renal malformation occurs in 9.2% of the patients in this study.
Therefore, Korean girls with Turner syndrome may have lower rates of
renal malformation.
Successful renal transplantation of three cases of oligomeganephronia.
H.C. Bae, P.K. Kim, Y.S. Kim, K.I. Park, H.J. Jeong, I.J. Choi, Departments
of Pediatrics, Surgery and Pathology, Yonsei University College of Medicine,
Seoul, Korea. Oligomeganephronia is a rare congenital form of bilateral
renal hypoplasia characterized histologically by a reduction in number and
hypertrophy of nephrons. Clinically, this condition is presented in early
infancy with vomiting, polyuria, polydipsia and dehydration. The problems
are readily corrected, but slowly progressive renal failure follows, accom-
panied by failure to thrive, short stature, and renal osteodystrophy. We
report these cases of oligomeganephronia with a review of the literatures.
Case 1 is a 3-2/12-year-old female child who was incidentally diagnosed as
renal failure at age of 2 months when she was hospitalized due to
pneumonia. She had open renal biopsy and was diagnosed as bilateral
dysplastic kidney. On OPD follow-up, she progressed to end-stage renal
failure (BUN/Cr 114/4.6 mg/dl) and had a renal transplantation. The
specimen was shrunk remarkably and light microscopy showed oligomega-
nephronia. Case 2 is a 14-8/12-year-old female child with proteinuria who
was detected in an annual urine screening program for school children;
she was diagnosed as renal failure (BUN/Cr 33.9/4.1 mg/dl), and had 5 3
4 3 3 cm sized mass on abdominal CT scan. She had renal biopsy, and the
specimen showed oligomeganephronia. She had hemodialysis for six
months, and renal transplantation along with bilateral nephrectomy was
performed. Case 3 is a 14-8/12-year-old male child diagnosed as having
chronic nephritis and chronic renal failure at 3 years old, progressed to
end-stage renal failure (BUN/Cr 87/9.6 mg/dl) on OPD follow-up, and had
a nephrectomy and renal transplantation. The biopsy specimen showed
oligomeganephronic hypoplasia, secondary focal segmental glomerulo-
sclerosis, and chronic interstitial nephritis. We report our experience of 3
cases of oligomeganephronia that progressed to end-stage renal failure
and had successful renal transplantation.
Cystic diseases of the kidney in children. J.-S. Lee, K.-S. Rho, P.-K. Kim,
Department of Pediatrics, Yonsei University, College of Medicine, Seoul,
Korea. The kidney is one of the most common sites of cyst formation.
Cystic diseases of the kidney are a diverse group of clinicopathologic
entities and prognosis. They span a wide range of both age of presentation
and severity of the renal disease, and many of them are systemic disorders
that share similar process of cyst formation. Recently, development of
imaging diagnosis is contributing widely to the diagnosis of the disease.
Treatment of the disease, however, is not established satisfactorily. We
performed this study to evaluate the occurrence and treatment of cystic
diseases of the kidney. We retrospectively reviewed the medical records of
43 patients of cystic disease of the kidney in the department of pediatrics,
during the last 11 years. In the 43 patients with cystic diseases of the
kidney, multicystic dysplastic kidney were found in 31 patients (72%), and
11 (35%) of them had a nephrectomy performed due to the differentiation
of neoplasm and severe abdominal distension. Polycystic kidney disease
was found 7 patients (16%), and all of them of the infantile type. Simple
cystic diseases of the kidney were in 5 patients (11%). No significant renal
failure developed. In 14 (32%) of 43 patients, cystic diseases of the kidney
were diagnosed in the neonatal or infantile period. The incidence of cystic
diseases of the kidney appeared very low, but further investigation on its
pathogenesis, classification, and indication of treatment are needed.
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Continuous ambulatory peritoneal dialysis (CAPD) in patients with
diabetic nephropathy. M.Y. Baek, J.C. Kim, S.H. Park, C.D. Kim, S.J. Kim,
J.H. Kim, T.H. Kwon, Y.L. Kim, and D.K. Cho, Department of Internal
Medicine, Kyungpook University Hospital, Taegu, Korea. Diabetic nephrop-
athy is now the leading cause of renal failure in patients referred for
uremia therapy. The ability to control anemia and hypertension without
sudden, drastic body fluid changes was thought to favor CAPD over
hemodialysis for the management of diabetics with severe cardiovascular
disease. To access the role of CAPD in diabetic end-stage renal failure,
clinical studies were carried out on the 68 cases among 361 CAPD patients
who had been treated from January 1988 to February 1997. The results
were as follows: (1) the mean age was 55.5 6 10.5 years and the sex
distribution was 43 males to 25 females. Mean CAPD duration was 16.4 6
13.3 months ranged from one to 68 months. (2) Five patients had
insulin-dependent diabetes and 63 had non-insulin-dependent diabetes.
Mean duration of diabetes was 13.8 6 6.5 years. (3) The incidence of
peritonitis was 1.1 episodes/patient-year and exit site infection was 0.3
episodes/patient-year. Other complications were dialysate leak (6 cases),
catheter dislodgment (6 cases), transient hypotension (3 cases), bleeding
(3 cases), and hernia (1 case). (4) Mean hospital stay was 54.9 6 47.2
days/year. (5) Patient survival rates at 1, 2, 3, and 4 years were 74, 51, 39,
and 32%, respectively, for diabetic CAPD patients and 90, 86, 78, and
74%, respectively, for non-diabetic patients. Diabetic CAPD patients had
significantly lower patient survival when compared to non-diabetics (P ,
0.001). (6) Catheter survival rates were 84% at one year, and 40% at three
years. Catheters were removed in 19 cases due to peritonitis (84.2%) and
catheter dislodgment and/or outflow obstruction (15.8%). (7) By the end
of the study, 38.2% of the patients were still on CAPD, 44.1% had died,
17.6% had transferred to hemodialysis. Common causes of death were
cachexia (60%), CAPD peritonitis with sepsis (13.3%), cerebrovascular
accident (3.3%) and cardiovascular complication (3.3%). In summary,
although diabetic CAPD patients had significantly lower patient survival
compared to non-diabetics, CAPD is an acceptable renal replacement
modality for patients with diabetic renal failure, in terms of comparable
catheter survival.
Any difference in the preservation of residual renal function between
diabetic and non-diabetic CAPD patients? S.K. Shin, H.J. Noh, I.H. Lee,
S.W. Kang, K.H. Choi, D.S. Han, and H.Y. Lee, Department of Internal
Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University,
Seoul, Korea. Residual renal function (RRF) contributes markedly to the
adequacy of CAPD in the early phase after CAPD but decreases
progressively with time. It is well known that RRF declines more rapidly
in hemodialysis than in CAPD patients, but there have been few studies on
the rate of decline in RRF in terms of the underlying disease of renal
failure. To evaluate whether there is any difference in the preservation of
RRF between diabetes (DM) and non-diabetes (non-DM) patients with
CAPD, we conducted a retrospective study in 15 DM and 25 non-DM
CAPD patients using 24-hour creatinine clearance as RRF, and compared
demographic data, biochemical parameters, and medication history be-
tween them. The mean age of DM group was 54.1 6 7.5 years and that of
non-DM group was 51.6 6 9.6 years, with a sex ratio 1.5:1, 0.92:1,
respectively. Predialysis BUN and creatinine in DM group (74.21 6 20.60
mg%, 9.25 6 2.30 mg%) were significantly lower than those in non-DM
group (106.70 6 43.14 mg%, 13.00 6 5.25 mg%, P , 0.05). The rate of
decline in RRF during the first 6 months after initiation of CAPD was
significantly higher in DM group (55.24 6 16.70%) than in non-DM group
(32.67 6 18.97%, P , 0.05) and its difference remained significant even
after adjusting the incidence of peritonitis, the usage of aminoglycoside,
and hemoglobin level between the two groups. However, the rate of
decline in RRF after the first 6 months of CAPD was comparable between
the two groups. In both groups, peritonitis and the usage of aminoglyco-
side were independent factors affecting the rate of decline in RRF. In
conclusion, DM patients seem to experience a greater decrease in RRF
than non-DM patients only during the first 6 months after initiation of
CAPD.
Effect of preoperative dialysis modality on kidney transplantation. S.J.
Kim, J.C. Kim, S.H. Park, C.D. Kim, M.Y. Baek, J.H. Kim, T.H. Kwon, Y.L.
Kim, and D.K. Cho, Department of Internal Medicine, Kyungpook University
Hospital, Taegu, Korea. Patients on CAPD may be more immunocompe-
tent and may face extra risks of infection from the peritoneal cavity and
catheter than the patient receiving hemodialysis (HD). Hence, the graft
and patients survival rates are supposed to be low in the transplanted
patients who were previously maintained on CAPD. However, there were
some variations from center to center, and there did not appear to be any
consistent trend in the survival of either graft or patient between the two
modalities of dialysis. We retrospectively reviewed the clinical outcome of
22 transplanted patients who were previously maintained on CAPD
(Group A). Then, for each of these patients, 22 comparison subjects were
chosen from the transplanted patients who were previously maintained on
HD. Matching variables were age, sex, length of dialysis and HLA
mismatch (Group B). Demographic characteristics between the two
groups were similar. In group A, 22 patients (17 male/5 female) with a
mean age of 38.7 6 12.9 years were treated with CAPD for 24.2 6 17.4
months. In group B, 22 patients (17 male/5 female) with a mean age of
40.5 6 14.5 years were treated with HD for 14.7 6 16.6 months. There
were no differences in the etiology, serum total protein, albumin, choles-
terol, hemoglobin, BUN and creatinine levels between the two groups
prior to transplantation. At 1 year, graft survival rates were 81.8% and
95.2% for Group A and B, respectively, and the patient survival rates were
86.4% and 95.5% (P , 0.05). At 5 years, graft survival rates were 59.9%
and 95.2% for Group A and B, respectively, and the patient survival rates
were 70.2% and 95.5% (P , 0.05). There were significant differences in
the graft and patient survival rates between the two groups. There were no
differences in the graft rejection, post-operative hospital stay, urinary tract
infection, allograft vascular thrombosis and hernia between the two
groups. Although the small sample size in this study limits definite
conclusions, transplanted patients who were previously maintained on
hemodialysis have better graft and patient survival rates.
Clinical features of chronic renal failure patients at the initiation of
dialysis. J.H. Shin, Y.K. Lee, S.W. Kim, S.M. Kim, Y.J. Kwon, H.J. Pyo.
Department of Internal Medicine, Medical College, Korea University, Seoul,
Korea. Since dialysis was introduced, many CRF patients have been
treated by this method. However, there are not sufficient reports in Korea
regarding clinical features of patients at the initiation of dialysis, indica-
tion of dialysis, outcome according to the time interval between the
referral to nephrologist and initiation of dialysis. We evaluated 270
patients who started dialysis therapy from 1987 to 1997 at Guro Hospital,
Korea University and studied the clinical features, indication for dialysis
and the interval between referral and initiation of dialysis. Finally, by
analyzing the outcome of patients, we tried to know when patients have to
be referred to nephrologist; when the dialysis has to be initiated; and what
are the indications of dialysis. A total of 270 patients were classified as
three groups by age: group I, 15–39 years-old; group II, 40–59 years-old;
group III, over 60-years-old. Early referral (ER) was defined as initiation
of dialysis over one month and late referral (LR) as initiation of dialysis
within one month after referral. Indications were divided as absolute and
relative indication (Hakim, 1995). The mean age was 46.2-years-old, and
ranged from 15 to 79 (M:F 5 170:100). The underlying diseases were
chronic glomerulonephritis (110 cases), diabetes mellitus (59 cases), and
hypertension (46 cases). In the referral pattern, ER was diagnosed in 130
cases (48.2%), and LR was in 140 cases (51.8%). In the indication of
dialysis, absolute indication was 173 cases (64%), and relative indication
was 97 cases (36%). The numbers of patients of each group were 107, 94,
69, respectively. In group I and II, male was predominant (64:36, 68:32,
respectively), but in the group III, the sex ratio was similar (48:52). The
most common underlying disease in group I (69%) was chronic glomeru-
lonephritis, and diabetes was the leading cause in groups II and III (23%,
43%). In group I, LR was more frequent than ER (66%:34%), but in
group II and III, ER was more frequent than LR (43%:57%, 43.3%:
56.7%). Especially in group III, ER outnumbered LR (P 5 0.015). There
was no significant difference in indication according to age and referral.
There were significant negative correlations between the age and labora-
tory results at the initiation of dialysis such as BUN, creatinine, and
phosphorus (P , 0.001). In the elderly, diabetes and ER were predomi-
nant, and absolute indication was frequent without severe laboratory
findings in initiation stage. Therefore, more careful follow-up and treat-
ment was warranted in the elderly.
Acute potassium repletion by the dialysate loaded with KCl during
CAPD. H.J. Kim, H.S. Moon, G.T. Park, T.Y. Kim, I.G. Park, Depts of Int
Med and Clinical Pathology, Hanyang University Kuri Hospital, Kuri, Korea.
This study was aimed to evaluate the effectiveness of acute potassium (K)
loading via the dialysate during CAPD. Sixteen patients with plasma
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potassium less than 4.0 mEq/liter were divided into 4 groups, and 4
patients of each group were loaded for 6 hours with 2 liters of 1.5%
dialysate containing 10, 20, 30 and 40 mEq of KCl, respectively. In all 4
study groups, equilibrium was similarly reached by dialysis dwelling for 6
hours, as evidenced by a dialysate to plasma K concentration ratio near to
1. The degree of the absorption of K via peritoneum was the highest (76 6
5.6%) in 40 mEq followed by 30 mEq (68 6 4.9%), 20 mEq (59 6 5.9%),
and 10 mEq (18 6 24%) of KCl. However, of the total amount of K
absorbed, the degree of intracellularly shifted K was variable in each
group (74 6 19% in 40 mEq, 87 6 8% in 30 mEq, 73 6 22% in 20 mEq,
and 108 6 111% in 10 mEq of KCl, respectively). The increments in
plasma K (mean 6 SD) were 0.8 6 0.19 mEq/liter in an exchange with 40
mEq, 0.3 6 0.18 mEq/liter with 30 mEq, 0.35 6 0.25 mEq/liter with 20
mEq, and 0.13 6 0.17 mEq/liter with 10 mEq of KCl. Despite loading with
KCl, 2 patients with 10 mEq, 1 with 20 mEq, and 1 with 30 mEq in the
dialysate remained hypokalemic less than 3.5 mEq/liter after an exchange.
No one in the group loaded with 40 mEq of KCl remained hypokalemic or
developed severe hyperkalemia more than 5.5 mEq/liters. This potassium
repletion was well tolerated except 1 out of 4 patients with the exchange
with 40 mEq of potassium developed mild abdominal cramp during initial
phase, temporarily. In conclusion, the assessment of increment in plasma
K concentration after K loading into the dialysate should consider the
variable degree of intracellularly translocated K in individual CAPD
patients besides the administered amount of KCl during an exchange.
Furthermore, we recommend that the dialysate (2 liter) containing 40
mEq of KCl could be used as a safe and effective method for the acute K
repletion for the mild to moderate degree of hypokalemia in CAPD
patients.
Hemodialysis (HD) improves the quality of sleep in patients with
chronic renal failure. S.J. Ahn, S.H. Lee, D.C. Jin, Y.S. Kim, E.J. Choi, Y.S.
Chang, B.K. Bang, Department of Internal Medicine, St Paul’s Hospital, The
Catholic University of Korea, Seoul, Korea. The aim of this study was to
investigate the prevalence of sleep-related symptoms in HD patients and
to examine the effect of HD in sleep architecture and sleep apnea. We
interviewed 47 patients using a sleep questionnaire, and randomly selected
15 patients to perform a polysomnographic study during the preHD and
postHD periods. Sleep-related symptoms in the sleep questionnaire were
noted in 84.8% of patients (N 5 39). The sleep apnea diagnosed by PSG
was 46.7% (N 5 7; 4 at preHD, 3 at postHD period). The type of apnea
analyzed for all apneic episodes did not have a meaningful difference from
before and after HD (central, 38.6% vs. 40.4%; obstructive, 16.0% vs.
14.5%; mixed, 44.0% vs. 45.2%). The sleep latency, and s2 and REM sleep
of total sleep time in sleep architecture were significantly different from
before and after HD. After HD the sleep onset latency period shortened
(preHD 49.7 6 26.5 min vs. postHD 19.6 6 12.8 min, P , 0.01) and the
proportion of REM sleep, stage 3 and 4 non-REM types of sleep for total
sleep time increased in all patients. We conclude that maintenance HD
patients complain frequently of sleep-related symptoms, and it’s somewhat
true that the prevalence of sleep apnea was high among them. However,
even though the hemodialysis did not significantly affect sleep apnea, it
improved sleep induction and deep sleep.
Is the measurements of vascular access flow rate and recirculation by
the Crit-Line valid? H.S. Kim, K.A. Ma, S.S. Kim, G.T. Shin, D.H. Kim, K.I.
Jung, Y.S. Kwak, Department of Nephrology, Diagnostic Radiology, Clinical
Pathology, College of Medicine, Ajou University, Seoul, Korea. Accurate
measurements of vascular access flow and blood re-circulation within
vascular access is an important aspect in delivering an optimal dialysis for
end-stage renal failure patients on hemodialysis. The use of the Crit-Line
monitor has become popularized recently as the change in intravascular
volume can be monitored continuously during a hemodialysis session.
Some researchers have also reported that this apparatus can be used to
estimate the vascular access flow as well as the re-circulation. We,
therefore, compared these two parameters estimated by the use of the
Crit-Line IIR (In-Line Diagnostics, UT, USA) to that obtained by more
conventional methods in 15 maintenance hemodialysis patients. The
conventional methods used were Duplex Doppler to estimate the vascular
access flow, and the low flow method to measure the re-circulation. The
Crit-Line method to measure the access flow requires saline injection
through the venous port and observing its dilution effect, whereas the
re-circulation measurement can be obtained by injecting an aliquot of
saline through the arterial port. Each patient underwent the same
measurements twice to compare the vascular access flow and three times
to compare the re-circulation. There were 15 patients (8M:7F) with an
average age of 53.9 6 10.5 years in this study. Re-circulation using the
Crit-Line method was 6.02 6 4.3% versus the low flow method, 1.79 6
2.32% (P 5 0.002). For vascular access flow, the Crit-Line method was
1079 6 1490 ml/min versus the Duplex Doppler 1208 6 617 ml/min (P 5
0.046). We feel that the use of the Crit-Line IIR to estimate vascular
access recirculation and its flow rate is not advisable to be incorporated
into routine quality control in maintenance hemodialysis therapy. How-
ever, because of our small sample size, further study is needed to draw a
definitive conclusion on its validity.
The use of Fraxiparine in high risk hemodialysis patients. K. Hwangbo,
S. Hwang, A.S. Lim, I.N. So, S.H. Chung, M.S. Park, S.D. Hwang, and H.B.
Lee, Hyonam Kidney Laboratory, Soon Chun Hyang University, Kidney
Center, Soon Chun Hyang University Hospital, Seoul, Korea. Anticoagula-
tion is vital in hemodialysis (HD) to maintain adequate dialysis. The use
of anticoagulating agent is, however, limited in patients with a high risk of
bleeding. To evaluate the effect of fractionated heparin (FH) in HD
patients (Pt) with high risk of bleeding. 19 Pt (10 major surgery, 7 gastric
bleeding, 1 each of renal cyst bleeding and pericardial effusion) were
included in this study. Four consecutive HD sessions using single intrave-
nous injection of FH (0.2 ml in patients with body weight 40–70 kg and 0.3
ml for over 70 kg) followed by 4 consecutive HD sessions with low dose or
no heparin (LH) were performed in 9 Pt and in reverse order in 10
patients. Major hemorrhagic episodes were recorded and pre- and
post-HD body weight, blood pressure, activated partial thromboplastin
time (APTT), hemoglobin (Hb), hematocrit (Hct), and platelet count (Plt)
were obtained. Clots in bubble trap and/or dialyzer was given scores: 0,
none; 1, fibrin ring; 2, fibrin ring requiring saline flush; 3, complete
obstruction. The color of dialyzer after completion of dialysis was given
the following scores: 0, pale; 1, pale pink; 2, pink. Time of compressing the
needling site to prevent vascular access bleeding was recorded. No
hypotensive episodes were observed during HD. Recurrence of gastric
bleeding in 3 Pt (5 episodes with FH and 4 episodes with LH) and renal
cyst bleeding (1 episode with FH) were observed during the study period.
No bleeding complications were observed in the other 15 Pt. No significant
differences in pre- and post-APTT, Hb, Hct, and Plt were observed
between FH and LH. Significantly fewer clots in bubble traps and/or
dialyzer were observed during HD with FH than LH (0.07 6 0.19 vs 0.79 6
0.91). No significant difference was observed in hemodialyzer color at the
end of dialysis and time of compressing needling site between FH and LH.
Tubing system was changed due to complete obstruction of bubble traps
and hemodialyzer in 4 episodes in 3 Pt with LH, but not with FH. In
conclusion, Fraxiparine was effective in preventing coagulation in the
extracorporeal circulation and did not increase bleeding complications
during HD in high risk Pt, and is recommended for use in HD Pt with high
risk of bleeding.
Effects of recombinant human erythropoietin (rHuEPO) therapy on
exercise capacity and quality of life in patients with end-stage renal
failure. H.C. Song, E.J. Choi, D.C. Jin, Y.S. Chang, S.N. Yun, S.Y. Kim, S.A.
Yoon, S.J. Ahn, S.H. Lee, Y.S. Shin, C.H. Park, Y.O. Kim, S. Kim, B.K. Bang,
Department of Medicine, The Catholic University of Korea, Seoul, Korea. To
determine whether rHuEPO improves the exercise capacity and the global
quality of life, 52 nondiabetic patients with end-stage renal failure
undergoing regular dialysis (hemodialysis 42, CAPD 10, M 34, F 18) were
selected from 7 affiliated hospitals with the Catholic University in Korea.
We injected rHuEPO (4000 units 3 times a week, Eprex prefilled syringe;
Jannsen Korea) subcutaneous to the patients with Hb levels 7–9 g/dl. After
the target Hb level of 10–12 g/dl was reached, it was maintained for
another 4 weeks. All patients received oral or intravenous iron through
trial. Exercise capacity was evaluated by using a standard incremental
cycle exercise protocol with a treadmill, step walk load in fixed floors, and
the global quality of life was assessed by means of an interview based
questionnaire (scale 1–7). The initial Hb level (7.4 6 0.9 g/dl) was
increased to the target Hb level (10.0–12.0 g/dl) on week 5.5 6 2.3 and
highest level (11.8 6 1.4 g/dl) at 8 weeks (P , 0.001). In the exercise
capacity test, the times of step walk before rHuEPO established two floors,
on target Hb, and after 4 weeks the target levels were decreased (15.3 6
5.0 sec, 14.5 6 4.4 sec, 13.9 6 4.7 sec, P , 0.01). The times of walking and
the amounts of work load on the treadmill before rHuEPO and after 4
weeks of target level were increased (walk time 482 6 143 sec, 572 6 147
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sec, P , 0.01, work load 9.4 6 2.5 mets, 11.0 6 2.5 mets, P , 0.01). In the
global quality of life, all scored an improvement of fatigue (4.3 6 1.1,
5.2 6 1.0, 5.4 6 1.0), the daily activity (4.8 6 1.4, 5.5 6 0.9, 5.5 6 1.1) and
the quality of life (4.0 6 1.1, 4.8 6 0.7, 4.9 6 0.8) were improved (P ,
0.01). In conclusion, it is meaningful to maintain the Hb level of 10–12 g/dl
for better quality of life and exercise capacity in patients with end-stage
renal failure who are undergoing dialysis.
Usefulness of intravenous iron supplement during recombinant human
erythropoietin (rHuEPO) therapy in hemodialysis (HD) patients. K.J.
Park, J.Y. Kang, W.S. Yang, S.B. Kim, J.S. Park, and C.D. Hong, Department
of Internal Medicine, College of Medicine, University of Ulsan, Seoul, Korea.
Compared with iron dextran, ICS is much cheaper and has better
bioavailability. To evaluate efficacy and safety of iron chondroitin sulfate
(ICS) in maintenance HD patients, i.v. ICS was given to 37 HD patients
(20 M, 17 F, median age 51 years, median duration of HD 21 months)
whose ferritin (Fer) , 100 mg/liter or transferrin saturation (TFS) ,20%
(Group I, 12 M, 10 F) or Hb , 9.0 g/dl in spite of increased rHuEpo dose,
Fer . 100 mg/liter and TFS . 20% (Group II, 8 M, 7 F). The patients had
taken oral iron [227 6 73 mg/day (mean 6 SD)] before this study. All
patients received 120 mg i.v. ICS weekly for 1 month. Then, the ICS
dosage was adjusted to 40–120 mg/week depending on Hb, Fer, and TFS
in the following 3 months. Hb, Fer, TFS, rHuEPO dose and side effects
were monitored monthly. The results were as follows:
Parameters Pre-ICS 4 Months
All patients Hb g/dl 8.3 6 0.9 9.7 6 0.9b
Fer mg/liter 162 6 149 472 6 255b
TFS % 24 6 13 41 6 18a
rHuEpo U/kg/week 95 6 50 69 6 28a
Group I Hb g/dl 8.5 6 1.1 9.9 6 0.9b
Fer mg/liter 90 6 48 379 6 186b
TFS % 18 6 9 36 6 16a
rHuEpo U/kg/week 87 6 45 69 6 27
Group II Hb g/dl 8.1 6 0.6 9.3 6 0.9b
Fer mg/liter 277 6 181 602 6 287b
TFS % 35 6 13 44 6 19
rHuEpo U/kg/week 108 6 55 69 6 31a
a P , 0.05; b P , 0.01, paired t-test
An annual cost reduction of 221 US dollars per patient was expected. No
significant side effect was observed. In conclusion, ICS is a effective and
safe intravenous iron preparation in HD patients.
Clinical significance of bone-specific alkaline phosphatase (bAP) as a
marker of bone turn-over in hemodialysis (HD) patients: Impact of
metabolic acidosis on these bone markers. K.R. Park, D.H. Kang, K.B.
Choi, K.I. Yoon, Department of Internal Medicine, Ewha Women’s University
College of Medicine, Seoul, Korea. Renal osteodystrophy is a leading cause
of morbidity in patients with end-stage renal disease (ESRD), including a
diverse clinical spectrum and histologic lesions. Because of the invasive-
ness and practical limitations of bone biopsy to diagnose the exact nature
of bone disease in ESRD patients, many attempts have been made to
investigate the biologic markers of bone disease. Serum alkaline phospha-
tase (tAP) is made up of isoenzymes produced by intestine, liver, kidney
and bone. Despite the heterogeneity of this enzyme, the measurement of
tAP activity provides only a rough information of osteoblastic activity.
Bone-specific alkaline phosphatase (bAP) is localized in the plasma
membrane of osteoblast to be involved in bone formation and skeletal
mineralization. This study was undertaken to evaluate the value of bAP in
the diagnosis of renal osteodystrophy, and to examine the correlation
between bAP (ELISA, Metro, USA) and other known markers of bone
turnover, tAP, intact parathyroid hormone (iPTH) and osteocalcin in 49
HD patients (M:F 29:20, mean age 43.6 years, mean HD duration 63.0
months). We also evaluated the impact of metabolic acidosis, which is
known to stimulate the osteoclastic activity and bone resorption, on
plasma levels of these bone markers. The median of bAP in HD patients
was 30.1 ng/ml (8.8–140.1 ng/ml), which was significantly higher than in
normal control patients. There was a significantly positive correlation
between the duration of HD and plasma levels of tAP, bAP, iPTH and
osteocalcin. A significantly positive correlation was also observed between
iPTH, bAP, tAP and osteocalcin. bAP correlated better with iPTH (r 5
0.8483, P , 0.001) than tAP (r 5 0.7588, P , 0.01). In the patient group
whose arterial blood bicarbonate below 20 mEq/liter (30 cases), plasma
iPTH and bAP were significantly lower compared to the patients with
arterial HCO3
2 higher than 20 mEq/liter. In conclusion, bAP can be an
useful marker of bone turnover in HD patients. Increased concentrations
of iPTH and bAP in patients with metabolic acidosis (arterial HCO3
2
below 20 mEq/liter) may reflect an increased bone resorption with a
resultant increase in osteoblast activity. However, a prospective study with
alkali supplementation and bone biopsy will be necessary to define the
exact role of metabolic acidosis in the development of renal osteodystro-
phy.
Soluble TNFa receptor I is not dialyzable and the serum level is
correlated with degree of renal failure. D.C. Jin, S.H. Lee, S.Y. Kim,
E.J. Choi, Y.S. Chang, B.K. Bang, Department of Internal Medicine, The
Catholic University of Korea, Seoul, Korea. TNFa is one of major inflam-
matory cytokines in glomerulonephritis and causes the first use syndrome
through the mechanism of release from monocytes after the contact with
new dialyzer membrane. Soluble TNFa receptor, cysteine rich glycopro-
tein, can block the TNFa function as natural inhibitor, and is accumulated
in the renal failure patient. This study is on the ESRD patient’s serum
level of TNFa and TNFa receptor I (55 kD) at the pre- and post-
hemodialysis state, and the level was compared with normal persons’ or
non-dialysis renal failure patients’ level. The subjects were 24 stable
ESRD patients (15 males and 9 females) over 3 months in hemodialysis
program with Cuprophan membrane dialyzer, whose mean predialysis
serum creatinine was 11.5 6 2.44 mg/dl. The compared group was
consisted of 12 moderate renal failure patients (10 males and 2 females)
who were not yet enrolled in a dialysis program, whose mean serum
creatinine was 4.71 6 3.1 mg/dl, and 15 normal persons (6 males and 9
females, mean serum creatinine 0.97 6 0.16 mg/dl). The measurement was
performed by the ELISA method (Biosource International, Medgenix).
The results were as follows: (1) TNFa levels were highly variable within
the groups, and were 6.44 6 7.4 pg/ml at pre-hemodialysis and 9.28 6 11.2
pg/ml at post-hemodialysis (no significant difference, P . 0.05). The levels
were 5.58 6 11.9 and 1.74 6 4.4 pg/ml in moderate renal failure group and
normal group, respectively (P . 0.05). The levels of TNFa R I were
significantly different between groups (P , 0.01), which were 27.5 6 7.9,
7.55 6 1.0, 1.47 6 0.28 pg/ml in hemodialysis group, moderate renal
failure group and normal group, respectively. (2) The TNFa R I receptor
level had a significantly positive correlation with creatinine levels through-
out the groups (P , 0.01, r 5 0.70). (3) The pre- and post-hemodialysis
TNFa R I level were not significantly different, but individual changes
were significantly correlated with the change of serum albumin (P , 0.01,
r 5 0.317), which suggested that the changes were due to ultrafiltration
and TNFa R I was not dialyzable. In summary, serum level of TNFa was
not significantly increased by exposure to dialyzer membrane. Soluble
TNFa receptor, which is not a dialyzable uremic toxin, could be regarded
as an potential indicator for residual renal function in moderate renal
failure patients and also hemodialysis patients.
Lipid profiles in chronic renal failure in patients with conservative
treatment (CT), continuous ambulatory peritoneal dialysis (CAPD),
hemodialysis (HD) and kidney transplant (KTP). K.-J. Kim, Y.H. Shin,
B.K. Kam, D. Huh, M.S. Kim, and S.R. Lee, Department of Internal
Medicine, Bong Saeng Hospital, Pusan, Korea. A higher risk of cardiovas-
cular disease was reported to be related to lipid abnormalities in patients
with chronic renal failure or renal replacement therapy. We compared
lipid profiles including apoprotein in patients with chronic renal failure
with conservative treatment, CAPD, HD, and KTP patients. We measured
the plasma levels of total cholesterol (TC), triglyceride (TG), high-density-
lipoprotein (HDL), low-density-lipoprotein (LDL), apoprotein-AI (apo-
AI) and apoprotein-B (apo-B) in patients with CT (N 5 38), CAPD (N 5
108), HD (N 5 113) and KTP (N 5 132). We compared lipid profiles
between these groups, and observed the number of patient with abnormal
EKG changes, cardio-thoracic ratio (C-T ratio), incidence of cerebro-
vascular accident (CVA), hemoglobin (Hb), body mass index (BMI) and
serum albumin. Also, lipid profiles were compared between patients with
and without diabetes mellitus (DM), in male and female patients, and in
KTP patients according to the different immunosuppressive regimens.
The TC, HDL, LDL, apo-AI and apo-B were significantly higher in KTP
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(219 6 45, 57 6 17, 129 6 37, 145 6 33, 119 6 34) than in any other
treatment group. TG was significantly higher in CAPD (173 6 82) than in
KTP, HD and CT. No significant correlations of lipid profile were found
between patients with and without DM, patients with and without
abnormal EKG changes, and in KTP patients with different immunosup-
pressive regimens. Incidence of patients with grade III EKG changes (ST,
T changes and or LVH) was significantly higher in HD than in KTP (17%
vs. 6%). In the HD group, the Hb level was significantly lower (9.4 6 1.2)
and the C-T ratio was higher (0.53 6 0.06) than in other groups. In
conclusion, (1) KTP patients had significantly higher levels of TC, HDL,
LDL, apo-AI and apo-B than any other treatment groups. (2) The TG was
significantly higher in CAPD than other groups. (3) Incidence of patients
with grade III EKG changes (ST, T changes and or LVH) was significantly
higher in HD than in KTP patients (17% vs. 6%). (4) In the HD group, the
Hb level was significantly lower and the C-T ratio was significantly higher
than in the other groups.
Apolipoprotein polymorphism and plasma lipid levels in male patients
with chronic renal failure. Y.H. Lee, H.Y. Kim, W. Huh, S.H. Chang, Y.G.
Kim, D.J. Kim, and H.Y. Oh. Department of Internal Medicine, Samsung
Seoul Hospital, Seoul, Korea Department of Internal Medicine, Gyeong Sang
National University, Jinju, Korea. Accelerated atherosclerosis is not only a
frequent complication, but also the most common cause of death in
patients with chronic renal failure (CRF). Although mechanisms are
unclear, disorder of lipid metabolism may be a major factor. Since
apolipoprotein (apo) E is known to play a major regulatory role in lipid
metabolism, we evaluated apo E genotype in 72 male patients with CRF
and compared with that in 104 male normal controls. In addition, we
measured plasma lipid and apolipoprotein concentrations and evaluated
them according to the apo E genotype in patients and controls. Apo E
genotype was determined with the INNO-LiPA Apo E kit (Innogenetics,
Belgium), which is based on reverse hybridization. The distribution of the
three major apo E alleles (e2 6.2%, e3 80.6%, e4 13.2%) in patients with
CRF was not different from that in controls (e2 4.1%, e3 87.6%, e4 8.3%).
In patients with CRF, total cholesterol, low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) levels were significantly lower and the
triglyceride and lipoprotein(a) levels were significantly higher than those
in controls, respectively. In controls, the E 4/3 group had significantly
lower levels of HDL than E 3/3 and E 3/2 groups. In patients with CRF,
the E 4/3 group had significantly higher levels of total cholesterol and apo
B lipoprotein than E 3/2 group. Although there was no significant
difference in the apo E genotype frequencies between male patients with
CRF and controls, apo E polymorphism may play an important role in the
determination of individual differences in plasma lipids in male patients
with CRF.
Homocysteine and atherosclerosis in chronic hemodialyzed patients.
Y.K. Lee, S.Y. Kim, J.H. Shin, K.S. Oh, D.R. Cha, Y.J. Kwon, W.Y. Cho, H.J.
Pyo, and H.K. Kim, Department of Internal Medicine, College of Medicine,
Korea University, Seoul, Korea. Homocysteine is an intermediate amino
acid produced by the metabolism of methionine. Hyperhomocysteinemia
has been proposed to be an independent risk factor for atherosclerosis and
induced occlusive vascular disease in chronic uremic patients. In this
study, we examined the correlation between homocysteine and atheroscle-
rosis, and the relative risk for cardiovascular disease in patients with
hyperhomocysteinemia. We studied 59 patients undergoing chronic he-
modialysis (27 men and 32 women with mean age 49.49 6 13.60) in Korea
University Hospital on October 1996. We determined atherosclerotic
score (ASS 2–20 points; Kim, 1994) in each patient by chest x-ray, ocular
fundus (Scheie classification), EKG, myocardiac infarction, cerebral in-
farction and peripheral vascular disease. We measured total plasma
homocysteine by the HPLC method, serum total lipid, total cholesterol,
triglyceride, HDL, LDL cholesterol, vitamin B12, folate and uric acid
levels. We evaluated history of diabetes, duration of dialysis, smoking
behavior and use of erythropoietin. The mode ASS was 3 (mean 5.63 6
3.60: min 2, max 13), and median plasma homocysteine level was 24.42 m
mol/liter (mean 26.88 6 16.17 m mol/liter). ASS was significantly corre-
lated with total plasma homocysteine level (r 5 0.39) and age (r 5 0.67),
and higher in patients with diabetes (P , 0.005). However, serum vitamin
B12, folate, uric acid, total lipid, LDL cholesterol level and smoking
behavior were not significantly associated with ASS. By univariate analysis,
in the high ASS group (6–13 points, 24 patients) the total plasma
homocystein level was 35.18 6 27.58 m mol/liter and in the low ASS group
(2–3 points, 20 patients) it was 20.93 6 6.53 m mol/liter (P 5 0.017). Mean
age (P , 0.005) and history of diabetes (P 5 0.038) were also significantly
higher in high ASS group. By multivariate analysis, total plasma homo-
cysteine level (P 5 0.017) and age (P 5 0.002) were significant risk factors
for high ASS group. The cardiovascular disease was developed more
frequently in the group with higher plasma homocysteine level than
median value (.24.42 m mol/liter) compared to the group with lower value
(,24.42 m mol/liter). The odds ratio was 8.40 (95% CI 2.08–33.98). This
study showed that atherosclerosis was developed more frequently in the
plasma homocysteine level above 24 m mol/liter. We suggest that the
therapy for hyperhomocysteinemia and follow-up evaluation are war-
ranted in this group.
Correlation between the concentrations of plasma homocysteine and
vitamin B6, vitamin B12 and folic acid in end-stage renal disease. S.Y.
Hong, D.H. Yang, S.K. Chang, Department of Internal Medicine and
Chemistry, Soonchunhyang University, Chunan City, Korea. To determine
whether replacement of folic acid, vitamins B6, and B12 could be used
therapeutically for hyperhomocysteinemia in dialysis patients, the rela-
tionship between the concentrations of homocysteine and these vitamins
was observed in patients with ESRD with or without hemodialysis. A cross
sectional study by quantitative measurement of vitamin B6, B12, folic acid,
and homocysteine was carried out among these 3 groups: 44 ESRD
patients on hemodialysis with replacement of folic acid, vitamin B6, and
B12 (hemodialysis group), 27 chronic renal failure patients without hemo-
dialysis (non-dialysis group), and 17 hypertensive patients (control group).
Homocysteine concentration was higher both in the dialysis group (15.5 6
6.6 mmol/liter and non-dialysis group (15.7 6 4.2 mmol/liter) than in the
control group (6.2 6 1.5 mmol/liter; P , 0.001). However, there was no
difference in the homocysteine concentration between the dialysis and
non-dialysis groups. In the control group, the homocysteine concentration
showed a reverse correlation with the concentrations of folic acid (r 5
0.584, P 5 0.014) and vitamin B12 (r 5 0.485, P 5 0.049) but not with
vitamin B6. In the non-dialysis group, the creatinine clearance levels
showed a direct correlation to the homocysteine concentrations (r 5
20.575, P 5 0.0126), and folic acid concentration (r 5 20.541, P 5
0.0204), but not to the vitamin B6 and B12 concentrations. The homocys-
teine concentration showed a reverse correlation to the both folic acid (r 5
0.431, P 5 0.0247) and vitamin B12 (r 5 20.562, P 5 0.023), but not to the
vitamin B6 concentrations. In contrary, these correlations were not seen in
the dialysis group. In conclusion, the homocysteine concentrations showed
a reverse correlation to both the folic acid and vitamin B12 concentrations
in both the control and non-dialysis groups, suggesting that hyperhomo-
cysteinemia may be lowered by the administration of vitamin B12 and folic
acid. However, these correlations were not seen in the dialysis group.
Hyperhomocysteinemia in the dialysis group does not seem to be lowered
by replacement of folic acid, vitamin B6, and vitamin B12.
Changes of hemostatic factors synthesized in the liver in CAPD
patients and its correlation with serum albumin (SAlb). S.B. Kim, W.S.
Yang, S.K. Lee, and J.S. Park, University of Ulsan, Seoul, Korea. There are
several studies that hypoalbuminemia leads to increased synthesis of
lipoproteins, including lipoprotein(a), in the liver. This study was per-
formed to evaluate (1) the changes of the hemostatic factors synthesized
in the liver in CAPD patients; (2) the association of SAlb and the plasma
concentration of hemostatic factors, and (3) the effect of raising of serum
Alb on hemostatic factors. We measured blood levels of SAlb, fibrinogen
(Fbg), factor II, factor VII (F.VII), protein C, free protein S, plasminogen,
a2-antiplasmin and antithrombin III in 103 CAPD patients and 30 normal
controls. Presence of atherosclerotic cardiovascular disease (CVD) was
determined in patients older than 40 years, by positive result in a stress
thallium SPECT or an ankle brachial index less than 0.9. The 22 patients
with SAlb , 3.5 g/dl were divided into two groups. In Group I (N 5 11),
hemostatic factors and SAlb were measured before, after repeated infusion
of 20% SAlb 100 cc three times per week for two weeks, and 4 weeks after
withdrawal of SAlb infusion. In Group II (N 5 11), the same parameters
were measured without SAlb infusion. C-reactive protein (CRP) and
hematocrit (Hct) were followed in both groups as indicators of acute
phase reactant and indirect measure of volume status. CAPD patients as
a whole had lower SAlb and higher Fbg and F.VII than normal controls
(3.4 6 0.6 vs. 4.5 6 0.3 g/dl, 516 6 145 vs. 304 6 78 mg/dl, 140 6 52% vs.
104 6 23%, respectively, P , 0.01). CAPD patients with CVD (N 5 20)
had higher Fbg than those without CVD (N 5 66) (608 6 149 vs. 506 6
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132 mg/dl, P , 0.05). SAlb and Fbg of diabetic patients (N 5 40) were
different from those of non-diabetic patients (N 5 63) (3.2 6 0.6 vs. 3.5 6
0.6 g/dl, 559 6 140 vs. 489 6 141 mg/dl, P , 0.05). There was no difference
in SAlb or hemostatic factors between rHuEPO-users (N 5 47) and
non-users (N 5 56). Only Fbg was correlated with SAlb [r 5 20.27, P ,
0.01]. SAlb in Group I increased from 2.7 6 0.4 to 3.5 6 0.6 g/L at the end
of repeated infusion of SAlb and Hct decreased from 26.6 6 4.4 to 24.9 6
5.2%. Fbg and F.VII decreased significantly, even after correction with
Hct (624 6 96 vs. 556 6 91 mg/dl, 160 6 36 vs. 121 6 44%, P , 0.05).
Other hemostatic parameters did not change. Four weeks after withdrawal
of SAlb infusion, serum Alb decreased to 2.7 6 0.5 g/dl, whereas Fbg and
F.VII increased to 619 6 78 mg/dl and 158 6 32% (P , 0.05). Serum Alb,
Hct and hemostatic factors in Group II did not change. CRP was stable
during the study period in both groups. These findings indicate that
hypoalbuminemia is an important trigger factor in the elevation of Fbg,
and possibly F.VII, in CAPD patients.
Association of plasma fibrinogen concentration with vascular access
occlusion (VAO) in hemodialysis (HD) patients: A prospective study. I.S.
Song, J.Y. Kang, W.S. Yang, S.B. Kim, J.S. Park, C.D. Hong, Department of
Internal Medicine, University of Ulsan, Seoul, Korea. Plasma fibrinogen
concentration is regarded as an important risk factor for ischemic heart
disease and other vascular disease; however, its association with VAO has
not been determined. We performed a prospective study to evaluate the
association of fibrinogen level with VAO in HD patients. Between
September 1989 and October 1995, 164 patients underwent vascular
access operation for HD, of whom 103 patients (55 M, 48 F) who had been
followed-up for more than 18 months were included in the analysis. Blood
fibrinogen, albumin, cholesterol, platelet count were measured for all
patients at the time of operation. Median age was 51 years (range 19–79)
and median duration of follow-up was 37 months (range 18–91). Under-
lying renal disease of 35 patients were diabetes mellitus. VAO occurred in
30 patients during the follow-up. Patients with VAO were older (54 6 10
vs. 47 6 14 years, P , 0.05) and had longer duration of follow-up (54 6
23 vs. 40 6 20 months, P , 0.01), higher fibrinogen (526 6 184 vs. 431 6
125 mg/dl, P , 0.01) and lower albumin level (35 6 5 vs. 32 6 6 g/liter, P ,
0.05) at the time of fistula operation than those without VAO. Sex,
cholesterol level, platelet count, use of PTFE graft (N 5 18) and presence
of diabetes as the underlying renal disease were not different between two
groups. Cox proportional hazard analysis showed that both age and
fibrinogen were independently associated with VAO (P , 0.01). In
conclusion, age and elevated fibrinogen level were independent risk
factors for vascular access occlusion in HD patients.
Effect of high-sodium dialysate hemodialysis on blood pressure. H.C.
Song, E.J. Choi, S.M. Park, Y.S. Kim, S.W. Kim, S.W. Jang, Y.O. Kim, S.Y.
Kim, Y.S. Jang, and B.K. Bang, Department of Internal Medicine Catholic
University, Seoul, Korea. Hypotensive episodes during hemodialysis are
one of the most serious complications. High-sodium dialysate is used for
relief of this problem but sometimes interdialytic weight gain or exacer-
bation of hypertension happen. To evaluate the effect of high-sodium
dialysate, 7 non-diabetic normotensive hemodialysis patients were treated
with 3 stages of sodium programs: stage A, sodium 138 mEq/liter for 4
hours; stage B, sodium 148 mEq/liter for 4 hours; stage C, initially sodium
148 mEq/liter for 3 hours and 138 mEq/liter for 1 hour. The final stage was
continued for 2 weeks. The incidence of hypotension (systolic blood
pressure ,90 mm Hg or treatment of hypotension) during HD were
significantly lower in group B (24%) than group A (65%) and C (48%)
(P , 0.05) and group B improved muscle cramp during hemodialysis (P ,
0.05). However, there was some exacerbation of thirst during hemodialysis
and postdialysis (P , 0.05). Interdialytic weight gain and predialysis blood
pressure were not significantly different in each group. Similarly, there
were no differences in the predialysis serum sodium concentration, serum
ANP concentration and serum osmolarity, but mid-dialysis (HD-2 hrs)
serum sodium concentration and serum osmolarity were higher in group B
(145.6 6 2.1 mEq/liter, 306 6 6.7 mOsm/kg z H2O) and group C (146.1 6
2.1 mEq/liter, 306 6 13.1 mOsm/kg z H2O) than group A (140.1 6 2.5
mEq/liter, 292 6 8.7 mOsm/kg z H2O) (P , 0.05). In the measurement of
postdialysis blood pressure, the diurnal variation was preserved in all
group and the incidence of postdialysis hypotension (systolic blood
pressure ,90 mm Hg) was not different significantly. In non-diabetic
normotensive patients, high-sodium dialysate was decreased the incidence
of hypotension and muscle cramp during hypotension. There was no
postdialytic blood pressure elevation and no loss of diurnal variation of
blood pressure.
Factors affecting left ventricular and systolic dysfunction in patients
with hemodialysis. S.H. Noh, E.S. Kim, J.H. Kim, H. Koh II, Department of
Internal Medicine, Inje University, Seoul Paik Hospital, Seoul, Korea. To
evaluate determinant factors of left ventricular (LV) hypertrophy and left
ventricular systolic dysfunction in patients with hemodialysis, M-mode and
two dimensional echocardiography were performed in 77 essential hyper-
tension without azotemia and 89 chronic renal failure patients receiving
maintenance hemodialysis. M-mode measurement including LV mass
(192.56 6 63.6 g vs. 300.01 6 95.99 g, P , 0.001), r/th (radius/LV
thickness, 4.41 6 0.97 vs. 4.74 6 1.0, P , 0.05), LV dimension and
fractional shortening (4.68 6 0.6 vs. 5.63 6 0.97, 9.1% vs. 27%, P , 0.001
respectively) showed more severe eccentric LV hypertrophy and LV
dysfunction in patients with hemodialysis than those of essential hyper-
tension. Using linear regression analysis in hemodialysis patients, systolic
and diastolic blood pressure were correlated with LV dimension and r/th
(y 5 0.018x 1 2.9266, r2 5 0.2021, P , 0.01, y 5 0.018x 1 2.9266, r2 5
0.2021, P , 0.01, respectively). In addition to these determinants, serum
PTH levels (y 5 20.024x 1 32.394, r2 5 0.14732, P , 0.001) and Kt/V (y 5
8.544 1 20.533, r2 5 0.1093, P , 0.001) were correlated with systolic
function. The hypertension and dialysis duration, patient’s age, renin,
angiotensin II, aldosterone level had no relationship with LV function and
mass in this study. In conclusion, LV hypertrophy and LV systolic
dysfunction occur more frequently in hemodialysis patients than in
essential hypertension patients. The strongest independent predictor of
LVH in this study was systolic blood pressure, and the independent
predictor of LV systolic dysfunction, which is actually related with the
patient’s quality of life, was partially explained by serum parathyroid level
and Kt/V. However, additional laboratory and prospective clinical studies
are needed to further elucidate the mechanisms involved in the develop-
ment of LVH and LV impairment in hemodialysis patients.
Changes of left ventricular function in chronic renal failure before and
after hemodialysis. Y.W. Kim, D.I. Kim, Y.H. Kim, Department of Internal
Medicine, Pusan Paik Hospital, University of Inje, Pusan, Korea. Cardiac
function in patients with chronic renal failure who have routine hemodi-
alysis for long periods is influenced by many factors, for example,
hypertension, anemia, artherosclerosis, interdialytic fluid collection, aci-
dosis. The fluid shifts that occur during dialysis can alter left ventricular
loading conditions. Hemodialysis may also influence left ventricular
contractility by virtue of its ability to correct electrolyte imbalances, BUN,
hematocrit and concentration of inotrophic mediates. Ten patients with
chronic renal failure, who have hemodialysis during more than 6 months
were studied for the effect of hemodialysis on left ventricular function
through echocardiography. Body weight and systolic blood pressure were
decreased (P , 0.05) and diastolic blood pressure, mean arterial blood
pressure and heart rate did not increased significantly. Serum calcium
increased and BUN and serum potassium decreased significantly (P ,
0.05). The prolonged preejection period, decreased left ventricular ejec-
tion time stroke volume, end systolic wall stress and increased rate
corrected velocity of circumferential fiber shortening, and shortening
fraction had statistical significance. In conclusion, hemodialysis can im-
prove cardiac function, as decreased preload and increased left ventricular
contractility from the patients with chronic renal failure were found in
these patients.
Effect of changes of inferior vena caval diameter on left ventricular
hypertrophy in hemodialysis patients. J.H. Shin, K.W. Kahng, S.M. Kim,
B.H. Lee, C.H. Park, C.M. Kang, H.C. Park, Department of Internal
Medicine, Hanyang University, College of Medicine, Seoul, Korea. The
general estimation of dry weight remains a major problems in the clinical
practice of dialysis. Echography of IVC as a tool to assess over- and
underhydration appears to be valuable, although it is mandatory to
evaluate the cardiac function of the patient first. We examined the effect
of changes of IVC diameter on left ventricular hypertrophy (LVH) in
chronic HD patients. Forty-eight end-stage renal disease patients on
maintenance HD were enrolled. IVC diameter corrected by body surface
area was decreased significantly from 13.8 6 3 mm to 11.5 6 2.5 mm (P ,
0.01) and collapsibility index (CI) was significantly increased from 15.5 6
10.5% to 26.7 6 14.3% (P , 0.01). IVC diameter and its CI were
corrected (r 5 20.34, P , 0.05) and body weight changes was correlated
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with IVC diameter (r 5 0.32, P , 0.05) and with CI (r 5 20.64, P , 0.05).
Ultrafiltration amount was also correlated with IVC diameter and CI (r 5
0.56 and r 5 20.35, respectively). Left ventricular mass index (LVMI)
correlated with the ultrafiltration amount, interdialysis weight gain, and
IVC diameter after HD, but LVMI was not correlated with blood pressure
before and after HD, or the duration of HD. LV geometry was composed
of normal (N 5 10, 20.8%), eccentric hypertrophy (N 5 20, 41.6%),
concentric hypertrophy (N 5 12, 5%), and concentric remodeling (N 5 4,
8.3%). There were no correlations between patterns of LV geometry and
IVC diameter and/or CI. In this study, we observed that echographic
findings of IVC, as a marker of intravascular volume change, was
significantly correlated with LVMI in chronic hemodialysis patients.
Survival analysis of patients undergoing chronic hemodialysis. S.S.
Kim, J.S. Kim, J.H. Kim, P.J. Hwang, G.R. Na, S.M. Oh, K.T. Bin, K.W. Lee,
M.H. Han, K.S. Lee, Y.T. Shin, Department of Internal Medicine, College of
Medicine, Chungnam National University Hospital, Taejeon, Korea. We
analyzed the survival rate and risk factors of 293 patients who started
hemodialysis in Chungnam National University Hospital between January
1986 and June 1996. Analyses were performed for primary cause of renal
diseases, age at initiation of dialysis, co-morbid chronic disease and
various laboratory tests. The causes of CRF were unknown (32.4%),
diabetes (29.7%), glomerulonephritis (16.4%), hypertension (15.0%),
polycystic kidney disease (3.4%) and other urologic diseases. The mean
survival of CRF was 8.4 years. Sixty-eight deaths (23%) were registered, of
which the major cause of death were unknown (34%), stroke (20%),
cardiovascular disease (8.2%) and sepsis (6%). Older age at initiation of
dialysis and diabetes were associated with a significantly increased risk of
death. Of laboratory variables, hyponatremia (,135 mEq/liter) and severe
anemia (Hb ,7.0 g/dl) were also significant risk factors. Hypoalbumine-
mia (,3.0 g/dl) was associated with an increased relative risk, but was not
statistically significant. In conclusion, the aggressive management of
correctable risk factors were needed.
Clinical factors affecting to the peritoneal membrane longevity in
patients with CAPD. I.H. Lee, H.J. Noh, S.K. Shin, S.W. Kang, K.H. Choi,
D.S. Han and H.Y. Lee, Department of Internal Medicine, College of
Medicine, Yonsei University, Institute of Kidney Disease, Seoul, Korea.
Ultrafiltration failure (UF) is a common complication in patients under-
going CAPD. It has been reported that 1.3% to 6.0% of CAPD patients
have to be withdrawn from the treatment because of UF. To evaluate the
clinical factors affecting to peritoneal membrane function in CAPD
patients, We conducted retrospective study in 7 patients who stopped
CAPD within 5 years after initiation due to UF (group I) and in 14
patients who performed CAPD for more than 10 years (group II), using
demographic data, biochemical parameters and medication history. The
mean age of patients at the start of CAPD was significantly higher in group
I (47.1 6 12.9 years) than that in group II (35.5 6 11.3 years) (P , 0.05).
The sex ratios were comparable (2.5:1 vs. 1.8:1). Compared to group II,
group I had larger body surface area (1.76 6 0.14 vs. 1.58 6 0.17 m2) and
greater peritonitis rate (0.74 vs. 0.52 episodes/patient-year), but there was
no significant difference between the two groups. There was also no
difference in the causative organism of peritonitis between the two groups.
Biochemical parameters including total protein, albumin, total choles-
terol, triglyceride, calcium and phosphate levels were not different be-
tween the two groups. In conclusion, old age rather than diabetes or
peritonitis seems to be associated with early ultrafiltration failure in
CAPD patients.
Cancer antigen 125 (CA125) as a bulk mass marker of peritoneal
mesothelial cell in CAPD patients. D.H. Kang, K.B. Choi, K.I. Yoon,
Department of Internal Medicine, Ewha Women’s University College of
Medicine, Seoul, Korea. The longevity of the peritoneum has been an
object of interest and speculation since the inception of CAPD. Peritoneal
mesothelial cells (MC) are the most important intraperitoneal cell quan-
titatively, and have the capability to secrete different types of substances
including lubricant and various cytokines. It may therefore be essential to
have information on the MC mass during peritoneal dialysis. However,
until recently there have been no specific tools to evaluate the exact status
of peritoneal membrane. Ca125 is a 22 kDa glycoprotein that is a clinically
useful tumor marker of non-mucinous epithelial ovarian carcinoma.
Recently, other cells including pleural and peritoneal MC have been
proven to express CA125. This study was undertaken to determine
whether CA125 can be used as a bulk marker of MC mass in 23 clinically
stable CAPD patients. We also analyzed whether the observed intraperi-
toneal production of CA125 can be attributed to MC using the culture
human peritoneal MC from omentum. The CA125 production by MC in
vitro was estimated by various numbers of MC (10,000–1,000,000/well) for
different periods of time. The median concentration of CA125 was
significantly higher in 24-hour spent dialysate than in serum (5.5 vs. 17.3
U/ml, P , 0.05). There was a significant negative correlation between the
dialysate CA125 level and the incidence of peritonitis. In vitro experiments
using cultured MC cells showed an exponential increase of the CA125
level during confluence (8th day of culture), which persistently increased
until 10 days of culture, reaching a plateau. A linear relation between the
number of MC and the amount of CA125 in supernatant was also
observed. In conclusion, CA125 is locally produced in the peritoneal cavity
and can be an useful marker of MC mass in stable CAPD patients. Since
the clinical significance of the inverse correlation between the CA125 level
and peritonitis incidence is uncertain (low CA125 as a second result of
repeated peritonitis or the importance of MC mass to regulate the
antibacterial defense mechanism?), a prospective follow-up study is
necessary to confirm the relation between dialysate CA125 and the
incidence of peritonitis.
Plasma amino acids (AA) level according to peritoneal membrane
transport characteristics in continuous ambulatory peritoneal dialysis
(CAPD) patients. S.W. Lee, K.H. Kwon, K.A. Kim, and M.J. Kim, Depart-
ment of Internal Medicine, Inha University College of Medicine, Incheon,
Korea. Recently, high peritoneal membrane transport characteristics have
been considered a risk factor for malnutrition in CAPD patients. To
ascertain the differences of plasma AA levels according to peritoneal
membrane transport characteristics, we measured the levels of AA in
plasma and 24 hour (hr) drained dialysate in 22 clinically stable CAPD
patients. By the 24 hr dialysate/plasma creatinine ratio (D/PCr), patients
were divided to normal transporter (NT) (D/PCr 0.50–0.80; N 5 10) and
high transporter (HT) (D/PCr . 0.80; N 5 12). There were no differences
between the two groups in age, sex, duration of CAPD, diabetes mellitus,
serum total CO2, and weekly Kt/V urea. Eighty percent of HT experienced
peritonitis more than 1 episode (80.0 vs. 41.7%, P , 0.05). Normalized
protein catabolic rate seemed to be lower in HT than NT (0.71 6 0.29 vs.
0.81 6 0.13 g/kg/day). There were no differences between HT and NT in
serum albumin (SAlb), prealbumin, IGF-I, and transferrin. On anthropo-
metric measurements, HT had significantly more patients with midarm
muscle circumference less than 50 percentile of normal than NT (75 vs.
30%, P , 0.05). Plasma leucine (108.6 6 33.5 vs. 76.6 6 30.9 mmol/liter),
valine (162.5 6 40.0 vs. 123.5 6 42.9 mmol/liter), and BCAA (334.7 6 82.3
vs. 250.3 6 87.9 mmol/liter) levels were significantly (P , 0.05) higher in
HT. Plasma isoleucine (63.6 6 15.8 vs. 50.2 6 15.5 mmol/liter, P 5 0.06),
histidine (80.3 6 33.5 vs. 55.3 6 27.2 mmol/liter, P 5 0.07), and EAA
(854.4 6 226.6 vs. 676.1 6 238.0 mmol/liter, P 5 0.09) levels appeared to
be higher in HT. Peritoneal clearance of BCAA, EAA, and NEAA were
not different between two groups. D/PCr was correlated with BCAA (r 5
0.55) and EAA (r 5 0.43). In conclusion, HT seems to have higher plasma
BCAA level than NT because BCAA cannot easily be transferred to
muscles.
Characteristics of convective transport of glucose during peritoneal
dialysis. E.Y. Lee, K.I. Yoon, M.S. Park, and H.B. Lee, Department of
Internal Medicine, College of Medicine, Ewha Womans University, Hyonam
Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea. The sieving
coefficient (S) representing convective transport of glucose during perito-
neal dialysis (PD) with glucose-containing dialysis solution has been
reported to be anomalous, lower than 0 or higher than 1. Hyperinsulin-
emia in PD may alter peritoneal glucose transport. If extra to intracellular
glucose transport mediated by insulin is involved in the peritoneal glucose
transport during PD with conventional glucose containing dialysis solu-
tions, the diffusive and convective transport characteristics for glucose
calculated using membrane model between two well-mixed compartments
may not represent true values. S can be calculated best when diffusion is
minimized. Male Sprague-Dawley rats were used. To minimize the
diffusive transport the glucose isochratic solutions containing approxi-
mately the same concentration as in serum were used. To maximize
ultrafiltration 3.86% mannitol was used as an osmotic agent. To evaluate
the effect of insulin on glucose transport, two different glucose concen-
trations, 100 mg/dl (NI) and 300 mg/dl (HI), were used. During dialysis
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with the HI solution a glucose clamp technique was performed to keep
blood glucose level approximately 300 mg/dl. A 2-hour peritoneal dialysis
was performed in 13 rats (7 NI and 6 HI). Intraperitoneal volume (VD)
was calculated using the volume marker, RISA, dilution method. The
diffusive mass transport coefficient (KBD) and S for urea and glucose were
calculated using the modified Babb-Randerson-Farrell model. D/P glu-
cose in NI was 0.61 6 0.05 due to the high blood glucose level, 187.2 6
17.9 mg/dl vs. 114.3 6 7.6 mg/dl in dialysate and 0.99 6 0.26 in HI (360.6 6
55.6 mg/dl in blood vs. 345.0 6 55.6 mg/dl). VD did not differ between the
two groups. KBD for urea and glucose, and S for urea did not differ
between the two groups. S for glucose in HI was a negative value and
significantly lower than that in NI (20.90 6 0.96 vs. 1.04 6 0.14, P , 0.05).
Plasma insulin level was significantly higher in HI compared with values in
NI and NC. Dialysate insulin level was similar in NI and HI. Dialysate
insulin level in NI was higher than plasma insulin level. The present result
that S for glucose at the hyperinsulinemic condition was anomalous
indicates that not only simple passive transport but also other transport
mechanisms mediated by insulin, such as glucose influx into cells, may be
involved in peritoneal glucose transport. The finding of the dialysate
insulin level higher than the plasma concentration in NI suggests a direct
leakage of insulin from pancreas or portal vein into the peritoneal cavity.
Inadequacy of hemodialysis prescription and delivery. N.S. Choi, S.P.
Hong, T.W. Lee, C.G. Ihm, M.J. Kim, Department of Internal Medicine,
College of Medicine, Kyung Hee University, Seoul, Korea. The dose of
dialysis is an important parameter that can influence the morbidity and
mortality of chronic dialysis patients. Urea kinetic modeling is the
parameter used to judge the adequacy of dialysis. The relative risk of
morbidity and mortality is significantly less for patients dialyzed with a
calculated Kt/V of greater than 1.2 than for patients with calculated Kt/V
of 1.0 or less. Although urea kinetic modeling represents a accurate
assessment of dialysis adequacy, it is not routinely carried out in most
dialysis units. In this study, we reviewed 25 chronic dialysis patients who
had been on hemodialysis for longer than 18 months in the Kyung Hee
University Hospital. For the measurements of dialysis adequacy, we
estimated the dialysis prescription (prescribed P-Kt/V) and the amount of
dialysis delivered to the patient (delivered D-Kt/V). A total of 25 patients
were enrolled in the study. All of them had no residual renal function
(anuria state; male:female 10:15; age 49.6 6 12.8 years). The average of
P-Kt/V and D-Kt/V were 1.2 6 0.2 and 1.1 6 0.1, respectively (P . 0.1).
The number of patients with P-Kt/V less than 1.0 was 6 of total 25 patients
(24%), and the number of patients with D-Kt/V less than 1.0 was 7 of total
25 patients (28%). The baseline characteristics (mean age and mean
duration of hemodialysis) of patients had no significant difference be-
tween the patients with D-Kt/V less than 1.0 and the patients with D-Kt/V
not less than 1.0. The days of hospitalization were 2.9 6 4.4 vs. 1.4 6 2.5
days, hematocrit levels were 21.8 6 3.4 vs. 24.4 6 4.8%, BUNs were 77.0 6
8.5 vs. 81.8 6 17.4 mg/dl, serum albumin levels were 3.9 6 0.5 vs. 4.3 6 0.5
g/dl, normalized protein catabolic rates were 0.98 6 0.11 vs. 1.16 6 0.25
g/kg/day, serum total cholesterol levels were 135 6 23 vs. 165 6 32 mg/dl
(P , 0.05). In conclusion, patients with D-Kt/V less than 1.0 had lower
values of several parameters that were related to high morbidity and high
mortality, and some of patients with ESRD may be dialyzed insufficiently
due to inadequate prescription. Therefore, we believe that a regular check
of Kt/V is necessary to deliver adequate dialysis.
On-line hemodiafiltration—A safe and efficient way to increase b2-
microglobulin removal. H.C. Kim, J.K. Kwon, T.H. Lee, K.J. Jang, and S.B.
Park, Department of Internal Medicine, Keimyung University School of
Medicine, Taegu, Korea. Efficient removal of b2-microglobulin (b2m) in
end-stage renal failure patients is a continuing preoccupation, as are the
incidence and severity of dialysis-associated amyloidosis increasing. To
evaluate comparative b2m removal we studied 10 stable end-stage renal
failure patients during hemodialysis (HD) and on-line hemodiafiltration
(HDF). One month of regular HD was followed by three months of
on-line HDF. Blood flow (200–250 ml/min), treatment time (4 hours) and
dialyzer type (1.4 m2 polyamide; Gambro AB) were kept unchanged for
each patient during the entire study. Dialysis fluid was prepared from
liquid A-concentrate (BiCart 204; Gambro, Sweden) and dry bicarbonate
powder (BiCart; Gambro AB). Sterility of substitution fluid was proved by
routine bacteriometric monitoring of the infusate. The removal rates of
urea and creatinine were 68.9% and 63.1% during HD, and 69.1% and
61.9% during HDF. These differences did not reach statistical signifi-
cance. The b2m clearance was 13.7 6 13.4 ml/min in HD, compared to
42.2 6 22.4 ml/min in HDF, which is statistically significant (P 5 0.001).
No pyrogenic reactions were observed during the study. In conclusion,
HDF is a safe method and more effective in eliminating b2m than HD.
Effect of oral nutritional supplement (Greenbia RDplus) in malnour-
ished continuous ambulatory peritoneal dialysis (CAPD) patients. I.H.
Lee, H.J. Noh, S.K. Shin, S.W. Kang, K.H. Choi, H.Y. Lee, S.M. Lee, E.Y.
Cho, J.H. Lee, and D.S. Han, Department of Internal Medicine, College of
Medicine, Department of Food and Nutrition, College of Human Ecology,
Institute of Kidney Disease, Yonsei University, Seoul, Korea. Protein-calorie
malnutrition is common in CAPD patients and is associated with in-
creased morbidity and mortality. To evaluate the effect of an oral
nutritional supplement (Greenbia RDplus; Dr. Chung’s Food Co., Ltd,
Seoul, Korea) providing 800 kcal and 24 g of protein daily in addition to
their usual diet on the nutritional status, we conducted a prospective study
in malnourished CAPD patients (N 5 22). Subjects were randomized into
2 groups: group I (N 5 12) taking Greenbia RDplus for 3 months, group II
(N 5 10) as the control. In group I, body weight increased significantly
after 3 months (52.5 6 8.3 vs. 54.2 6 8.8, P , 0.05) but not in group II
(56.2 6 6.1 vs. 56.1 6 6.3, P . 0.05). There were no statistically significant
changes in serum albumin, prealbumin, IGF-I and other biochemical
parameters during study period in group I as well as in group II. Total
calorie (1343.0 6 284.7 vs. 1696.9 6 248.5 kcal/day, P , 0.05) and protein
intake (1.08 6 0.29 vs. 1.20 6 0.23 g/kg/day, P , 0.05) assessed by 72-hour
dietary recall method increased significantly in group I with the oral
supplement. Body mass index (18.7 6 1.8 vs. 19.4 6 2.1, P , 0.05), % body
fat (13.2 6 4.2 vs. 15.3 6 3.8%, P , 0.05), total body muscle (16.8 6 3.7
vs. 18.2 6 3.3 kg, P , 0.05), midarm circumference (22.8 6 2.1 vs. 23.7 6
2.2 cm, P , 0.05) and calculated arm muscle area (25.9 6 7.1 vs. 28.9 6
6.0 cm2, P , 0.05) increased significantly in group I after 3 months. Biceps
and triceps skinfold thickness tended to increase following oral nutritional
supplement, but there was no statistical significance. Anthropometric
parameters remained unchanged in group II. Kt/V urea, normalized
protein catabolic rate and standardized creatinine clearance did not
change in both groups. No clinical side effects were observed during the
study period. In conclusion, the oral supplement was well tolerated and
was effective in improving the nutritional status of malnourished CAPD
patients.
Serum C-reactive protein: A predictor of mortality in continuous
ambulatory peritoneal dialysis patients. H.J. Noh, S.K. Shin, I.H. Lee, S.W.
Kang, K.H. Choi, H.Y. Lee, and D.S. Han. Department of Internal Medicine,
College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul,
Korea. An increased serum C-reactive protein (sCRP) has been demon-
strated to be an independent marker of mortality in hemodialysis patients,
but the predictive role of sCRP in CAPD patients is not clear. Previously,
we reported that serum albumin levels are influenced not only by
nutritional factors, but also by non-nutritional factors such as the presence
of acute phase protein response in a cross-sectional study involving 106
CAPD patients. We have prospectively followed these patients for 2 years
and report here on the predictive value of the initial sCRP as a marker of
mortality. The mean age was 49 years; the male to female ratio was 1:1.1;
CAPD duration was 43.5 months; 11.3% of patients had diabetes and
9.5% of the patients had cardiovascular disease. The peritonitis rate was
0.96 episodes/patient-year and the hospitalized days were 8.7 days/patient-
year. Patients were subdivided into two groups based on sCRP level:
normal sCRP group (N 5 92, sCRP # 0.8 mg/dl) and increased sCRP
group (N 5 13, sCRP . 0.8 mg/dl). The mean sCRP levels were 0.15 6
0.17 mg/dl and 4.25 6 5.04 mg/dl, respectively (P , 0.05). In the increased
sCRP group, there were more male patients (M:F 5 3.3:1 vs. 0.7:1, P ,
0.05) and more diabetic patients (30.7% vs. 8.6%, P , 0.05), and the
serum albumin level was significantly lower compared to the normal sCRP
group (3.5 6 0.6 g/dl vs. 3.9 6 0.5 g/dl, P , 0.05). Serum CRP was
negatively correlated with serum albumin (r 5 20.37, P 5 0.0003) and
positively correlated with presence of diabetes mellitus (r 5 0.33, P 5
0.0003) by stepwise multiple regression analysis. By Cox proportional
hazard model, independent predictors of mortality risk were coronary
vascular disease (relative risk, RR 5 0.11, P , 0.05), high hematocrit
(RR 5 1.18, P , 0.05) and increased sCRP level (RR 5 1.19, P , 0.05).
The two-year patient survival rate (66.7% vs. 94.1%, P , 0.005) was
significantly lower in increased sCRP group than normal sCRP group, but
there were no significant differences in technical failure, peritonitis rate
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and hospitalized days between the two groups. We conclude that sCRP is
an independent predictor of mortality risk and inversely correlated with
serum albumin.
Protein intake and nutritional status in predialysis patients with
chronic renal failure. H.Y. Kim, Y.H. Lee, W. Huh, D.J. Kim, Y.G. Kim,
H.Y. Oh, K.L. Park, and Y.Y. Cho, Department of Internal Medicine and
Department of Dietetics, Samsung Seoul Hospital, Seoul, Korea. Although
dietary protein restriction may protect against progression of renal failure,
it is important to consider whether protein restriction can be attained
without inducing malnutrition, which is a strong predictor of subsequent
increased mortality on dialysis. In this study, we assessed the dietary
protein intake (DPI) by 24-hour urinary collection, food intake, biochem-
ical nutritional indices and the results of arthropometric measurement in
58 predialysis patients with chronic renal failure. We categorized patients
into two groups according to the level of creatinine clearance (CCr) 25
ml/min. The mean (6SD) DPI was 1.00 6 0.56 g/kg/day in patients with
CCr over 25 ml/min and was significantly higher than 0.84 6 0.22 g/kg/day
in patients with CCr below 25 ml/min (P , 0.05). The DPI was positively
correlate with the CCr (r 5 0.47, P , 0.05). The mean (6SD) proportion
of high biologic value protein to the total protein intake in patients with
CCr over 25 ml/min was 46.7 6 15.7% and was not different from 53.2 6
10.8% in patients with CCr below 25 ml/min. The mean (6SD) caloric
intake was low in both patients with CCr over 25 ml/min (26.9 6 5.4
Kcal/kg/day) and patients with CCr below 25 ml/min (26.9 6 8.2 Kcal/kg/
day). The mean (6SD) total lymphocyte count (TLC) in patients with CCr
over 25 ml/min was 2,235 6 568/mm3 and significantly higher than 1,893 6
467/mm3 in patients with CCr below 25 ml/min (P , 0.05). There was no
difference in the levels of transferrin, insulin-like growth factor-1 and
cholesterol between two groups. There was no difference in nutritional
indices obtained by arthropometric measurements between two groups. In
conclusion, the caloric and high biological value protein intake was
reduced in predialysis patients with chronic renal failure, and dietary
protein intake (DPI) decreased as renal function declines. Thus, to
prevent malnutrition in predialysis patients with chronic renal failure, we
should stress adequate caloric and high biological value protein intake and
the objective measurement of dietary protein intake should be considered
to calculate a low protein diet, especially in patients with CCr below 25
ml/min.
Relationship between bioimpedance indices and plasma amino acids
(AA) level in hemodialysis patients. S.W. Lee, K.H. Kwon, H.J. Shin, K.S.
Song, M.-J. Kim, and M.W. Oh, Departments of Internal Medicine and
Preventive Medicine, Inha University College of Medicine, Incheon, Korea.
Bioimpedance analysis (BIA) is increasingly used for assessing the nutri-
tional status in hemodialysis (HD) patients. To examine the correlation of
bioimpedance indices [R (resistance), Xc (reactance), and Xc/R ratio]
with nutritional parameters, especially plasma amino acid (AA) level, BIA
(using 50 kHz after HD session), plasma AA, other biochemical and
anthropometric measurements were performed in 11 stable HD patients.
The mean age was 44 6 12 (SD) years, the sex ratio 1:1.2, the mean
duration on HD 71.9 6 40.3 months. Plasma essential AA(EAA) was
58.9 6 11.9% of normal, branched-chain AA(BCAA) 55.6 6 11.7%, and
non-essential AA(NEAA) 90.9 6 24.1%. Xc was significantly (P , 0.05)
correlated with plasma leucine (r 5 0.73), tyrosine (r 5 0.61), and
prealbumin (r 5 0.81); R with citrulline (r 5 0.64), leucine (r 5 0.75), and
prealbumin (r 5 0.78); Xc/R ratio with leucine (r 5 0.72), glutamine (r 5
0.74), citrulline (r 5 0.71), and midarm circumference (MAC) (r 5 0.64).
When the patients were divided into group I (Xc/R ratio , 0.10) and II
(Xc/R ratio . 0.10) according to Xc/R ratio, plasma leucine level (79.9 6
9.8 vs. 56.3 6 10.1 nmol/ml, P , 0.05), MAC (25.0 6 2.4 vs. 21.8 6 2.7 cm,
P 5 0.07) and prealbumin (43.6 6 8.2 vs. 34.0 6 2.8 mg/dl, P 5 0.07) were
higher in group II. In conclusion, bioimpedance indices usually seem to be
related to the plasma leucine level, which is pivotal to the control of
protein storage in muscle.
Effect of anabolic steroid (AS) on nutritional parameters in malnour-
ished continuous ambulatory peritoneal dialysis (CAPD) patients. K.H.
Kwon, M.-J. Kim, S.W. Lee, K.A. Kim, H.J. Shin, K.S. Song, and J.J. Kim,
Departments of Internal Medicine and Clinical Pathology, Inha University
College of Medicine, Incheon, Korea. Protein-energy malnutrition is fre-
quently observed in CAPD patients, and it is closely correlated with
morbidity and mortality. We investigated the effect of AS on the nutri-
tional parameters in malnourished CAPD patients. Ten CAPD patients
who were proved to be malnourished by biochemical and anthropometric
measurements, not admitted for 2 months recently received intramuscu-
larly 200 mg of long-acting AS, nandrolone decanoate, monthly. After AS
was administered for more than 12 weeks, the nutritional parameters were
checked. The mean age of patients was 55.2 6 8.5 (SD) years, the sex ratio
was 1:2.3. The mean duration of CAPD was 37.0 6 22.8 months. Three
patients were diabetics. The mean duration of AS administered was 19.0 6
4.2 weeks. Seventy percent of patients improved their subjective symp-
toms. The mean dosage of AS was 571 mg. There were significant
increases in hemoglobin (6.9 6 0.9 vs. 7.5 6 1.0 g/dl), hematocrit (20.1 6
2.8 vs. 25.9 6 2.9%), insulin-like growth factor I (166.8 6 75.4 vs. 206.8 6
76.5 ng/ml), prealbumin (28.8 6 10.6 vs. 38.2 6 11.8 mg/dl) and transferrin
(207.3 6 50.9 vs. 240.0 6 50.5 mg/dl) (P , 0.05). There were no changes
in albumin, total lymphocyte, cholesterol, triglyceride, weekly Kt/V urea
and weekly creatinine clearance. There was a trend that was decreased in
urea nitrogen appearance (3751.7 6 1079.4 vs. 3621.5 6 1292.7 mg/day).
On anthropometric measurements, midarm muscle circumference (21.4 6
3.1 vs. 23.3 6 3.3 cm, P , 0.05), body weight (67.7 6 8.3 vs. 69.5 6 6.4 kg,
P , 0.05) and lean body mass (57.6 6 12.7 vs. 60.5 6 11.4%, P , 0.05)
were increased, but triceps skinfold thickness, and body mass index were
not changed. Edema was observed in 5 patients and acne was noted in a
patient as side effect. Among these patients, 2 patients developed severe
edema and ultrafiltration failure. The mean time that edema developed
was 17.6 6 4.6 weeks. In conclusion, AS seems to be useful in correcting
malnutrition with their protein anabolic effect.
Causative organisms of CAPD peritonitis for 5 years in a single center.
D.C. Jin, S.N. Youn, C.W. Park, Y.S. Chang, B.K. Bang, Dept. of Internal
Medicine, The Catholic University of Korea, Seoul, Korea. Peritonitis is the
most serious complication and most common cause of cessation of CAPD,
affecting 24% ESRD patients in Korea at the end of 1995. This study is an
analysis on the incidence and etiology of CAPD peritonitis from 1992 to
1996 in St. Mary’s Hospital, The Catholic University of Korea. All of the
enrolled patients were managed with a two-bag CAPD system consisting
of a Tenchkoff straight two-cuff catheter inserted by midline surgical
approach, one week’s occlusive dressing and the same break-in schedule.
The laboratory study and antibiotics therapy protocol was not changed for
5 years. The number of enrolled patients was 124 (71 males and 53
females), and the mean age was 54.4 6 15.0 year-old. 50.8% of the
patients were diabetics. The overall incidence of CAPD peritonitis was
0.635/patient-year and the peritonitis caused by gram positive bacteria was
40.4%, gram negative was 16.9%, others was 5.9%, and peritonitis with
negative bacterial culture was 36.8%.
Table 1. Incidence and causative organisms of the CAPD peritonitis in
each yeara
’92 ’93 ’94 ’95 ’96 Total
No. of peritonitis episodes 22 31 30 29 26 138
No. of peritonitis patients 17 24 24 20 21 75
Mean no. of CAPD patients 36 43 45 47 46.5 43.5
Incidence (peritonitis/pt-year) 0.611 0.721 0.667 0.617 0.559 0.635
Gram (1) bacteria % 27.3 45.2 50.0 37.9 42.3 40.4
Gram (2) bacteria % 27.3 9.7 20.0 24.1 7.7 16.9
Culture negative % 36.4 41.9 26.7 37.9 34.6 36.8
a The isolated causative organism percent (percentage in culture posi-
tive cases). Gram (1) bacteria (64.0%) included: S. aureus (27.9%),
Coagulase Neg. Staphylo. (23.3%), Strepto. (9.3%), Other G(1) (3.5%).
Gram (2) bacteria (26.7%) included: Pseudomonas (5.8%), E. coli
(5.8%), Acinobacter. (4.7%), Klebsiella (3.5%), Other G(2) (7.0%).
Other cause (9.3%) were Candida (7.0%) and M. tuberculosis (2.3%).
In summary, the most common causative organism of CAPD with the two
bag system was Gram positive bacteria (64%, especially staphylococcus at
51.2%). The peritonitis with Gram negative bacteria was 26.7% and fungal
peritonitis was 7%.
Chemical peritonitis after intraperitoneal use of vancomycin. G.S. Do,
J.Y. Do, and K.W. Yoon, Department of Internal Medicine, College of
Medicine, Yeungnam University, Taegu, Korea. Intraperitoneal (i.p.) vanco-
mycin has been widely used for the treatment of peritonitis or exit-site
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infection associated with continuous ambulatory peritoneal dialysis
(CAPD). However, some previous reports in the literature have suggested
that i.p. administration of certain vancomycin may be associated with
chemical peritonitis in CAPD patients. We retrospectively compared the
incidence of chemical peritonitis after using two different preparations of
vancomycin from different pharmaceutical companies, namely vancocin
CPt and vancomycint. Thirty-three cases (all 26 cases given vancocin CPt
and 7 out of the 9 cases given vancomycint) showed improvement. None
of them developed fever, abdominal pain or cloudy dialysate. Out of the
9 cases given i.p. vancomycint, two who currently did not have abdominal
pain and cloudy dialysis effluent developed these symptoms and signs at 5
and 6 hours after administration of i.p. vancomycin. The chemical
peritonitis may be secondary to prolonged contact of the peritoneal
membrane with one or more of the impurities present in vancomycin
preparation. According to Lilly laboratories, the measured chromato-
graphic purity of vancomycint ranges from 81% to 89%, whereas that of
vancocin CPt ranges from 91.3% to 94.8%. In summary, it is necessary for
the nephrologist to be aware of the possible chemical peritonitis that can
be caused by the impurities of certain brands of vancomycin.
A clinical study of Pseudomonas peritonitis in patients on continuous
ambulatory peritoneal dialysis (CAPD). S.W. Kim, Y.J. Lee, J.M. Lee, D.R.
Cha, Y.J. Kwon, W.Y. Cho, H.J. Pyo, H.K. Kim, Department of Internal
Medicine, College of Medicine, Korea University, Seoul, Korea. Among
patients with the CAPD peritonitis, Pseudomonas peritonitis is relatively
uncommon but the prognosis is poor, and removal of peritoneal catheter
is a frequent treatment modality. We evaluated risk factors, clinical
manifestations, treatments and outcomes of 29 episodes of Pseudomonas
peritonitis during the past 7 years. We divided them two groups: Group I
patients responded to antibiotic treatment or were not complicated by
peritonitis within 4 weeks after catheter exchange; Group II patients did
not respond to antibiotic treatment or were complicated by peritonitis
within 4 weeks after catheter exchange. There were no significant differ-
ences in age, sex, underlying diseases, serum albumin, BUN, serum
creatinine, or clinical signs such as fever, abdominal pain, diarrhea,
abdominal tenderness, paralytic ileus. The frequency of preceeding peri-
tonitis was one time in 7 patients and there was no preceeding peritonitis
in 9. The pathogens of group I were Pseudomonas putida in 4 episodes,
Xanthomonas maltophilia in 3 and Pseudomonas aeruginosa in 2. Those of
group II were Xanthomonas maltophilia in 9 episodes, Pseudomonas
aeruginosa in 6, Pseudomonas putida in 1 and Xanthomonas hydrophilia in
1. There were no significant differences in the duration of antibiotic
treatment, the number of the prescribed susceptible antibiotics, the initial
WBC count of peritoneal effluent and the reduction rate of WBC in the
third day of treatment between two groups (P . 0.05). There were no
significant differences in duration of admission and rate of death between
two groups (P . 0.05). In conclusion, there were no significant differences
in clinical signs and risk factors between the group that responded to
antibiotic treatment and the others. We suggested that the prognosis in
Pseudomonas peritonitis depended on the causative organism.
A clinical study of polymicrobial peritonitis in patients on continuous
ambulatory peritoneal dialysis (CAPD). S.W. Kim, J.H. Shin, Y.K. Lee,
D.R. Cha, Y.J. Kwon, W.Y. Cho, H.J. Pyo, H.K. Kim, Department of Internal
Medicine, College of Medicine, Korea University, Seoul, Korea. Polymicro-
bial peritonitis is a relatively uncommon complication, and its clinical
characteristics, risk factor and optimal management remains controversial.
We retrospectively analyzed clinical manifestation, laboratory findings,
microbiologic examination, treatment and outcome of the 18 episodes of
polymicribial peritonitis occurred in 18 of our patients during past 7 years.
The mean age of patients was 67-years-old (M:F 9:9). The patients
responded to antibiotics only were 5 (28%) and those needed catheter
removal were 13 (72%). The underlying diseases of CRF were DM in 5
(33%) and non-DM in 13 (67%). The duration of peritoneal dialysis (0 to
90 months) was less than 6 months in 7 (39%) and the frequency of
preceeding peritonitis (0 to 3 times) was one time in 10 (56%). There were
no significant differences in clinical data, serum albumin, BUN, serum
creatinine, total lymphocyte count between the patients who responded to
antibiotics only and the others. The microorganisms isolated were Pseudo-
monas (11 episodes), Staphylococcus (6), Acinetobacter (6), fungus (4) and
Enterobacter (4). In patients who responded to antibiotics only, Enter-
obacter, Acinetobacter and Pseudomonas were involved in 2 episodes,
respectively. Nine episodes of Pseudomonas were treated by catheter
removal; also 6 episodes of Staphylococcus, 4 of Acinetobacter and 3 of
fungus were treated by catheter removal. Therefore, catheter removal was
necessary to treat the infection in 6 of 6 episodes by Staphylococcus, 9 of
11 by Pseudomonas, 3 of 4 by fungus and 4 of 6 by Acinetobacter. Among
combination of causative organisms in polymicrobial peritonitis, most of
Staphylococcus, and Pseudomonas, fungus and Acinetobacter were treated
by catheter removal. We suggested the type of organism isolated influ-
enced on the outcome of polymicrobial peritonitis. Further study of more
patients is needed to evaluate predictors and otimal treatment in polymi-
crobial peritonitis.
Concentrations of IL-6, TNF-a, phospholipid and CA125 in dialysis
fluid during the course of CAPD peritonitis. D.H. Kang, K.B. Choi, and
K.I. Yoon, Department of Internal Medicine, Ewha Women’s University
College of Medicine, Seoul, Korea. Bacterial peritonitis remains one of the
major problem in patients undergoing CAPD, resulting in massive me-
sothelial cell (MC) death, remesothelialization failure, fibrosis and scle-
rosis. Since the preservation of the functional integrity of peritoneal
membrane as a dialyzing organ is essential, complete resolution from
peritonitis and adequate remesothelialization is necessary. This study was
performed to investigate the effects of peritonitis on the number, secretory
and regulatory function of MC. There were nine episodes of peritonitis in
7 CAPD patients (M:F 4:3, mean age 45.8 years, mean CAPD duration
32.9 months). Dialysate CA125 and phospholipid were measured as
markers of MC mass, and we also checked the level of IL-6 and TNF-a,
specific cytokines that can be detected in dialysate effluent. The concen-
trations of above-mentioned substances were measured from the first
cloudy bag, and thereafter all night effluent was collected daily during the
course of peritonitis and 4 weeks after discontinuation of antibiotics.
Dialysate CA125 reached a peak on the second day of peritonitis (median
38.9 U/ml) and showed a second peak on seventh day (median 24.1 U/ml).
Other substances also showed a sharp increase on first day of peritonitis,
and returned to the baseline value rapidly. No differences in changes of
the dialysate CA125, phospholipid and cytokine levels were noted accord-
ing to the causative organism. There was no significant correlation
between the values of MC marker and cytokines. In one patient who
experienced 3 consecutive peritonitis with a one-month interval, there was
no second peak in dialysate CA125 level, and phospholipid remained the
lowest level (1 mg/dl). He finally died due to sclerosing peritonitis and
sepsis. In conclusion, MC markers and cytokines in peritoneal effluent can
be used to follow the effects of inflammation in the peritoneal cavity.
CA125 can be regarded both as a marker of MC damage and regenera-
tion. Therefore, regular follow-up of CA125 during peritonitis can be an
indicator to adequate treatment and remesothelialization.
Interleukin-1b induced MCP-1 and fibronectin mRNA expression by
human peritoneal mesothelial cell. W.S. Yang, S.B. Kim, S.K. Park, S.K.
Lee, and J.S. Park, Departments of Internal Medicine, University of Ulsan,
Seoul, Korea. Peritonitis is one of the most frequent complications in
patients on continuous ambulatory peritoneal dialysis (CAPD). Repeated
episodes of peritonitis is associated with peritoneal fibrosis, which de-
crease the efficacy of peritoneal dialysis. This study was performed to
evaluate the effect of interleukin-1b (IL-1b), a cytokine that is released
into the peritoneal cavity during peritonitis, on the expression of macro-
phage chemoattractant protein-1 (MCP-1) and fibronectin mRNA by
cultured human peritoneal mesothelial cells. Mesothelial cells were cul-
tured after isolation with incubation of omentum with trypsin. The
expression of mRNA was assessed by Northern blot analysis. The addition
of IL-1b (1 ng/ml) increased the expression of MCP-1 mRNA, which
peaked at 3–6 hours and subsequently decreased in a time dependent
pattern. The expression of MCP-1 mRNA was also dose-dependent when
mesothelial cells were incubated with IL-1b in concentrations of 0, 0.01,
0.05, 0.1, 0.5, and 1.0 ng/ml. Incubation of mesothelial cells with peritoneal
dialysate of patients with peritonitis also increased the expression of
MCP-1 mRNA in a similar pattern when they were incubated with IL-1b.
The addition of IL-1b (1 ng/ml) also caused an increased expression of
fibronectin mRNA that was increased in a time dependent pattern with a
peak at 96 hours. In conclusion, IL-1b may have a role in the pathogenesis
of peritoneal fibrosis by stimulating the synthesis of fibronectin as well as
MCP-1, which participates in the process of inflammation.
Changes of lower esophageal sphincter pressure (LESP) and 24-hour
esophageal pH monitoring in CAPD patients. K.H. Kwon, S.W. Lee, K.S.
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Kwon, P.S. Kim, and M.-J. Kim, Department of Internal Medicine, Inha
University College of Medicine, Incheon, Korea. Nausea and vomiting are
frequently observed in CAPD patients and these may be related to the rise
in intraperitoneal pressure (IPP) by dialysate. To investigate the changes
of lower esophageal sphincter pressure (LESP) according to the amount
of dialysate and position (supine and sitting) and the relationship between
LESP and 24-hour esophageal pH monitoring, esophageal manometry
and 24-hour esophageal pH monitoring were performed in 9 CAPD
patients. The sex ratio was 1:2. All patients except one were less than 1
month on CAPD. Two patients were diabetics. The mean age and body
weight were 50 6 17 years and 49.4 6 20.2 kg, respectively. There were no
changes in LESP in supine position (LESPsup) according to the amount of
dialysate (29.6 6 9.3 at 0, 31.8 6 9.6 at 500, 30.6 6 4.8 at 1000, 31.3 6 5.6
at 1500, 29.8 6 8.4 mm Hg at 2000 ml). LESP in sitting position (LESPsit)
rose significantly at 500 ml (22.4 6 5.7 at 0 vs. 26.9 6 6.4 mm Hg at 500
ml, P , 0.05) and were elevated persistently but not in a linear pattern
(26.0 6 7.4 at 1000, 26.4 6 6.8 at 1500, and 27.3 6 7.5 mm Hg at 2000 ml).
LESPsup at 0 ml was significantly higher than LESPsit at 0 ml (29.6 6 9.3
vs. 22.4 6 5.7 mm Hg, P , 0.05). This difference maintained at 500, 1000,
and 1500 ml except at 2000 ml (29.8 6 8.4 vs. 27.3 6 7.5 mm Hg). There
were no differences in LESPsup and LESPsit by age, sex, and diabetes.
LESPsup at 2000 ml strongly correlated with total reflux episodes (r 5
20.93, P , 0.01), total duration of pH , 4.0 (r 5 20.86, P , 0.01), and
total reflux score (r 5 20.91, P , 0.05), but LESPsit at 2000 ml did not.
When the patients were divided into group I (,30 mm Hg) and II (.30
mm Hg) according to LESPsup at 2000 ml, group I had more total reflux
episodes (73.3 6 26.0 vs. 13.5 6 11.8, P , 0.05), total duration of pH ,
4.0 (43.5 6 34.1 vs. 7.8 6 5.9 min, P , 0.05), and total reflux score (13.0 6
5.6 vs. 2.9 6 1.7 points, P , 0.05) than II. In conclusion, CAPD patients
seem to have a risk of gastroesophageal reflux due to an elevated IPP if
LESPsup values were lower than normal.
Characterization of hemodialysis ascites with regard to serum ascites
albumin gradient (SAAG). H.R. Kim, J.S. Lee, J.R. Koo, H.J. Kim, K.H.
Kim, R.W. Chun, D.W. Chae, J.W. Noh, I. Yang, H.T. Kim, Department of
Internal Medicine, and Department of Radiology, Department of Clinical
Pathology, College of Medicine, Hallym University, Seoul, Korea. Hemodi-
alysis ascites (HA) can be defined as ascites without discernable cause in
a patient with chronic renal failure maintained on hemodialysis. Clinically,
HA itself is known as a kind of warning sign of poor prognosis. HA is
regarded as a type of exudate with a high protein concentration over 2.5
g/dl. Therefore, HA should be differentiated from ascites due to other
causes showing features of exudate. SAAG is a novel method currently
being used in the differentiation of ascites. SAAG can be calculated by
extracting albumin concentration of ascites from that of serum. High
SAAG (.1.1 g/dl) is known as a presence of portal hypertension, while the
reverse is also true. Hemodynamics of some but not all patients on
hemodialysis through AVF may be altered to give some changes in central
venous pressure and pressures of hepatic vein and subsequently portal
vein. We can thus postulate the possibility that SAAG levels may be a little
elevated even without the presence of portal hypertension due to chronic
liver diseases in these patients. However, SAAG in patients with hemo-
dialysis ascites has never been checked before. We measured the SAAG in
these patients on chronic hemodialysis and determined those having
hemodialysis ascites for the first time. Any definite causes for ascites such
as tuberculous peritonitis, portal hypertension due to chronic liver dis-
eases, malignancies with peritoneal seeding, heart failure, hepatic vein
thrombosis, etc., were excluded through laboratory evaluations including
cytologic, bacteriologic and ADA examination for ascitic fluid. Ultra-
sonography and echo-cardiography show no specific findings. Protein
concentrations of each ascitic fluids were over 3.5 g/dl in all cases. SAAGs
were elevated over 1.1 g/dl in four among five cases. This characterization
on hemodialysis ascites on the basis of SAAG and protein level of ascites
may be helpful in identifying underlying causes of ascites developed in the
patients with CRF on chronic hemodialysis management.
Comparison of survival in end-stage renal disease (ESRD) patients
with pre-existing liver cirrhosis (LC) between those treated with hemodi-
alysis (HD) and CAPD. K.I. Song, S.H. Lee, S.B. Kim, D.H. Yang, M.S.
Park, H.B. Lee, Kangnung Hospital, Catholic University, University of Ulsan,
Soon Chun Hyang University, Seoul, Korea. Although a number of ESRD
patients with LC has been treated on dialysis, the controversy regarding
superiority of one dialysis over the other is still unsettled. To compare
survival in ESRD patients with pre-existing LC between those who chose
HD (N 5 22: 19 M, 3 F) and CAPD (N 5 17: 15 M, 2 F) we performed
a multicenter, retrospective analysis. They had been on same modality of
dialysis for more than 3 months. The mean age and the mean duration of
dialysis were 48 6 2 (SD) years and 18 6 4 months in HD, 44 6 3 years,
35 6 4 months in CAPD, respectively. The common cause of ESRD was
chronic glomerulonephritis (44%) and diabetic nephropathy (28%: 9 HD,
2 CAPD). The most common cause of LC was hepatitis B virus infection
(92%). Sixteen patients died during the follow-up and major cause of
death was hepatic failure (56%). Hepatocellular carcinoma was found in
4 patients. Cox-proportional hazards model analysis showed that sum of
points of Child’s classification (RR 5 2.77, P 5 0.0003) and combined
diabetes (RR 5 5.63, P 5 0.02), but the modality of dialysis (P 5 0.12 with
HD as reference), age, sex, hospital days, serum albumin, creatinine and
cholesterol were not associated with survival. The overall unadjusted
patient survival rates were 72 and 47% for HD and 94 and 61% for CAPD
at 1 and 3 years, respectively. Selection adjusted patient survival rates were
98 and 88% for HD and 96 and 37% for CAPD at 1 and 3 years,
respectively. No statistically significant difference was found between HD
and CAPD. It is concluded that sum of points of Child’s classification and
combined diabetes, but not the mode of dialysis, affect survival in ESRD
patients with pre-existing LC.
Treatment of chronic hepatitis C with interferon-alpha in dialysis
patients and renal allograft recipients. Y.O. Kim, C.W. Yang, Y.S. Kim,
Y.M. Park, and B.K. Bang, Department of Internal Medicine, The Catholic
University of Korea, Seoul, Korea. Chronic hepatitis C is one of common
complications in dialysis patients and can be a relative contraindication to
renal transplantation because of possible progression of hepatitis. Al-
though interferon-alpha (IFN) has been used for treatment of chronic
hepatitis C, its effect in immune compromised patients, such as dialysis
patients and renal allograft recipients, is not clearly defined. We observed
the effect of IFN on the treatment of chronic hepatitis C in dialysis
patients and renal transplant recipients. Three dialysis patients (2 PD, 1
HD) and 2 renal allograft recipients (serum Cr 1.4 mg/dl, 2.0 mg/dl,
respectively) were included. Four patients received three million units of
IFN three times a week subcutaneously for 6 months and 1 patient
received it for 3 months.
Age/
sex RRT (Duration)
HCV RNA, SGOT/ SGPT IU/liter
Pre-Tx
Post-Tx
1 month 3 months 6 months
57/M PD (7 months) 158/56 160/90 231/38
37/M PD (16 months) 1135/105 236/21 224/20 221/16
55/M HD (55 months) 189/151 222/41 212/19 215/19
28/M KT (93 months) 1119/266 220/26 213/11 214/9
59/M KT (142 months) 1101/196 259/109 264/98 224/21
During the initial several days of treatment, 3 patients had high fever. In
the renal transplant recipients, serum creatinine was slightly elevated
during the treatment from 1.4 to 1.6 mg/dl, from 2.0 to 2.4 mg/dl,
respectively, and renal function was stable after finishing treatment. This
study shows that IFN is effective on the treatment of chronic hepatitis C
in dialysis patients and renal allograft recipients without serious compli-
cation.
Hepatitis G virus infection in hemodialysis and CAPD patients. H.J.
Noh, S.K. Shin, I.H. Lee, S.W. Kang, K.H. Choi, D.S. Han, H.B. Shin, H.S.
Kim, and H.Y. Lee, Department of Internal Medicine, College of Medicine,
Institute of Kidney Disease, Department of Clinical Pathology, Yonsei
University, Seoul, Korea. Patients on maintenance hemodialysis (HD) are
at increased risk of infection with parenterally transmitted viral agents,
and it is likely to be extended to a recently discovered hepatitis G virus
(HGV). Little is known about the clinical significance of HGV infection in
dialysis patients and whether some differences exist between HD and
continuous ambulatory peritoneal dialysis (CAPD) patients. We studied
49 HD patients and 31 CAPD patients to determine the prevalence and
clinical relevance of HGV infection. HGV-RNA was identified by a
reverse-transcription (RT) polymerase chain reaction (PCR) assay with
primers from the 59-untranslated region of the viral genome. The mean
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age (50.0 6 13.1 vs. 44.8 6 10.5 years), male to female ratio (1.1:1, vs.
0.8:1), history of transfusion (69.4 vs. 48.4%) and numbers of transfusion
(8.9 6 18.9 vs. 2.4 6 4.2 units) were not different between HD and CAPD
groups, but dialysis duration was significantly longer in HD group (88.5 6
66.7 vs. 43.2 6 34.1 months, P , 0.05). HGV-RNA was detected in 12.2%
(6/49) of the patients on HD as compared with 25.8% (8/31) of CAPD
patients. In HD group, the presence of HGV was not significantly related
to age, sex, dialysis duration, history of transfusion, numbers of transfu-
sion, increased ALT and the presence of HBV or HCV. However, in
CAPD group, the patients with HGV-RNA received more transfusion
(6.0 6 6.7 vs. 1.2 6 1.9 units, P , 0.05). In both HD and CAPD groups,
past episodes of hypertransaminasemia (ALT . twice upper normal
value) and mean ALT of the recent 6 months were not significantly
different between HGV-RNA positive and negative groups. A history of
increased ALT and mean ALT levels were not different among the
patients with isolated HBV, HCV and HGV infection, HBV and HGV or
HCV and HGV coinfection. In conclusion, HGV infection was not rare in
both HD and CAPD patients, and it can be transmitted by transfusions but
may be transmitted by other means.
Incidence and clinical significance of hepatitis G virus infection in
hemodialysis patients. Y.O. Kim, Y.S. Kim, E.J. Choi, Y.S. Chang, and B.K.
Bang, Department of Internal Medicine, The Catholic University of Korea,
Seoul, Korea. Hepatitis G virus (HGV) is known to be transmitted through
transfusion. The incidence and clinical significance of HGV infection in
chronic hemodialysis patients, who are immune compromised and have
frequent transfusions, are not well determined. Sixty-eight patients on
chronic hemodialysis at Kangnam St. Mary’s Hospital were tested for
HGV RNA by polymerase chain reaction assay. They were 52 6 13
(28–85)-years-old and male to female ratio was 1:1 (34:34). Dialysis
duration was 41 6 45 months (2–180 months). Nineteen patients (27.9%)
had a history of renal transplantation. Of the total 68 patients, 12 patients
(17.6%) had no history of blood transfusion, 9 patients (13.2%) less than
10 units, 20 patients (29.4%) 10–20 units, and 27 patients (39.7%) over 20
units. Of the total patients, 5 patients (7.4%) had positive HGV RNA, 15
patients (22.0%) had positive anti-hepatitis C virus (anti-HCV), and 4
patients (5.9%) had positive hepatitis B surface antigen (HBs Ag). Of the
five patients with positive HGV RNA, anti-HCV was combined in two
patients, who showed liver dysfunction. Three HGV RNA-positive pa-
tients who were not combined with B or C hepatitis virus showed normal
liver function. The amount of blood transfusion, level of SGOT and
SGPTT were not different between the patients with isolated HGV
infection and the patients with combined HGV and HCV infection. The
patients with positive HGV RNA showed no difference in age, sex,
duration of dialysis, amount of blood transfusion, history of renal trans-
plantation compared with the patients with negative HGV RNA. In
conclusion, the incidence of HGV infection in hemodialysis patients was
7.4%. It is suggested that HGV infection is not directly related to the
clinically overt hepatic dysfunction.
Renal osteodystrophy (ROD) in predialysis patients (pts) in Korea.
G.T. Shin, K.A. Ma, S.H. Koo, H.S. Kim, Y.S. Kwak, S.K. Ha, D.J. Sherrard,
and D.H. Kim, Department of Nephrology, Clinical Pathology, College of
Medicine, Ajou University. Department of Nephrology, College of Medicine,
Yonsei University, Seoul, Korea, and Division of Nephrology, University of
Washington, Seattle, USA. ROD is one of the major long-term complica-
tions in pts with ESRD. It is also present in the majority of predialysis pts.
Patients with ROD are often asymptomatic, and therefore a number of
biochemical markers and non-invasive imaging techniques have been used
for a diagnostic purpose. However, the quantitative bone histomorphom-
etry is the gold standard method. We now report the data on 49 pts who
underwent bone biopsies prior to their initiation of maintenance dialysis
therapy from Nov. 95 to Dec. 96 at the Ajou University Hospital. We also
measured i-PTH, osteocalcin, alkaline phosphatase, serum albumin, delta
serum aluminum pre and post desferrioxamine infusion. We found that:
(1.) there were 49 pts (26 M, 23 F). The mean age was 47.8 6 13.4 years.
There were 15 diabetic pts (31%). (2.) By histomorphometric criteria,
there were 19 pts (38.8%) with mild lesion, 5 pts (10.2%) with osteitis
fibrosa, 6 pts (12.2%) with mixed lesion, 6 pts (12.2%) with osteomalacia,
and 10 pts (20.4%) with adynamic bone disease. The remaining 4 pts had
normal findings. (3.) There was a positive correlation between i-PTH and
bone formation rate (b 5 0.338, P 5 0.03), i-PTH and fibrosis area (b 5
0.318, P 5 0.028), osteocalcin and fibrosis area (b 5 0.499, P 5 0.007),
alkaline phosphatase and osteoid area (b 5 0.629, P 5 0.001), and alkaline
phosphatase and mineralization lag time (b 5 0.51, P 5 0.001). (4.) Serum
osteocalcin levels above and below 50 ng/ml showed 80% sensitivity and
90% negative predictive value, respectively, in diagnosing osteitis fibrosa,
whereas levels below and above 20 ng/ml showed 70% sensitivity and 80%
negative predictive value, respectively, in diagnosing aplastic bone disease.
Serum alkaline phosphatase levels below 100 IU/liter showed 100%
sensitivity and 80% negative predictive value, respectively, in diagnosing
the aplastic bone disease. (5.) There were no pts with aluminum related
bone disease. (6.) The incidence of aplastic bone disease was more
prevalent in diabetics than in non-diabetics (40% vs. 14%, P 5 0.044). In
conclusion, the incidence of mild lesion was most prevalent in predialysis
pts in Korea. This is in contrast to reports from abroad. Aluminum-related
bone disease is not a problem. The biochemical parameters such as
alkaline phosphatase osteocalcin, and i-PTH can be of some use as
non-invasive diagnostic tools.
Bone mineral density (BMD) and bone turnover markers in chronic
renal failure (CRF) patients initiating hemodialysis (HD). J.H. Song, and
J.H. Ahn, Department of Internal Medicine, Pocheon CHA Medical College,
Kyunggi-do, Korea. To evaluate bone loss in renal osteodystrophy, we
measured regional (distal radius) BMD by quantitative computed tomog-
raphy in 43 CRF patients initiating HD and in 84 healthy controls. We also
measured intact parathyroid hormone (iPTH), serum total alkaline phos-
phatase (T-ALP), osteocalcin (OC), and urine deoxypridinoline (DPD) as
bone turn-over markers. The mean ages of CRF patients and control
group were 49.8 and 49.7 years, respectively. M/F ratio were 1:1.1 and
1:1.3 in each group. Serum T-ALP and OC levels in CRF patients were
significantly higher than in the control group (263.9 6 264.5 U/liter, 43.5 6
27.6 ng/ml vs. 167.4 6 46.6 U/liter, 8.8 6 3.9 ng/ml), but urine DPD was
not significant different. Total density, trabecular density and cortical
density were significantly reduced in CRF patients than in the control
group (340.4 6 83.6, 172.9 6 48.4, 477.2 6 123.5 vs. 393.2 6 49.1, 210.6 6
32.9, 541.3 6 76.2 mg/cm3). Serum T-ALP, iPTH, OC, urine DPD values
were not correlated with BMD in CRF patients. In the control group,
serum OC was correlated inversely with BMD. In CRF patients (N 5 22)
who were had an iPTH above 300 pg/ml, serum OC and urine DPD were
significantly higher than in CRF patients (N 5 21) who were had iPTH
levels below 300 pg/ml (52.6 6 28.8 ng/ml, 6.8 6 5.1 nmol/mmol z Cr vs.
33.9 6 23.3 ng/ml, 3.7 6 1.9 nmol/mmol z Cr). However, serum T-ALP and
BMD were not significantly different between two groups. In CRF
patients who had an iPTH above 300 pg/ml, iPTH and serum OC were
inversely correlated with total density (r 5 20.58, r 5 20.61) cortical
density (r 5 20.52, r 5 20.66), but urine DPD were only inversely
correlated with trabecular density (r 5 20.47). In CRF patients initiating
HD, BMD was significantly reduced, but serum T-ALP, OC, iPTH and
urine DPD were not correlated with BMD. In CRF patients who were had
an iPTH above 300 pg/ml, BMD was inversely correlated with serum OC,
iPTH and urine DPD.
Serum markers of renal osteodystrophy. S.G. Lee, H.J. Jin, J.H. Park,
J.Y. Joung, C. Ahn, J.S. Han, S. Kim, J.S. Lee, Department of Internal
Medicine, Seoul National University, College of Medicine, Seoul, Korea. The
most common complication of the end-stage renal disease is renal
osteodystrophy (ROD). Some reports recommended bone biopsy in the
differential diagnosis of ROD. However, ROD is a syndrome with various
pathogenetic results. We studied the serial changes of the serum markers
that reflected the pathogenetic changes of the ROD, especially aplastic
bone disease (ABD). Fifty-two patients on CAPD with diabetic end-stage
renal disease, which was frequently complicated by ABD, were included.
The serum markers of ROD were compared with those in 73 pre-dialysis
diabetic patients and 99 patients with non-diabetic end-stage renal disease.
Serum calcium, phosphorus, alkaline phosphatase, intact parathyroid
hormone (iPTH) and osteocalcin as a serum markers, were repeatedly
measured every 3 to 6 months. The median follow-up period in CAPD
patients was 23 months (median, range 0–80). (1) The level of the serum
markers to the renal function in diabetic patients. A total of 73 diabetic
patients were grouped as follows: I, patients with no diabetic nephropathy
(N 5 15); II, with diabetic nephropathy and serum creatinine equal or less
than 1.4 mg/dL (N 5 15); III, with serum creatinine within the range of 1.4
to 2.5 mg/dl (N 5 14); IV, with serum creatinine above 2.5 mg/dl; V, on
hemodialysis due to diabetic end-stage renal disease. No difference was
found between the groups in age and sex distribution. After adjustment for
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age and sex, all serum markers were significantly affected by creatinine
(ANACOVA test, P , 0.05). Except for calcium, all Spearman correlation
coefficients were positive. The levels of serum calcium, phosphorus, iPTH
and osteocalcin were significantly different between groups I, II, II and IV
(one-way ANOVA test, Duncan-Tukey test, P , 0.05), but the level of
alkaline phosphatase was not significantly different. A significant correla-
tion was found between osteocalcin, phosphorus, alkaline phosphatase
and iPTH (P , 0.05), but no difference was found between the patients on
hemodialysis and those on CAPD. (2) The changes of serum markers in
CAPD. The level of iPTH and osteocalcin appeared to decrease after the
initial 3 month period in patients with diabetic end-stage renal disease.
Diabetic patients had lower levels of phosphorus, iPTH and osteocalcin
than those of non-diabetics and higher levels of alkaline phosphatase at 6
months and 12 months. We found the bone biopsy of 4 diabetic patients
and 2 non-diabetic revealed as ABD, whose iPTH and osteocalcin
decreased from 214 pg/ml, 12.2 ng/ml and 207 pg/ml, 29.5 ng/ml to 5 pg/ml,
3.6 ng/ml and 144 pg/ml, 9.8 ng/ml. Therefore, we observed more
conspicuous decreases of the markers of osteoblastic and osteoclastic
activity in diabetic than in non-diabetics as they proceeded on CAPD.
Previous reports on ROD were cross-sectionally based on bone biopsy, but
we demonstrated that ROD was a dynamic disease affected by the
duration of dialysis and the severity of uremia and the other metabolic
derangement as diabetes, etc.
Incidence and predictor of hyperparathyroidism in renal allograft
recipients with stable renal function. Y.O. Kim, Y.J. Sung, Y.S. Kim, and
B.K. Bang, Department of Internal Medicine, The Catholic University of
Korea, Seoul, Korea. Hyperparathyroidism, which causes renal osteodys-
trophy, is a common complication in patients with end-stage renal disease.
It is usually normalized after successful renal transplantation, but it
continues in some renal transplant recipients. To investigate the incidence
and predictors of hyperparathyroidism in renal allograft recipients, we
measured intact parathyroid hormone (iPTH) in 148 renal allograft
patients with stable renal and hepatic function. The mean age of the
patients was 42 6 12 (13–76) years old and male-to-female ratio was 1.96
(98:50). The patients were on pre-transplant dialysis for 15.8 6 20.6
months (0–130) and were followed up for 38.3 6 32.1 months (2–204).
The iPTH level was high in 10 patients (6.8%) out of a total 148 patients.
Serum phosphorous and calcium levels were normal in all patients, except
that 2 patients having high iPTH showed high serum calcium level. The
alkaline phosphatase level was elevated in 16 patients (11.6%) out of total
138 patients having a normal iPTH and 5 patients (50%) out of total 10
patients having high iPTH (P , 0.001). iPTH levels were positively
correlated to serum alkaline phosphatase levels (r 5 0.80, P , 0.001). Pre-
and post-transplant serum alkaline phosphatase levels were higher in the
patients having high iPTH than those in the patients having normal iPTH
(P , 0.001), but there was no difference in pre- and post-transplant serum
calcium and phosphorus, post-transplant serum creatinine and hemoglo-
bin between the patients. Between the patients having high and normal
iPTH, there were no statistical differences in age, sex, duration of
pre-transplant dialysis, duration of post-transplant follow-up, number of
transplantations, donor type, primary renal disease, and episodes of acute
rejection. In conclusion, the incidence of hyperparathyroidism in renal
transplantation with stable renal function was 6.8%, and pre- and post-
transplant serum alkaline phosphatase levels are good predictive markers
in the diagnosis of hyperparathyroidism.
A prospective study of the effect of calcitriol treatment according to
administration route in CAPD patients. I.H. Lee, H.J. Noh, S.K. Shin, S.W.
Kang, K.H. Choi, H.Y. Lee, and D.S. Han, Department of Internal Medicine,
College of Medicine, Yonsei University, Institute of Kidney Disease, Seoul,
Korea. To determine the adequate dose and administration route of
calcitriol (C) in CAPD patients with secondary hyperparathyroidism, we
conducted a prospective study of 33 patients who were on CAPD for more
than 6 months and whose intact parathyroid hormone (iPTH) level was
higher than 250 pg/ml. The patients were randomized into 3 groups: IP
(N 5 11), 1.0 mg of C once daily via an intraperitoneal route by overnight
retention with dialysate; SQ (N 5 11), 1.0 mg of C three times a week via
subcutaneous route; and PO (N 5 11); 1.0 mg of C three times a week by
ingestion. Eleven out of 33 patients (6 in IP, 4 in SQ, and 1 in PO) dropped
out during the 6-month study period, and 5 among the 6 patients in IP
were due to peritonitis. Biochemical data including calcium (Ca), phos-
phorus, iPTH, alkaline phosphatase (ALP), bone-specific alkaline phos-
phatase (B-ALP), osteocalcin (OC) and 1,25-dihydroxycholecalciferol
(Vit-D3) were measured regularly, and the data of 22 patients who
completed the 6-month study were analyzed. There was a statistically
significant decrease in iPTH level (pg/ml) in all three groups (IP; 812.0 6
276.7 vs. 354.7 6 129.4, SQ; 786.1 6 535.0 vs. 512.7 6 674.5, PO; 571.8 6
330.7 vs. 159.6 6 192.3, respectively, P , 0.05), but there was no
differences in the percentage of decrease in iPTH from the baseline
among the three groups. ALP, B-ALP and OC also decreased significantly
from the baseline values in all three groups (IP; 53.1 6 14.6, 67.6 6 11.6,
46.3 6 33.5%; SQ; 22.4 6 14.8, 36.0 6 20.80, 40.4 6 24.2%; PO; 40.9 6
24.4, 46.6 6 33.5, 41.8 6 19.6%, respectively, P , 0.05), but they were not
different from each other. During the study period, hypercalcemia (Ca $
10.5 mg/dl) occurred in 7 patients (7/22, 31.8%). IP (2/5, 40%) and SQ
(5/7, 71.4%) had significantly higher incidence of hypercalcemia than PO
(0/10, 0%, P , 0.05). Peritonitis occurred significantly more in IP than in
SQ and PO (5.2 vs. 0.6, 2.4 episodes/patient z year, respectively, P , 0.05).
In conclusion, C treatment resulted in a significant decrement in iPTH
levels in CAPD patients and no significant differences were noted in the
PTH-suppressive effect of C according to the administration route.
Because of the higher incidence of peritonitis and hypercalcemia in IP and
SQ groups, oral ingestion may be the most optimal route for calcitriol
treatment in CAPD patients.
Oral calcitriol therapy in hemodialysis patients with secondary hyper-
parathyroidism: The effect of dose adjustment according to therapeutic
responses. J.S. Lee, J.Y. Kang, S. Park, S.K. Lee, and J.S. Park, Dept. of
Internal Medicine, College of Medicine, University of Ulsan, Ulsan, Korea.
Calcitriol therapy is a mainstay for treatment of secondary hyperparathy-
roidism. However, controversy exists over the appropriate route, fre-
quency and dose of calcitriol replacement. Any methods of calcitriol
administration increase the risk of hypercalcemia and hyperphosphatemia
and are poorly tolerated long-term at high doses. To examine the proper
dose of oral calcitriol, we prospectively studied the long-term effects of
oral calcitriol in 17 hemodialysis patients with secondary hyperparathy-
roidism for 12 months. Low-dose oral pulse calcitriol was initiated.
Subsequently, the dose adjustments were made every month based upon
serum IRMA-PTH, total calcium and inorganic phosphorus. Total cal-
cium and inorganic phosphorus were measured every week for first four
weeks and then every 2 weeks; alkaline phosphatase and IRMA-PTH were
measured monthly. Before and after the treatment, bone mineral density
was measured by DEXA. With calcitriol therapy both IRMA-PTH and
alkaline phosphatase decreased from 702 6 83 to 311 6 94 pg/ml (P ,
0.001), and from 439 6 75 U/liter to 189 6 55 U/liter (P , 0.01),
respectively. The mean dose of calcitriol was 3.7 6 0.5 mg per week. The
maximum and mean maximum doses of calcitriol were 15 and 5.6 6 0.5 mg
per week, respectively. The incidence of hypercalcemia and hyperphos-
phatemia was 5.7% and 14.8%, respectively. The bone mineral density of
lumbar spine (P 5 0.010) and femoral neck (P 5 0.017) was increased but
that of distal ulnar was not. In conclusion, the method that adjusts the
dose of calcitriol based upon therapeutic responses, effectively suppresses
the secondary hyperparathyroidism with relative low dose and can mini-
mize the complications of hypercalcemia and hyperphosphatemia.
Sequential substitution from Sandimmune to Implanta and from
Implanta to its microemulsion formulation, Neoplanta, as cyclosporine
preparations in renal transplant patients. H.J. Kim and S.C. Song,
Department of Internal Medicine, Hanyang University Kuri Hospital, Kuri,
Korea. Clinical trial of cyclosporines produced from two different manu-
facturers were performed in 33 renal transplant patients for 16 months
divided into 2 phases. A 1:1 conversion on a milligram-to-milligram basis
was used for switching from Sandimmune (Sandoz Pharma Ltd, Switzer-
land) to Implanta (Hanmi Pharma Co, Korea) as the first phase and from
Implanta to its microemulsion formulation, Neoplanta, as the second
phase. Throughout two phases, the cyclosporine dose, blood pressure, and
hemoglobin were not changed significantly. Serum creatinine was reduced
from the baseline (1.76 6 0.5 mg/dl) only during the middle 2 months of
the first phase (month 3, 1.57 6 0.4 mg/dl; P , 0.05; month 5: 1.58 6 0.4
mg/dl; P , 0.05), but it was not changed significantly during the second
phase at all. However, blood urea nitrogen (BUN) was increased from
baseline throughout the second phase, significantly. Cyclosporine through
level was reduced from baseline (181 6 57 ng/ml) during the last 3 months
of the first phase (month 6: 132 6 61 ng/ml, P , 0.05, month 7: 137 6 82
ng/ml, P , 0.05, month 8: 135 6 58 ng/ml, P , 0.05), while those were
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increased from baseline to during the early 2 months (month 1, 172 6 64,
P , 0.05; month 2, 170 6 50 ng/ml, P , 0.05) and returned to baseline
during the remaining 6 months of the second phase. No one developed
rejection, but 8 admissions in 7 patients occurred due to cyclosporine
nephrotoxicity related elevation of serum creatinine (N 5 2 in the first
phase, N 5 3 in the second phase), cellulitis in leg (N 5 1), partial
colectomy for colon cancer (N 5 1) and reduction of fractured arm (N 5
1), respectively. Mild abdominal discomfort in 2 patients and nausea with
fishy smell on cyclosporine intakes in 3 patients during the early first phase
were noted transiently, but no one developed such adverse side effects
during the second phase. In conclusion, there were no discernible differ-
ences in safety and effectiveness in cyclosporine products from two
different manufacturers. Furthermore, the comparable effects between
the conventional cyclosporine (Implanta) and the microemulsion formu-
lation (Neoplanta) were noted without requiring the dose reduction after
the 1:1 conversion.
Anti-endothelial cell antibodies in hemodialysis patients and renal
transplant recipients. Y.S. Shin, C.H. Kim, C.W. Yang, D.C. Jin, Y.S. Kim,
S.Y. Kim, Y.S. Chang, and B.K. Bang, Department of Internal Medicine, The
Catholic University of Korea, Seoul, Korea. Vascular endothelial cells play
an active role in inflammatory and immune processes. They can promote
inflammation and influence response through different ways. Recently,
anti-endothelial cell antibodies (AECA) reacting directly with endothelial
cells were demonstrated in a variety of autoimmune diseases, thromocy-
topenic purpura and Kawasaki syndrome. The antibodies were also
demonstrated in renal vasculature of renal transplant recipients having
vascular rejection. We studied the expressions of AECA in chronic
hemodialysis patients and renal transplant recipients. Human umbilical
vein endothelial cells (HUVEC) were harvested and incubated with sera
from 61 renal transplant recipients, 111 hemodialysis patients, and 48
healthy controls at 37°C for 1 hr. Rabbit anti-human IgG was added to the
plates for 1 hr, and the plates were read at 405 nm in a ELISA reader. The
AECA titers in sera of hemodialysis patients were higher than those in
sera of healthy controls (13.92 6 4.96 U/ml vs. 4.76 6 2.26 U/ml, P ,
0.001). The serially measured AECA titers in the pre- and post-transplant
sera were decreased from 7.73 6 3.8 U/ml to 4.73 6 2.66 U/ml (P , 0.01).
The decreased post-transplant AECA titers (6.05 6 1.39 U/ml) increased
when acute rejection developed (10.25 6 5.25 U/ml), and decreased again
when acute rejection was treated (6.88 6 2.27 U/ml). AECA titers in the
pre-transplant sera were higher in the recipients who developed acute
rejection during post-transplant 4 weeks (N 5 28) than those in the
recipients whose post-transplant renal function was stable (N 5 33; 14.0 6
8.57 U/ml vs. 7.73 6 3.8 U/ml, P , 0.01). In summary, the high AECA
titers in the sera of chronic hemodialysis patients were decreased after
transplantation, and the AECA titers increased during an episode of acute
rejection. These observations indicate that vascular endothelial cells might
play a role in the pathogenesis of acute rejection in the renal transplant
recipients.
Donor specific transfusion 24 hours prior to (-24h DST) living donor
renal transplantation. S.D. Jung, D.Y. Kim, K.Y. Kim, and J.M. Kong.
Department of Internal Medicine, Maryknoll Hospital, Pusan, Korea. The
goal of the immunologic maneuvering for organ transplantation may be
the donor specific immune tolerance rather than non-specific immuno-
suppression. Although DST is one of the most extensively studied methods
for donor specific immune hyporesponsiveness, it is not widely used in
recent years because of possible sensitization and overall improvement of
graft survival without DST. Several human and animal studies showed that
-24h DST with concurrent cyclosporine (CsA) administration improved
graft survival. -24 DST may not induce adverse sensitization that precludes
subsequent transplantation, the procedure is simple and does not delay
the operation in living donor transplantation. Between February 1994 and
December 1996, 32 patients received 100 to 200 ml of fresh whole blood
from the kidney donors 1 day before transplantation. Seventeen donors
were living related and 15 donors were non-related. Mean age was 40. One
patient was diabetic. Two received secondary allograft and the rest
primary graft. CyA and prednisolone were the primary immunosuppres-
sants that started 3 days before transplantation. Acute rejection occurred
in 11 recipients (34%). Acute rejection tended to occur earlier. Eight of
the 11 first episodes were within 3 days post-transplant, which all
responded to either steroid pulse or OKT3 therapy. Two patients died
with functioning graft of hepatic failure and sepsis, respectively. All the
other patients have stable graft function at the mean follow-up of 18
(1–37) months. There was no immunologic graft loss. We conclude that
-24h DST may be a valuable option of immune modulation for renal
transplantation with no demonstrable adverse reaction. Its beneficial
effect needs to be confirmed by a larger controlled study.
Pathologic analyses of renal biopsy specimens. M.H. Park, K.W. Kahng,
C.H. Park, C.M. Kang, H.C. Park, J.Y. Kwak, Department of Pathology,
Internal Medicine, and Surgery, College of Medicine, Hanyang University,
Seoul, Korea. The allograft biopsies have been performed to confirm graft
rejection, in some patients, to diagnose drug toxicity, and to find the renal
etiologies in patients with hematuria or proteinuria. We reviewed renal
biopsy specimens that were taken by needle biopsy or nephrectomy from
100 patients who were diagnosed from January 1985 to December 1995.
The most frequent pathologic diagnosis was rejection, including acute
cellular rejection (52 cases), hyperacute rejection (7 cases), acute vascular
rejection (6 cases), acute tubular necrosis (6 cases), and infarct (5 cases),
in descending order of frequency. Glomerular lesions following transplan-
tation occurred in 33 patients and among them, IgA nephropathy,
considered to be a recurrent case, was the most frequent glomerular
lesion. Other glomerular lesions such as diabetic glomerulosclerosis (2
cases), transplant glomerulopathy (5 cases), de novo membranous glo-
merulonephropathy (5 cases), focal segmental glomerulosclerosis (3 cas-
es), mesangioproliferative glomerulonephritis (3 cases), minimal change
disease (1 case), Henoch-Scho¨nlein nephropathy (1 case) also occurred,
and these lesions were frequently associated with various lesions of
rejection. The cases of IgA nephropathy were diagnosed in an average of
2.8 years (8 months to 8 years) after transplantation and clinically
presented proteinuria (21 to 31 in dipstick test) and hematuria in almost
all cases. The cases of transplant glomerulopathy were diagnosed in an
average of 2.8 years (1 to 5 years) after transplantation. In conclusion,
there are some differences in the distribution of recurrent glomerular
diseases between Korean and Western renal transplant recipients and
these may reflect the distribution of glomerular diseases in Korea. The
renal biopsy is considered to be the most reliable diagnostic test for the
differential diagnosis of renal disease in renal transplants with long-term
follow-up.
Clinical characteristics of the acute rejection in transplanted kidney.
S.J. Kim, Y.O. Jeong, W.S. Yang, S.C. Kim, D.J. Han, C.D. Hong, S.K. Park,
Department of Internal Medicine and General Surgery, College of Medicine,
Ulsan University, Seoul, Korea. Acute rejection is a frequent cause of early
graft dysfunction in renal transplantation, and serum creatinine is the
useful guideline of clinical response to anti-rejection therapy. In this study,
we evaluated the change of the creatinine during acute rejection and the
determinants that might influence the response of the anti-rejection
therapy in 499 renal transplant recipients (living-related donor 323, living
unrelated 69, cadaveric donor 107) with 49 episodes of biopsy-proven
rejection from 1990 to 1996. Acute rejection was developed 26 (7.7%) of
the living related donors, 10 (14%) of the living unrelated donors and 13
(12%) of the cadaveric donors; however, there was no difference in acute
rejection rate between three groups. The acute rejection rate was not
related to HLA mismatch in living donors and HLA-DR mismatch in
cadaveric donors. The maximal creatinine during the anti-rejection ther-
apy in the recipients with acute rejection within 2 months after transplan-
tation (N 5 32, 65%) was 5.8 6 3.7 mg/dl, and the recipients whose acute
rejection developed after 2 months (N 5 17, 35%) was 3.6 6 1.8 mg/dl
(P , 0.01); however, the difference in maximal creatinine had no effect on
response to anti-rejection therapy. The serum creatinine at diagnosis,
discharge and of the peak level during treatment of the salvage treatment
group with OKT3 was higher than solumedrol treatment group (P , 0.05).
Predictive factors that influence the response of anti-rejection therapy
were HLA-DR mismatch (P , 0.05) and peak creatinine during anti-
rejection therapy (P , 0.05). In summary, there was no difference in the
acute rejection rate between donor types, and the most important
determinants of response to anti-rejection therapy were HLA-DR mis-
match and peak creatinine during anti-rejection therapy.
Hemoglobin levels after renal transplantation. K.W. Kahng, S.M. Kim,
C.H. Park, C.M. Kang, H.C. Park, and J.Y. Kwak, Department of Internal
Medicine and Surgery, College of Medicine, Hanyang University, Seoul,
Korea. Renal transplantation is the most effective treatment of anemia in
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end-stage renal disease patients. However, some patients still have anemia
and others have post-transplantation erythrocytosis after transplantation.
Many factors have been considered to affect the hemoglobin (Hb) levels
after transplantation. Therefore, we tried to evaluate changes of serum Hb
levels and to find significant factors that may have an effect on the serum
Hb levels after renal transplantation in Korean patients. This study
included 97 patients, 64 male and 33 female, who underwent renal
transplantations and had functioning allografts for more than 2 years.
Among these, 85 patients received cyclosporine (CsA) 1 azathioprine
(Aza) 1 prednisolone (Pds) immunosuppressive therapy, 11 patients
CsA 1 Aza, 1 patient Aza 1 Pds immunosuppressive therapy. Patients
were followed up for 147 weeks (average) after transplantation. The serum
creatinine (SCr) level was 1.52 mg/dl (SD 0.46) and no patient experienced
graft failure during the follow-up period. The serum Hb levels at 12 weeks,
24 weeks, 36 weeks, 48 weeks, 72 weeks, 96 weeks were 11.99 (SD 1.88),
13.09 (SD 2.24), 13.22 (SD 2.15), 13.55 (SD 2.46), 13.62 (SD 2.46), 13.63 (SD
2.48) g/dl, respectively. Post-transplantation erythrocytosis (male Hb . 17
g/dl, female Hb . 15 g/dl) occurred in 17 patients (male 14, female 3).
Iron deficiency anemia (IDA) occurred in 12 patients (male 5, female 7).
Forty-three patients (male 32, female 11) experienced anemia (male Hb ,
12.8 g/dl, female , 11.2 g/dl) that were not related to IDA. Hb levels were
not influenced by angiotensin converting enzyme inhibitor (ACEI) in
patients who had stable SCr below 2.0 mg/dl during the follow-up period.
From these results, we conclude that anemia after transplantation occurs
frequently in Korean renal transplants. Because iron deficiency anemia is
a major cause of anemia in renal transplants and is easy to correct
compared with other types of anemia, a further iron study and supply may
be needed.
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